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Abstract 
The present study examined whether women with premenstrual symptoms (PMS) exhibit 
a different pattern of performance on psychophysical tasks across the menstrual cycle in 
comparison to control women. Research has shown that a related and more extreme 
presentation of this phenomenon, Premenstrual Dysphoric Disorder (PMDD) may be 
experienced as the result of a heightened sensitivity to normal phasic changes in sex 
steroid concentrations. In addition, research suggests that performance on certain 
measures of visuo-perceptual ability is associated with changing levels of estradiol. Thus, 
women who are more sensitive to changing hormonal levels (e.g., women with PMS) 
may exhibit different performance on such tasks when compared to controls; and as a 
function of the menstrual cycle. Control women (N= 18) and women with PMS 
symptoms (N= 16) performed a series of four psychophysical tasks during laboratory 
sessions at both the late-follicular (LF) and late-luteal (LL) phases of the menstrual cycle. 
Women provided salivary estradiol samples and participated in: two chromatic contrast 
sensitivity (CCS) measurements, a test of short-wavelength automated perimetry 
(SWAP), a texture discrimination task (TDT), and an eye tracking procedure. Results 
indicated that control women experienced a significant shift in salivary estradiol 
concentrations between menstrual cycle phases, while women with PMS symptoms did 
not. A significant overall effect of phase was observed for the CCS procedure. With 
respect to the SWAP procedure, higher levels of estradiol in the LL phase were predictive 
of higher S-cone sensitivity in the LF phase. As well, an inverse relationship was found 
between SWAP performance and changes in estradiol levels between the LF and LL 
phases. Significant phase-order effects were observed with respect to texture learning; 
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with the most robust improvements noted in women who trained in the LL phase and 
tested in the LF phase. No significant effects were noted for eye tracking. For all four 
tasks, trends were found involving group or phase effects or interactions. Findings are 
discussed with reference to relevant neurological mechanisms, and the potential influence 
exerted on these systems by changing levels of reproductive hormones across the 
menstrual cycle in women with and without PMS symptoms. 
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V isuo-perceptual Task Performance Across the Menstrual Cycle in Women With and 
Without Premenstrual Symptoms: Potential Influences of Estradiol and Estradiol 
Sensitivity on Retinogeniculostriate, Extrastriate, and E lementary  
Retinal-Based Smooth Pursuit Pathways 
 
 Decades of research have provided support for the observation that women are more 
likely than men to experience episodes of mood-related disturbance following adolescence. The 
epidemiological evidence suggests that after adolescence women exhibit a greater lifetime risk 
for major depressive disorders (MDD) (Weissman, Leaf, & Holzer, 1984), the depressive 
subtype of bipolar illness (Arnold, 2003), and cyclical forms of affective disruption such as rapid 
cycling (Schneck, Miklowitz, Calabrese, Allen, Thomas et al., 2004) and seasonal affective 
disorder or SAD (Rosenthal, Sack, Gillin, Lewy, Godwin, Davenport et al., 1984). In addition to 
sex differences in these disorders, many mood episodes experienced by women are often  
associated with known changes in ovarian steroid levels and the reproductive axis (e.g., mood 
changes during the premenstrual, post-partum, and menopausal periods) (Noble, 2005).  
 In recent years, the elucidation of effects exerted by gonadal steroids, outside of simple 
reproductive function, has begun to influence our conceptualization of such things as learning, 
memory, and perception (e.g., Spencer, Waters, Romeo, Wood, Milner & McEwan, 2008). 
Research has demonstrated that gonadal hormone receptors are located in diffuse regions 
throughout the mammalian brain, thereby implicating candidates such as estradiol and 
progesterone in a variety of nonreproductive cognitive operations never before considered 
(McEwan, 2001; Spencer et al., 2008). In addition to functional modulation, ovarian hormones 
are thought to exert their effects on mood either directly or indirectly through interactions with 
neurotransmitter, neuroendocrine, and/or circadian systems (e.g., McEwan, 2001; Parry & 
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Newton, 2001). Given the cyclic fluctuations of ovarian steroids throughout the different phases 
of the reproductive cycle, the discovery of hormonal receptors in the brain offers unique 
opportunities to investigate the neurological and circadian functioning of both normal and 
potentially dysrhythmic endocrine systems throughout the CNS. 
Mood disturbance associated with the premenstrual portion of the menstrual cycle has 
been referred to historically as premenstrual syndrome (PMS). Clinically significant versions of 
such mood disturbances have been defined more rigorously as late luteal phase dysphoric 
disorder (LLPDD) in the DSM-III-R; and as premenstrual dysphoric disorder (PMDD) in the 
DSM-IV (American Psychiatric Association 1994).  
 PMS is a reproductive phenomenon in women that is, in general, poorly understood. It is 
a syndrome characterized by somatic and mood complaints in the late luteal phase of the 
menstrual cycle. In women, premenstrual symptoms are conceptualized along a continuum. 
While some women experience few symptoms, up to 8% have been found to experience them to 
an extent that is debilitating. This more severe form of the presentation is commonly referred to 
DV30''+DOEUHLFK%DFNVWURP(ULNVVRQ2¶%ULHQ&DOLO&HVNRYDHWDO$OWKRXJK
symptoms of PMS are endorsed by a large number of women, and have been estimated to 
parallel a level of impairment comparable to that of the major dysphoric disorders (Halbreich, 
Borenstein, Pearlstein, & Kahn, 2003), the World Health Organization (WHO) failed to include 
either PMDD or PMS in its comprehensive report on disease control priorities related to mental, 
neurological, developmental, and substance abuse disorders (World Health Organization, 2006). 
In addition, it remains as an entry in the appendices (i.e., Appendix B) of the DSM-IV-TR (APA, 
2000) among several other conditions that require further research validation.  
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concentrations of ovarian hormones (Schmidt, Nieman, Danaceau, Adams, & Rubinow, 1998). 
Several studies have demonstrated that women with PMS or PMDD do not possess dissimilar 
levels of estradiol or progesterone compared to women without such symptoms (Payne, 2003). 
Unlike non-PMDD women, however, women with PMDD do seem to respond favorably to 
bright light and wake therapy, and to Selective Serotonin Reuptake Inhibitor (SSRI) 
pharmacotherapy, implicating PMDD as a mood-related disorder influenced by the endocrine 
system (Lam, Carter, Misri, Kuan, Yatham, & Zis, 1999; Terman & Terman, 2005). The 
apparent lack of steroid concentration differences between PMDD and non-PMDD women, and 
the efficacious nature of light and wake therapy suggests that the symptoms of PMDD are caused 
by either (1) deficits in biorhythmic functioning (i.e. circadian behaviours or phenomena, such as 
sleep, that are regulated by internal pacemakers or neuroendocrine systems), or (2) increased 
sensitivity to hormone levels or hormonal change. Over the course of the past two decades, 
research findings with respect to chronobiological factors such as sleep and melatonin rhythms in 
women with PMDD have been inconsistent (for a review see Moline, Broch, Zak, & Gross, 
2003), indicating that much work remains in understanding the influence reproductive hormones 
exert on circadian systems, the spectrum of phenotypic expression resulting from this 
relationship, and the neurological mechanisms that underlie it. 
 Based upon observations that women with PMDD have been found to exhibit differences 
in sleep parameters, including melatonin rhythms (Parry, Berga, Mostofi, Klauber, & Resnick, 
1997); and colour perception (Eisner, Burke, & Toomy, 2004), the purpose of the present study 
was to determine whether women with symptoms of PMS can be differentiated from healthy 
control women on performance measures obtained at two distinct points in the menstrual cycle. 
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To assess such periodic functionality, we used noninvasive psychophysical measures designed to 
assess visual functionality that target specific parallel processing streams making up the visual 
pathway: the parvocellular (PC), and more notably the koniocellular (KC) visual stream. 
Preliminary evidence has suggested that the KC stream may respond differentially to changes in 
levels of estradiol (Eisner, et al., 2004a; 2004b). The KC stream is involved with colour 
perception with specific responsive properties to the blue-yellow opponency channel (e.g., 
Calkins, 2001).  In addition to examining direct, bottom-up chromatic processing streams, we 
examined visual learning phenomena. Across animal studies, research has demonstrated that 
estrogen enhances synaptic plasticity, and improves performance on hippocampal-dependent 
cognitive behaviours (see review in Spencer et al., 2008). To determine whether similar 
estradiol-based modulations exist in cortical vision pathways, we investigated visual learning in 
women with and without PMS symptoms based on the performance measures of a texture 
discrimination task (Karni & Sagi, 1993; Stickgold, Whidbee, Schirmer, Patel, & Hobson, 2000).  
These measures have been shown to demonstrate rapid learning in initial sessions, resistance to 
decay (e.g., 100% retention after 5 weeks) (Karni & Sagi, 1991), and support the localization of 
texture learning to long-term experience dependent changes in V1 (plasticity). In other words, 
performance improvement may be solely based on V1 modifications analogous to those that 
have been observed in comparative hippocampus studies.  For the present study, the 
hippocampus was used as a model for estradiol-based plasticity in V1 operations. Finally, the 
potential effects of estradiol-induced alteration of GABAergic systems on motor control and 
inhibition were assessed with the use of an eye tracking procedure. Pursuit-related neural activity 
is observed in the rostral regions of the  superior colliculus (rSC), which contain cells that 
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respond to both smooth pursuit eye movements and project via the cerebellum to extra-ocular 
muscles in the brainstem (Krauzlis, Basso, & Wurtz, 2000). 
 Overall, it is our intent to better understand the potential effects of ovarian steroid 
disruptions and periodicity in women with and without PMS symptoms by assessing 
performance across a series of psychophysical tasks designed to probe sensory systems 
implicated in rhythmic, reproductive steroid functioning. Given the large proportion of women 
reporting symptoms of PMS, and the fact that self-report constitutes the basis for diagnosis, the 
establishment of physiological or perceptual parameters along which those with PMS or PMDD 
differ could serve to provide a more concrete marker for its detection, thereby contributing to the 
validity of the category. In addition to the potential to establish a marker for symptoms of 
hormonally mediated somatic and affective dysregulation, this study furthers our understanding 
of how hormonal-based neural modulation may impose functional changes and plasticity not 
only in hippocampus, but also in visual sensory and perceptual systems along the entire neuro-
visual hierarchy.  
Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PM DD)  
Premenstrual syndrome (PMS) is prevalent among women of reproductive age. 
Dysphoric symptoms are among the most prevalent and bothersome premenstrual symptoms and 
are often the reason for treatment seeking (Halbreich et al., 2003). The hallmark feature of PMS 
is the predictable cyclic nature of symptoms that begin in the late luteal phase of the menstrual 
cycle and remits shortly after the onset of menstruation (Steiner, Pearlstein, Cohen, Endicott, 
Kornstein, Roberts et al., 2006).  
The constellation of symptoms experienced premenstrually by many women occurs along 
a continuum of severity. The symptoms associated with PMS may be somatic, emotional, or 
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behavioral in nature, and may or may not impair daily functioning. On the far end of the 
spectrum is PMDD, which is differentiated from PMS by its increased severity of symptoms, 
predominance of mood disturbances, and significant functional impairment. Past epidemiological 
studies on the prevalence of PMDD have been difficult to conduct given the loosely defined 
criteria for the disorder, as well as the fact that many women endorse meeting, or having met at 
least one of the criteria (e.g., Wittchen, Becker, Lieb, & Krause, 2002). The currently accepted 
definition for the disorder, as defined by the American Psychiatric Association (1994), stipulates 
that women with PMDD must experience marked disruptions in their relationships, work, or 
social activities at levels similar to those with major depression. Differentiating PMDD from 
major depression is the cyclic nature, or timing, of the symptoms, which, for PMDD, must occur 
premenstrually and abate after the termination of the menstrual period.  As previously described, 
symptoms of PMDD are representative of three distinct classes and can manifest in the form of 
physical, behavioural, or emotional complaints. The DSM IV-TR (APA, 1994) stipulates that 
over the course of a year, five (or more) of the following symptoms must be entrained in more 
menstrual cycles than not: (1) markedly depressed mood, feelings of hopelessness, or self-
deprecating thoughts; (2) PDUNHGDQ[LHW\WHQVLRQIHHOLQJVRIEHLQJNH\HGXSRURQHGJH´
(3) marked affective lability (e.g., feeling suddenly sad or tearful or increased sensitivity to 
rejection); (4) persistent and marked anger or irritability, or increased interpersonal conflicts; (5) 
decreased interest in usual activities (e.g., work, school, friends, hobbies); (6) a subjective sense 
of difficulty in concentrating; (7) lethargy, easy fatigability, (8) or marked lack of energy; 
marked change in appetite, overeating, or specific food cravings; (9) hypersomnia or insomnia; 
(10) a subjective sense of being overwhelmed or out of control; and finally, (11) other physical 
symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a sensation of 
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"bloating," and/or weight gain. These criteria, particularly the requirement of five symptoms, 
each with a severity that disrupts functioning, has resulted in a more restrictive diagnosis of 
PMDD over the past decade (Freeman, 2003). Despite the fact that the strict application of 
symptom criteria has served to strengthen the reliability, and increase the homogeneity of groups 
involved in studies examining PMDD, controversy still exists with respect to the arbitrary nature 
of the number of selection criteria required for the diagnosis (Freeman, 2003). As well, there 
continues to be disagreement surrounding the categories of symptoms that should be included in 
the diagnosis. For example, the under-representation of physiological symptoms in the 
consideration of a diagnosis of PMDD may prohibit a thorough conceptualization of the true 
pathophysiology of the disorder (Freeman, 2003). Freeman also notes that the World Health 
Organization classified premenstrual tension within a category designated for gynecological 
disorders, rather than psychological disorders, in its International Classification of Diseases 
(ICD) 10th edition. Classified in this context, the cyclical nature of physiological symptoms such 
as migraine headaches are emphasized in order to establish the nature of a somatic syndrome 
QDPHG³SUHPHQVWUXDOWHQVLRQ´7KLVHPSKDVLVRQSK\VLRORJLFDOFRPSODLQWVPD\ be an attempt by 
the authors of the ICD to more firmly establish the validity of a category that to date has been 
dependent on self-reports of vaguely defined mood-related symptoms. This classification system 
lacks other specific criteria as well, such as symptom severity, degree of symptom change in the 
cycle, or relationship with other disorders, and therefore makes it difficult to differentiate the 
distinct clinically significant diagnosis of premenstrual related distress from other physiological 
symptoms expressed by psychological disorders such as anxiety, depression and SAD. 
Additionally, the APA definition of PMDD does not provide a means of quantifying the 
magnitude of the distress of the symptoms, nor the level of impairment in female functioning.  A 
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factor analytic study supported the existence of a two-factor model of PMDD, with dysphoric-
somatic complaints represented as a primary factor, and functional/behavioural impairment 
constituting a second order factor (e.g., Wang, Teng, Vieira-Filho, Gorenstein, & Andrade, 
2007). These findings suggest that both symptoms and impairment level should be investigated 
in studies of PMS and/or PMDD.  
In an effort to examine the symptoms, duration, subjective distress, social impairment, 
patterns of comorbidity and personality features associated with PMS, Angst, Sellaro, Stolar, 
Merikangas, and Endicott (2001) conducted a prospective longitudinal study of a representative 
community cohort of women who were interviewed five times between the ages of 21 and 35 
years. The results of their study suggest that irritability, nervousness, and tension constitute the 
core elements of PMS. More importantly, they state that, despite the findings of other researchers 
describing high levels of comorbidity with depression and anxiety, there are also a substantial 
proportion of women who manifest the core features of PMS without depressed mood. This data 
suggests that premenstrual symptoms are expressed as a unique constellation of symptoms that 
can occur with or without depressed mood. 
Epidemiology of PM DD  
Although few comprehensive epidemiological studies are available, the research of 
Wittchun et al. (2002) suggests that the 12-month prevalence of DSM-IV PMDD is 5.8%.  
Application of the diagnostic exclusion rules with regard to concurrent major depression and 
dysthymia decreased this rate only slightly to 5.3%. The authors classified an additional 18.6% 
RIWKHVHSDUWLFLSDQWVDV³QHDU-WKUHVKROG´FDVHVSUHGRPLQDWHO\EHFDXVHWKH\IDLOHGWRPHHWWKH
mandatory impairment criteria. Lifetime incidence was cited as 7.4%, and PMDD was found to 
be stable across 48 months, with a 10% rate of remission among baseline PMDD cases. Of note, 
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and potentially problematic in conducting studies with pure samples was the fact that 12-month 
and lifetime co-morbidity rates with depression, anxiety, and somatoform disorders were high, 
with incidence rates of 47.4%, 22.9%, and 28.4% respectively. Only 26.5% of women diagnosed 
with PMDD did not exhibit characteristics of another mental disorder. These findings suggest 
that studies comparing women with and without PMDD need to either use pure PMDD samples, 
or include control groups of women with similar rates of depression, anxiety, and other 
somatoform disorders.  
Estrogen and Mood 
Major Depressive Disorder (MDD) is the most commonly diagnosed psychiatric disorder 
among adults, with U.S. lifetime prevalence rates of 20 to 25% for women and 9 to 12% for 
men; point prevalence rates are approximately 6% and 3% for women and men respectively 
(APA, 2000). Thus, in terms of MDD, there appears to be a sex bias in that rates of MDD in 
women are approximately twice those of men. 
 Although the reason for this gender difference is most likely due to a combination of 
biological, social, and environmental factors, it has been suggested that estrogen may play a key 
role in this phenomenon (Steiner, Dunn, & Born, 2003). For example, women are known to 
experience depressive episodes at times of hormonal change in their reproductive years. 
Affective disorders such as premenstrual syndrome (PMS), postnatal depression, and post-
menopausal depression all occur at times of low serum levels of estrogen (see review by 
Pearlstein, Rosen, & Stone, 1997). Furthermore, many women experience negative physiological 
and mood-related side effects when taking hormonal contraceptives, which also lead to 
dramatically reduced levels of endogenous gonadal hormone levels (Rapkin & Sonalkar, 2011).  
Such side effects include headaches, fatigue, negative mood change, weight gain, irregular 
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bleeding, and loss of sexual interest or pleasure (Oinonen, 2009). Many symptoms of PMS are 
similar to oral contraceptive side effects and are also associated with a number of aversive 
physical and mood complaints. Consistently reported in epidemiological studies are the 
symptoms of irritability, tension, depression, bloating, mastalgia, and headache. Dysphoric 
symptoms are among the most prevalent and bothersome premenstrual symptoms and are often 
the reason for treatment seeking (Freeman, 2003). Currently, it is repeatedly cited that 3 to 9% of 
women report having dysphoric PMS that is severe enough to seek and warrant treatment (e.g., 
Halbreich et al., 2003).  Thus, reductions in endogenous gonadal hormone levels, especially 
estrogen, are associated with mood-related complaints, and PMS is one example of this.  
 The effects of estrogen on mood are most notable in studies examining the treatment of 
women in the peri- and post-menopausal periods.  Several studies have demonstrated the efficacy 
of estrogen administration for depression during these periods (see revieZE\=ZLIHO	2¶%ULHQ
1997). As well, a 2002 review examining estrogen as a treatment for depression concluded that it 
is superior to placebo in treating reproductive ±related mood disorders including those in the peri 
and post-menopausal periods (Grigoriadis & Sidney, 2002). These authors cite difficulties in the 
interpretation of the literature, however, due to several different methodological considerations 
such as the combining of women of different ages together into groups, failure to confirm life 
stage, the use of different types of estrogens, the inclusion of women with a range of mood 
disturbances, and the enrollment of women with concurrent psychiatric illness.  
Despite the rigorous methodological considerations required to investigate the effects of 
estrogen on mood, Soares, Almeida, Joffe, and Cohen (2001) investigated the efficacy of 17-ȕ
estradiol for the treatment of depressive disorders in endocrinologically-confirmed 
perimenopausal women. Of 50 women enrolled in the study, 26 met DSM-IV criteria for major 
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depressive disorder, 11 for dysthymic disorder, and 13 for minor depressive disorder. Through 
random assignment, women were introduced to either a treatment condition consisting of 
transdermal patches of 17-ȕHVWUDGLROȝJRUDSODFHERcondition, which employed 
physiologically inert patches. After 12 weeks, remission of depression was observed in 68% 
women treated with 17-ȕHVWUDGLROFRPSDUHGZLWKLQWKHSODFHERJURXSP = .001).  
 Similarly, Schmidt, Nieman, Danaceau, Tobin, Roca and Murphy (2000) examined the 
efficacy of estrogen in the treatment of depression in perimenopausal women with and without 
hot flashes. Women with perimenopause-related depression were randomized in a double blind 
SDUDOOHOGHVLJQWRUHFHLYHHLWKHUȕ-estradiol or placebo administered via an active or inert patch 
changed every three days for three weeks. Subsequently, women receiving estradiol during the 
first three weeks continued receiving estradiol for an additional three weeks, whereas women 
who had received placebo crossed over to estradiol for three weeks. This extra three weeks of 
treatment was included to permit the comparison of effects of estradiol on mood at three and six 
weeks as well as to determine the proportion of women who would respond to both placebo and 
estradiol. Outcome measures included standardized mood rating scales and a visual analog scale 
self-report instrument. Of 34 female participants, 16 received estradiol first and 18 received 
placebo first. After three weeks of estradiol treatment, standardized mood rating scale scores and 
visual analog scale symptom scores (e.g., sadness, anhedonia, and social isolation) were 
significantly decreased compared with baseline scores and were significantly lower than scores 
in women receiving placebo, who showed no significant improvement. Neither the presence of 
hot flushes nor the duration of treatment (three weeks or six weeks) influenced outcome. A full 
or partial therapeutic response was seen in 80% of participants receiving estradiol and 22% of 
those receiving placebo. The results of the above studies indicate that estradiol administration 
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may aid in the amelioration of depressive symptoms, and provide evidence for the role of ovarian 
steroids in the regulation of mood and affect. 
 Results similar to those observed with estradiol administration in women with 
perimenopausal depression have also been documented in women with post partum depressive 
depression (PPD). Although additional safety and efficacy data are required prior to estradiol 
being considered as a first-line treatment for PPD, a preliminary review suggests that few side 
effects and minimal passage to infants through breast milk makes it a promising candidate for 
treatment (Moses-Kolko, Berga, Kalro, Sit & Wisner, 2009). Very few clinical trials have been 
published in this area, however, in one such study Ahokas, Kaukoranta, Wahlbeck, and Aito 
(2001) administered sublingual estradiol to 23 women fulfilling ICD-10 criteria for major 
depression with postpartum onset for eight weeks. Serum estradiol concentrations were measured 
at baseline and weekly for the duration of the study. The treatment effect was assessed using the 
Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated depression symptom 
scale. Baseline assessment indicated that all patients were severely depressed at the inception of 
the study and had low serum estradiol concentrations. Remarkably, in 69% of patients, estradiol 
concentrations were lower than the threshold value for gonadal failure. Results indicated that 
during the first week of estradiol treatment, depressive symptoms diminished significantly, and 
serum estradiol concentrations approached those of the follicular phase. At the end of the second 
week of treatment, the MADRS scores were compatible with clinical recovery in 83% of 
patients. 
 While very few studies have documented the effect of estradiol administration as a 
treatment for PMDD, Rapkin, McDonald, and Winer (2007) reported that a combined oral 
contraceptive pill containing 20 µg of ethinyl estradiol and 3 mg of the progestin drospirenone in 
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a novel dose regimen (24 active pills followed by 4 placebo pills) demonstrated efficacy for the 
treatment of symptoms of premenstrual dysphoric disorder. Similarly, Smith, Studd, Zamblera, 
and Holland (1995) reported significant symptom improvement in a group of women with severe 
306V\PSWRPVZKRZHUHDGPLQLVWHUHGWZLFHZHHNO\GRVHVRIHLWKHUȝJRUȝJRI
estradiol transdermally over an eight-month period.  
 The results of these studies indicate that already low or declining levels of estradiol may 
contribute to mood disturbances in women who are sensitive to changes in hormonal 
concentrations, and that supplementation or administration of exogenous estradiol can aid in the 
amelioration of these negative mood side effects. These data also provide evidence for the 
supposition that that there is a subgroup of women who appear to be vulnerable to hormonally 
triggered negative mood changes. This effect may be exacerbated in women with pre-existing 
mood conditions such as depression or bipolar disorder, indicating that women who are 
vulnerable to one type of hormonally triggered mood disturbance may also be vulnerable to other 
types (Payne, 2003).   
Overview of the Menstrual Cycle  
 The adult human menstrual cycle can be divided into follicular and luteal phases, with 
ovulation occurring between the two. Neuroendocrine control of this recurring reproductive 
event requires the pulsatile secretion of gonadotropin releasing hormone released into the 
pituitary portal system to stimulate the synthesis and secretion of follicle stimulating hormone 
(FSH) and luteinizing hormone (LH) from the gonadotropes of the anterior pituitary (Hall, 
2004). The follicular phase begins on day one of the cycle, the first day of menstrual bleeding. At 
this time, the growth of ovarian follicles is stimulated by a rise in follicle stimulating hormone 
(FSH) released by the anterior pituitary gland. Generally, only one follicle of several will 
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become dominant and continue to grow. As it grows, the dominant follicle produces increasing 
amounts of estradiol, thereby initiating the breakdown of smaller competing follicles. Coinciding 
with the peak in serum estradiol concentrations is the maturation of the growing follicle, and 
consequently the release of (LH) from the anterior pituitary. The release of LH from the 
adenohypophysis stimulates the release of the immature ovum, or secondary oocyte from the 
follicle.  The rupturing of the follicle and release of the secondary oocyte constitutes ovulation, 
which occurs approximately 13 to14 days into the cycle, marking the end of the follicular phase. 
Ovulation lasts between 16 and 32 hours and is terminated upon the release of the egg.  In the 
final steps of ovulation, the secondary oocyte matures into an ovum, at which point it is swept 
into the fallopian tube where it is absorbed by the body if left unfertilized. The luteal phase 
begins following ovulation, at which point the ruptured follicle closes and forms a body known 
as the corpus luteum, which produces increasing amounts of progesterone.  It is the increase in 
progesterone produced by the corpus luteum that causes the uterine lining to develop for ovum 
maintenance in case of successful fertilization. It also causes body temperature to increase 
slightly during the luteal phase and remain elevated until the onset of menses. This increase in 
temperature can be used to estimate whether ovulation has occurred. If fertilization does not 
occur, the corpus luteum degenerates, thereby leading to a cessation of secreted progesterone and 
the sloughing off of the blood-enriched uterine lining. It is the fall in progesterone levels that 
trigger the re-release of FSH and the beginning of a new menstrual cycle (Hampson & Young, 
2008). Figure 1 illustrates an overview of hormonal fluctuations across the menstrual cycle. 
To study specific shifts in hormone concentrations, studies have divided the menstrual 
cycle into finer time periods, in order to more thoroughly examine discrete events such as 
ovulation. For example, both the follicular and luteal phases can be subdivided into early, mid, 
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and late periods. As well, some authors define the period around ovulation as the periovulatory 
phase (e.g. Oinonen & Mazmanian, 2007). The early portion of the follicular phase is marked by 
menses, typically lasting from one to five days (Hall, 2004), while the mid-follicular phase has 
been defined as days 6 to10 days where day 1 is the first day of menses (Parry et al., 1997; Parry, 
Meliska, Martinez, Lopez, Sorenson, Hauger et al., 2008; Parry, Mostofi, LeVeau, Cover-
Nahum, Golshan, Laughlin, & Gillin, 1999). It is during the late follicular phase (LF; days 11 to 
13) that levels of estradiol begin to rise as the dominant follicle reaches maturity. Both the 
ovulatory period as well as the phase of the cycle immediately following ovulation in which 
levels of estradiol and LH are falling warrant investigation in women with premenstrual 
symptoms as they are associated with changing hormone levels. If women with PMS and/or 
PMDD are indeed more sensitive to normal fluctuations of ovarian steroids, differential 
performance may be observed between women with and without such symptoms during the LF 
and LL phases on tasks that are putatively influenced by estradiol. In contrast to the follicular 
phase, the luteal phase is marked by decreases in estradiol, LH, and FSH, and increases in levels 
of progesterone. Research has shown that the length of the luteal phase is relatively fixed 
between 13 and 15 days (Hampson & Young, 2008). Thus, much of the variation in cycle length 
between women is attributable to differences in the length of the follicular phase (Hampson & 
Young, 2008). Based on the mid-cycle luteinizing hormone surge and assuming a 14-day luteal 
phase, the mid luteal phase corresponds to approximately days five or six following the LH surge 
(Baker, Waner, Viera, Taylor, Driver, & Mitchell, 2001) and is characterized by elevated levels 
of progesterone, and low levels of LH and FSH. At this point, levels of estradiol are intermittent 
between levels seen at ovulation (high) and levels seen at menses (low). The late luteal (LL) 
phase has been defined as 12 r 2 days following the LH surge (Parry et al., 1997). It is at this 
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juncture that both levels of estradiol and progesterone begin to fall and women are most likely to 
experience symptoms of PMDD characterized by mood-related and somatic disturbance 
(Rubinow & Schmidt, 2006; Schmidt et al., 1998). 
O rigins of PM DD  
The absence of objective indicators to substantiate the presence of PMDD speaks to the 
likelihood of an interaction of several different factors in its origin and development. Despite the 
absence of such markers, theories abound as to the cause and maintenance of dysphoric and 
somatic complaints associated with the syndrome. Abnormal levels of estrogen and progesterone 
have been suggested as causal factors in PMDD, however, it has been shown that women who 
exhibit symptoms of PMDD do not have abnormally high or low concentrations of circulating 
estradiol or progesterone (e.g., Schmidt et al., 1998). This has led researchers such as Schmidt 
and colleagues (1998) to propose that normal plasma concentrations of gonadal steroids can 
trigger abnormal behavioural responses (e.g., change in mood state or somatic complaints) in 
women who may be susceptible. Evidence supporting this hypothesis was obtained from an 
elegant experiment in which the symptoms of PMDD were eliminated via ovarian suppression 
with the administration of leuprolide, a gonadotropin releasing hormone (GnRH) agonist 
(Rubinow & Schmidt, 2006). GnRH agonists bind to gonadotropin receptors in the pituitary 
gland. When GnRH agonists are administered early in the menstrual cycle, an initial stimulatory 
³IODUH´ HIIHFW FDXVHV D UHOHDVH RI JRQDGRWURSLQV from the pituitary gland for 1 to 2 weeks. As 
compared to endogenous GnRH, exogenous agonists such as leuprolide occupy gonadotropin 
receptors for a longer period of time, and through negative feedback, reduce secretion of 
endogenous gonadotropin which in turn decreases the amount of released FSH, consequently 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      30 
preventing ovarian stimulation. Thus, the inhibition of follicular stimulation at later stages of 
leuprolide treatment prevents the estradiol surge brought about by the mature ovum.  
In a double-blind, placebo crossover design, women with PMDD were treated with 
leuprolide, which led to a significant reduction in self-reported premenstrual symptoms. In a 
subsequent phase of the study, both control women and women with PMDD were administered 
both estrogen and progesterone, or placebo following leuprolide administration. With respect to 
mood, women with PMDD had significant increases in symptoms during treatment with 
leuprolide plus hormone replacement, as compared to those administered leuprolide treatment 
alone. Interestingly, normal women remained asymptomatic following administration of estrogen 
and progesterone. Specifically, the symptoms that increased in women with PMDD included 
sadness, anxiety, impaired functioning, and irritability. Despite the fact that all women in the 
study were screened for normal pituitary-gonadal functioning, non-PMDD women did not 
experience changes in mood as a result of either the leuprolide or hormone replacement 
treatments. The results of this study provide evidence for the hypothesis that in contrast to 
women without PMDD, women with PMDD exhibit aberrant physiological and psychological 
reactions to normal concentrations of circulating ovarian steroids. 
It has been suggested that the pathophysiology of severe PMS and PMDD may be closely 
linked to an overactive hypothalamic-pituitary-gonadal (HPG) axis (Steiner et al., 2006). The 
menstrual cyclicity of the ovarian hormones is most likely the trigger for the psychological as 
well as the somatic premenstrual symptoms. As previously described, however, there seems to be 
no demonstrable hormonal imbalance in women with severe PMS or PMDD. Rather, it is 
assumed that normal ovarian function triggers biochemical events both in the central and 
peripheral nervous systems, which in turn precipitate premenstrual symptoms in vulnerable or 
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predisposed women (Steiner et al., 2006). In a recent study using the estrogen challenge test, 
Eriksson, Backstrom, Stridsberg, Hammarlund-Udenaes, and Naessen (2006) tested the 
hypothesis that brain responsiveness to normal hormonal fluctuations is increased in women with 
premenstrual dysphoria. The estrogen challenge test consists of the administration of 
intramuscular injections of estradiol, and the subsequent monitoring of the rates of change of 
concentrations of hormones contingent upon the presence of the injected estrogen. The aim of 
the Eriksson et al. (2006) study was to test whether the sensitivity of the brain to a standardized 
gonadal steroid challenge differed between women with and without severe premenstrual mood 
symptoms. The authors hypothesized that the brains of women with PMDD (n=13) would be 
more sensitive to the estradiol challenge than those of non-PMDD controls (n=12), as determined 
by faster and stronger feedback effects involving the release of LH and FSH.  They also 
hypothesized that the strength of the feedback response would correlate with the severity of self-
reported mood symptoms during menstrual cycles before the challenge. Estradiol (estradiol 
benzoate 0.04 mg/kg), was administered as an intramuscular gluteal injection in the morning on 
day three or four of the menstrual cycle for all participants, and blood samples were collected at 
eleven intervals ranging from 0 to 144 hrs post injection. For all samples, levels of estradiol, 
FSH and LH were measured. Results indicated a significantly different LH response to estrogen 
in women with PMDD as compared to controls. Specifically, compared to controls, women with 
PMDD demonstrated a stronger negative feedback response to the point of nadir LH levels, 
higher LH levels at the nadir, more LH surge-like reactions, and showed LH concentrations over 
time that were 50% higher than the controls. With respect to self-report measures taken before 
the experimental estradiol challenge, the authors further discovered that an association between 
changes in LH and luteal-phase-self-reported irritability differed significantly between women 
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with and without PMDD. Specifically, the mean visual analog score for premenstrual irritability 
(days 1-10 before menstrual onset) in the pre-experimental cycle positively correlated with the 
area under the curve for LH in the negative feedback phase, and with the area under the curve for 
LH during the negative feedback plateau. The LH response during negative feedback also 
correlated with the self-rated perception of the physiological symptom of bloating in a pre-
challenge menstrual cycle. The FSH response in women with PMDD was not statistically 
different from that of the asymptomatic controls. In accordance with the work of Schmidt et al. 
(1998) the authors of the above study postulate that women with PMDD may exhibit a variable 
response to normal concentrations of gonadal steroids, which implies different neuroendocrine 
feedback regulation in women with PMDD from that in asymptomatic, non-PMDD women. 
 Additional studies have implicated concentrations of luteal phase estradiol and LH in the 
severity of premenstrual symptoms. Seippel and Backstrom (1998) found a relationship between 
high serum concentrations of estradiol during the luteal phase, and the severity of premenstrual 
symptoms defined by five negative mood symptoms (depression, anxiety, tension, fatigue, and 
irritability) and three somatic signs (breast tenderness, swelling/water retention, headache), as 
well as the severity of menstrual bleeding. A similar relationship was seen between high LH 
levels and symptom severity (14  r  0.7 IU/L across 10 premenstrual days). This implies that 
estradiol might exert effects indirectly by influencing the LH response that in turn increases 
subjective symptoms of PMDD. 
Elucidating the mechanisms responsible for symptoms of PMS and PMDD has the 
potential to offer much in the way of understanding affective dysregulation in both menstrual-
related disorders and in other conditions as well. This will not be accomplished, however, by 
subscribing to simple cause and effect, or hormone deficiency models (Rubninow & Schmidt, 
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2006). As suggested by previously described studies, a complex interplay between the normal 
fluctuation of ovarian steroid levels, and a sensitivity at the physiological/molecular level in 
predisposed individuals likely accounts for the observed differences between those who 
experience symptoms of PMDD and those who do not. The understanding of PMDD requires a 
model that accounts for the timing of symptoms, their emergence over the course of the lifespan, 
as well as their minimal expression in the overall population of women (Rubinow & Schmidt, 
2006). A more in depth understanding of the role played by estradiol, including its influence on 
brain structure and function, as well as its interactions with other neurotransmitter and endocrine 
systems can only further serve to enhance our knowledge of reproductive disorders in women. 
Complex targets for estradiol may include the serotonergic system, as well as candidate neural 
signaling systems such as particular elements of the cyclic adenosine monophospate (cAMP) 
response element binding protein (CREB) system and Protein Kinase C (PKC) pathways. These 
are some examples of mechanisms through which estradiol is capable of exerting its effects 
indirectly (Payne, 2003). Given the proliferative quality of the above systems, and their abilities 
to influence cellular activity at the nuclear level, a more in depth examination of estradiol in the 
nervous system is warranted.  
Where Does Estrogen Exert its E ffects in the B rain? 
 Estrogens have most commonly been examined in the context of reproductive behaviour. 
For example, early animal studies focused on estrogenic actions on the hypothalamus affecting 
ovulation and reproductive behavior (Boiling & Blandeau, 1939). Since this time, estrogen 
receptors have been located throughout the brain and have been implicated in such complex 
functions as learning and behaviour, emotion and affect, motor coordination, pain sensitivity and 
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neuroprotective function (see review by McEwan & Alves, 1999). Recent work has also detected 
the presence of estradiol receptors in the retina (Gupta, Johar, Nagpal, & Vasvada, 2005) 
Indeed, the effects of estrogens on the brain are diffuse and widespread, influencing 
several neurotransmitter systems including serotonin or 5-hydroxytryptamine (5-HT), 
norepinephrine (NE), dopamine (DA), acetylcholine (ACh), J-amino butyric acid (GABA), and 
glutamate (GLU) (Rubinow & Schmidt, 2006). In addition, the hippocampus, a structure 
important for declarative and episodic memory, as well as spatial learning, is responsive to 
estrogens (McEwen, 2002). Cerebral blood vessels and glial cells have also been shown to 
respond to the actions of estrogens (see review by McEwan & Alves, 1999).  
With respect to learning and memory, Heikkinen, Puolivali, Liu, Rissanen, and Tanila 
(2002) examined the effects of long-term estrogen treatment on learning in both radial arm 
(RAM) and T-maze tasks. In addition, they correlated choline-acetyl-transferase (ChAT) and 
hippocampal monoamine levels at the end of the study to task performance. Both sham-operated 
(gonadally intact) and ovariectomized (OVX) female mice (n=95) were treated with estradiol for 
either 7 or 40 days prior to behavioral testing (maze performance). Heikkinen et al. (2002) 
reported that ovariectomies impaired and estrogen administration improved performance in the 
RAM task in both sham operated and OVX mice. Seven-day estrogen treatment also improved 
the acquisition of the T-maze task, however, only in OVX mice. The improvement induced by 
the estrogen treatment was even more pronounced when the treatment for these mice was 
extended to 40 days. In addition, the authors found decreased concentrations of several 
neurotransmitters, associated enzymes, and enzyme-metabolites in the OVX mice including: 
hippocampal noradrenalin (NA), ChAT, 5-hydroxyindoleacetic acid (5-HIAA), and 
dihydroxyphenylacetic acid (DOPAC). Furthermore, the effects of estrogen treatment on 
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hippocampal levels of 5-HT neurotransmitter and its metabolite 5-HIAA were different in sham-
operated mice compared to OVX mice. Among hippocampal neurotransmitters, the serotonergic 
system was most affected by the estrogen treatment. The concentrations of hippocampal 5-HT 
and 5-HIAA appeared to depend on the duration of the estrogen treatment and ovarian status. 
Although the 7-day estrogen treatment led to an increased 5-HIAA/5-HT ratio in sham-operated 
mice, the 5-HIAA/5-HT ratio was significantly increased after the 40-day treatment. In contrast, 
OVX mice in the 7-day estrogen treatment showed notable, though nonsignificant, decreases in 
their hippocampal 5-HIAA/5-HT ratios after 7 and 40 days. Thus, changing levels of estradiol or 
sensitivity to changes in estradiol may lead to alterations in serotonergic functioning. This 
relationship between estrogen and serotonin, although found in mice, may contribute to the 
affective symptoms associated with PMS in women. 
 Although several studies have implicated estrogen in the regulation of the serotonergic 
system (Bethea, Gundlah, & Mirkes, 2000; Bethea, Pecins-Thompson, Schutzer, Gundlah, & Lu, 
1998; Huttner & Shepherd, 2003; Joffe & Cohen, 1998; Rubinow, Schmidt, & Roca, 1998), the 
mechanisms behind this action are poorly understood and speculative at best. Many studies to 
date have focused extensively on animal models (Amin, Canli, & Epperson, 2005) and current 
research findings are in need of integration and translation to human populations (Amin et al., 
2005). At the biochemical level, estrogen has been found to increase the production of 
tryptophan hydroxylase, the key enzyme responsible for 5-HT synthesis, and to suppress the 
expression of the serotonin transporter gene (5-HTT) in macaque raphé nuclei (see review by 
McEwan & Alves, 1999). Additionally, estrogen and progesterone treatment has been found to 
alter the expression of several genes responsible for serotonergic transmission within the dorsal 
raphé nucleus of the rat including the expression of the postsynaptic 5-HT2A receptor (Cavus & 
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Duman, 2003), the presynaptic 5-HT reuptake transporter (SERT) gene (McQueen, Wilson, & 
Fink, 1998), and the vesicular monoamine transporter. These findings suggest that estradiol acts 
as a modulator, capable of enhancing serotonergic transmission at the cellular level within the 
dorsal raphé nucleus either through enzymatic biosynthesis of 5-HT, or through nuclear 
functional genomics of receptor and transporter systems. 
Serotonin is known to exert widespread effects on mood, and thus it is possible that 
cycling ovarian hormones in women may affect mood and behaviour through the regulation of a 
multiplicity of pre- and post-synaptic serotonergic expressions (Moses, Drevets, Smith, Mathis, 
Kalro, Butters, et al., 2000).  In a recent study examining the effect of the absence of estrogen E-
isoform receptors (ERE) in mice, Imwalle, Gustafsson, and Rissman (2005) found that female 
knockout (EREKO) mice exhibited enhanced anxiety as measured by level of exploration in the 
elevated plus maze as well as decreased concentrations of 5-HT and DA in several brain regions. 
EREKO females exhibited reduced serotonin content in the bed nucleus of stria terminalis, 
preoptic area (POA), and hippocampus. The authors hypothesized that ERE is required during 
development to modulate the effects of estrogen on anxiety and catecholamine concentrations in 
female mouse brains. 
 In keeping with the findings of Imwalle et al. (2005), additional studies have found that 
treatment with estradiol alone or ER receptor agonists increase the availability of 5-HT 
metabolites and/or 5-HT precursors, providing additional evidence for the augmentation of 
serotonergic systems by estrogens. Lubbers, Zafian, Gautreaux, Gordon, Alves, Correa et al. 
(2010) found that the administration of 17-E estradiol to OVX rats increased levels of the 5-HT 
metabolite 5-HIAA by 38% in the striatum, ventral hippocampus, and ventral tegmenatal area. 
Availability of the metabolite may be indicative of increased metabolism of 5-HT to 5-HIAA as 
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the result of enhanced uptake of 5-HT to cells via the serotonin transporter (SERT) or increased 
activity of monoamine oxidase (MAO).  With respect to the influence of ERE agonists on 5-HT 
precursors, Donner and Handa (2009) found that subcutaneous injections of the selective ERE 
agonist diarylpropionitrile (DPN) to OVX rats (N= 8) daily for a period of eight days, elevated 
the expression of tryptophan hydroxyase-2 (tph2) mRNA in the caudal and mid-dorsal dorsal 
raphe nucleus. Behaviourally, this effect manifested in decreased anxiety in open field tests and 
elevated plus maze performance. Similar results were obtained by Hiroi, McDevitt, and 
Neumaier (2006) who noted increased levels of tph2 mRNA in the mid-­ventromedial  and  caudal  
subregions  of  the  dorsal  and  medial  raphé  nuclei  of OVX rats treated with 17-E estradiol for a 
two week period.  
The results of these studies may have implications for women who experience 
premenstrual symptoms. The above studies indicate that estradiol exerts an influence on the 
serotonergic system which may affect the release, metabolism, reuptake, and/or synthesis of 5-
HT. Thus, a predisposition to negative mood and affective symptoms in women with PMS 
symptoms could be the result: of 1) a potentially blunted response to the estradiol-induced 
release and regulation of 5-HT at points in the menstrual cycle when estradiol is high, such as in 
the periovulatory period, or 2) A heightened sensitivity of the serotonergic system to decreasing 
levels of estradiol from the periovulatory phase to the LL phase of the menstrual cycle resulting 
in more rapid decreases in or metabolism of 5-HT. 
 As reviewed above, the administration of estrogens has been found to exert 
antidepressant effects in times of affective dysregulation (Ahokas et al., 2001; Soares et al., 
2001), and estrogen treatment has been found to influence the response to SSRI treatment in 
postmenopausal women with depression (Lee, Yang, Ko, & Joe, 2008). These findings are not 
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surprising given that many areas of the brain that have been implicated in mood disturbances 
such as depression, including the prefrontal cortex (PFC), amygdala, hippocampus, striatum, and 
thalamus (Drevets, 2000; Drevets, 2003; Posener, Wang, Price, Gado, Province, Miller, et al., 
2003). These regions have also been found to contain estrogen receptors indicating that their 
functionality and the neurological processes governed by them may be modulated by the 
presence of estradiol, and these functions may be differentially affected in men and women (see 
review by McEwan & Alves, 1999). For example, in a study using positron emission 
tomography to examine cortical activity in women performing the Wisconsin Card Sorting Test 
(WCST), Berman, Schmidt, Rubinow, Danaceau, Van Horn, Esposito et al. (1997) demonstrated 
that regional cerebral blood flow (rCBF) was reduced in the PFC of women who had been 
administered the GnRH-agonist leuprolide, (which results in ovarian suppression). When either 
progesterone or estrogen was added to the leuprolide regimen, a reversal to typical rCBF 
activation patterns observed during WCST performance was observed (e.g. higher activation in 
the PFC). These findings suggest that ovarian steroids modulate cognition-related gross neural 
activity in humans, and consequently may be implicated in information processing deficits at 
higher cortical levels. This is of particular interest because processing deficits have been 
demonstrated in individuals with mood-related disturbances such as major depressive and bipolar 
disorders (Clark, Chamberlain, & Sahakian, 2009). Given that estradiol exerts its effects at so 
many areas of the brain, and has been linked with a multiplicity of effects within the serotonergic 
system, it is likely that it also contributes to mood regulation. Many women are susceptible to 
changes in mood and affect during the LL phase of the menstrual cycle as well as at other times 
of altered estrogen levels across the lifespan. It is therefore possible that both estrogen and 
serotonin play a role in the development and/or maintenance of PMS symptoms. 
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Evidence for the interaction of Estrogen and Serotonin in PM DD  
 The observation that women with PMDD respond favorably to SSRI treatment and less 
well to other categories of antidepressants (Rubinow, Schmidt, & Roca, 1998) suggests that 5-
HT may play a greater role than other neurotransmitters in the pathophysiology of the illness. In 
addition to these behavioral observations, a review by Noble (2005) reports that several 
biological markers believed to reflect brain serotonergic functioning have been found to differ in 
women with PMDD compared to healthy controls. These include platelet monoamine oxidase 
activity; density of 5-HT transporters in platelets; serotonin-mediated release of prolactin; and 
the ratios between the DA metabolite, homovanillic acid; and the 5-HT metabolite 5-
hydroxyindoleacetic acid in cerebrospinal fluid. By binding to intracellular receptors, estrogen 
mediates a broad range of cellular effects, including the transcription of genes that encode 
enzymes that regulate numerous pathways involved in the synthesis and metabolism of 
neurotransmitters, neuropeptides and their receptors, neurotransmitter transporters, nerve growth 
factors, and signal transduction proteins (Amin et al., 2005; McEwan & Alves, 1999; Rubinow et 
al., 1998). Although estrogen has not been demonstrated to interact with all 5-HT receptors, 
manipulation of estrogen levels has been shown to affect 5-HT2A (Sumner & Fink, 1995) and 5-
HT1 (Biegon & McEwen, 1982) receptors.  
Much of the research examining the effects of serotonergic activity in response to 
manipulations of estrogen to date has been conducted in animals, but the behavioral findings in 
these comparative studies demonstrate the need for further human study. An example of this can 
be seen in a study by Krezel, Dupont, Krust, Chambon, and Chapman (2001), who showed a 
relationship between estrogen, serotonin receptor function, changes in electrophysiology, and 
affective behavioral response, when comparing ERD knockouts, ERE knockouts, and wild-type 
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mice. In females, there was increased anxiety in ERE mutants according to the open field test and 
elevated plus maze, whereas the rotarod test of motor function showed no differences. This 
agrees with the Imwalle et DO¶VVWXG\GHVFULEHGHDUOLHUZKLFK showed greater maze-
running anxiety with concomitant decreases in 5-HT and DA brain concentrations in female 
knockout (EREKO) mice. Furthermore, with electrophysiological stimulation of the amygdala 
and hippocampus, Krezel et al. (2001) showed a reduced threshold for induction of synaptic 
plasticity in the basolateral amygdala in these knockouts. In addition, there was a local increase 
in 5-HT1A receptor expression in the medial amygdala but not in the basolateral amygdala or 
ventral posterolateral thalamus, structures adjacent to and in close proximity to the amygdala 
respectively. These findings suggest that ERE dysfunction results in changes in emotional 
behavior (i.e., anxiety), increased amygdala sensitivity, and increased 5-HT1A receptor 
expression in the amygdala; mechanisms that may be implicated in the phenotypic expression of 
severe premenstrual symptoms. 
As described previously, Steiner et al. (2006) reported that antidepressant treatment with 
665,VZRUNVDVDQHIIHFWLYHILUVWOLQHWUHDWPHQWRI30''7KHDXWKRUVVWDWHWKDW³665,VFDQEH
administered continuously throughout the entire month, intermittently from ovulation to the 
onset of menstruation, or semi-LQWHUPLWWHQWO\ZLWKGRVDJHLQFUHDVHVGXULQJWKHODWHOXWHDOSKDVH´
(Steiner et al. 2006, p. 57). These authors further state that SSRIs have been found to ameliorate 
both emotional and physical symptoms of PMDD including irritability, depressed mood, 
dysphoria, as well as bloating, breast tenderness, and appetite changes. These results have been 
confirmed in several studies and reiterated in a review by Freeman (2004), who states that 
sertraline, fluoxetine and paroxetine (as an extended-release formulation) are approved by the 
Unites States Food and Drug Administration for use continuously or in the luteal phase alone. 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      41 
Among these studies was a double blind, placebo controlled study conducted by Freeman, 
Rickels, Sondheimer, Polanski, and Xiao (2004). They found that two sertraline-treated groups 
improved significantly more than a placebo group as assessed by total premenstrual Daily 
Symptom Rating Form scores over three treatment months. The Daily Symptom Rating Form 
factors that showed significant improvement were reflective of mood and physical symptoms. A 
history of major depression was not associated with treatment response. In addition, a greater 
number of sertraline-treated women reported improved functioning in the domains of family 
relationships, social activities, and sexual activity. The observation of symptom improvement in 
ZRPHQZLWK30''ZKHQWUHDWHGZLWK665,VIXUWKHUVXSSRUWVVHURWRQLQ¶VUROHLQWKH
maintenance and/or development of PMDD.  
Additional Roles of Estradiol in the Nervous System 
  Recently, it has been shown that steroid receptors, including estradiol receptors, exist in 
the human eye. These receptors have been found in several locations including the cornea, lens, 
iris and ciliary body, retina, lacrimal gland, meibomian gland, and conjunctiva (Gupta, Johar, 
Nagpal, & Vasavada, 2005). In addition, estradiol receptors have been located in the 
suprachiasmatic nucleus (SCN) (Kruijver & Swaab, 2002), an area associated with vegetative 
visual processing and circadian rhythms. Aromatase, the enzyme responsible for catalyzing 
estradiol synthesis, also has been mapped in regions of basal forebrain, cerebral cortex, 
hippocampus, thalamus, cerebellum and brainstem (Azcoltia, Yague, & Garcia-Segura, 2011). 
These observations suggest that the actions of sex steroid hormones may modulate functioning at 
the sensory/perceptual level, and that, in addition, hormonally mediated events such as age, 
menopause, menarche, pregnancy, and menstrual cycles may affect visual processes and the 
circadian rhythms that are entrained by them.  
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      42 
 In 2001, using immunohistochemical techniques and reverse transcription-polymerase 
chain reaction (RT-PCR), Munaut, Lambert, Noel, Frankenne, Deprez,  Foidart et al. (2001), 
discovered estrogen receptor (ER) mRNA in macular and extramacular regions of the retina as 
well as in the choroids of male and female eyes. Additionally, ER protein was localized in the 
ganglion cell layer and in the choroid. At the transcriptional level, mRNA for both ERD and ERE 
receptor subtypes was present. Local differences in the expression level were observed, however, 
suggesting the possibility of variation in the ratio between the two different subtypes. The 
presence of two ER subtypes in the human ocular posterior segment raises questions about their 
potential physiological role and the potential role of estrogen in regulating and/or entraining 
various visual systems and their associated pathways.  
Recent hypotheses regarding mood disturbance are concerned with deficits in 
neuroplasticity and neuronal/glial survival in the CNS (Rubinow & Schmidt, 2006) and this fact 
may have bearing on long-term estradiol influences. For example, it has been shown that cell 
survival proteins (cytoprotective proteins) like B-cell lymphoma 2 (Bcl-2) and brain derived 
neurotrophic factor (BDNF) are altered under conditions of stress and depression (e.g., Charney 
& Manji, 2004; Manji, Drevets, & Charney, 2001).  This alteration may take place through a 
variety of mechanisms, including the facilitation of glutamatergic transmission via NMDA and 
non-NMDA receptors, and through the reduction RIWKHFHOO¶VHQHUJ\FDSDFLW\YLDWKHGLVUXSWLRQ
of mitochondrial calcium uptake. One of the major mechanisms by which BDNF promotes cell 
survival is by increasing the expression of Bcl-2. Bcl-2 attenuates cell death via a variety of 
mechanisms, including impairing the release of calcium and cytochrome c, sequestering 
proforms of death-inducing caspase enzymes, and enhancing mitochondrial calcium uptake. The 
chronic administration of a variety of antidepressants increases the expression of BDNF, and its 
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receptor.  For example, lithium and VPA are known to robustly upregulate Bcl-2 (Charney & 
Manji, 2004). Of importance to our study is the fact that the long-term administration of estradiol 
also increases BDNF activity (Cavus & Dumon, 2003), indicating that estradiol may act on 
pathways similar to that of the traditional antidepressants.  This suggests that women who are 
more sensitive to changing concentrations of ovarian steroids may be vulnerable to deficits in 
neuroprotective mechanisms, and consequently alterations in mood symptoms. 
Melatonin, the C ircadian and Menstrual Cycles, and Mood 
 Melatonin is a ubiquitous substance found in several plant and animal species, including 
humans (Hardeland & Fuhrberg, 1996). Widely distributed in nature, its presence has been 
documented in unicellular organisms, plants, fungi, and animals. In many vertebrates including 
humans, melatonin is synthesized primarily in the pineal gland and is regulated by the 
environmental light/dark cycle via the SCN (e.g., Pandi-Perumal, Srinivasan, Maestroni, 
Cardinali, Poeggeler, & Hardeland, 2006). The synthesis and release of melatonin are stimulated 
by darkness and inhibited by light (Brezezinski, 1997). Similar to 5-HT, melatonin is derived 
from the amino acid precursor tryptophan. In the brain, tryptophan is converted from 5±
hydroxytryptophan to 5-HT. Serotonin is then acetylated to form N-acetylserotonin by 
arylakylamine N-acetyltranferase (AA-NAT). Finally, N-acetylserotonin is converted into 
melatonin by hydroxyindole-O-methytransferase (Pandi-Perumal et al., 2006).  
 The production and secretion of melatonin are mediated largely by hypothalamic-
paraventricular postganglionic retinal nerve fibers of the retinohypothalamic tract, which are 
responsible for the transmission of information regarding the daily pattern of light and darkness. 
More specifically, the light/dark cycle information is passed through the retinohypothalamic tract 
to the SCN, then to the superior cervical ganglion, and finally to the pineal gland (Brzezinski, 
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1997). Humans seem to require light of considerably greater intensity for melatonin suppression 
than do other mammals (Lewy, Wehr, Goodwin, Newsome, & Markey, 1980). As both the pineal 
gland and the retinohypothalamic tract are implicated in the production of melatonin, in the latter 
case via projection to the SCN, it is not surprising that melatonin has been associated with the 
regulation of sleep/wake cycles. These cycles are known to be disrupted in those with mood 
disorders, most specifically those with SAD. However, as described later in this review, 
melatonin levels and sleep architecture have also been found to differ across the menstrual cycle 
and in those who are hormonally sensitive.  
 The observation that women with PMDD have been found to exhibit biorhythmic 
disruptions similar to those individuals with SAD suggests that they may share a common, 
underlying, neurological mechanism that is influenced by ovarian steroids. Therefore, the 
examination of sleep-stage and circadian profiles in women with PMDD may offer clues as to 
underlying neurological mechanisms, and suggest possible targets for investigation at the 
perceptual level. 
 It is well documented that individuals suffering from mood disturbances experience 
alterations in their sleep patterns. In fact, disrupted sleep represents a core criterion for nearly all 
major mood disorders within the DSM IV-TR (APA, 1994). Impairment in sleep quality is 
pervasive in those diagnosed with depression (Hayashino, Yamazaki, Takegami, Nakayama, 
Sokejima, & Fukuhara, 2010; Kupfer, 2006; Peterson & Benca, 2008). Typically, patients suffer 
from difficulties falling asleep, frequent nocturnal awakenings, and early morning awakening 
(Riemann, Berger, & Voderholzer, 2001). Measurements of melatonin either in saliva or plasma, 
or of its main metabolite 6-sulfatoxymelaton in urine, have shown decreased amplitudes in some 
depressed patients during the acute phase of illness (Srinivasan, Smits, Spence, Lowe, Kayumov, 
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Pandi-Perumal, et al., 2006). As will be discussed below, this pattern has also been observed in 
women with PMDD.  
 As with the light/dark and seasonal cycle, the pineal gland has been found to play a role 
in the neuroendocrine control of reproductive physiology as evidenced in seasonally breeding 
animals.  Although humans are not seasonal breeders, research has shown that seasonal 
fluctuations have been found in human reproduction patterns. In a review, Aleandri, Spina, and 
Morini, (1996) report that in northern countries, the conception rate is reported to be higher in 
summer than in winter, and as a consequence, the birth rate reaches a maximum in the spring 
season. This is in contrast to areas with warmer climates, in which peaks in conception rates have 
been found during winter months.  The authors further report that in northern countries, where 
there are greater seasonal fluctuations in levels of light, the photoperiod is more likely to affect 
the activity of the human reproductive axis. This has been corroborated by observations of 
reduced activity of the anterior pituitary±ovarian axis and increases in serum melatonin during 
winter months (Rojanski, Brzezinski, & Schenker, 1992). In addition, Kivela, Kauppila, 
Ylostalo, Vakkuri, and Leppaluoto, (1988) report increased levels of darkness affecting plasma 
concentrations of melatonin and LH significantly in those living in northern countries in winter 
months; higher nocturnal plasma melatonin concentrations on day 10 of the menstrual cycle in 
winter than in summer; and higher nocturnal plasma LH levels in summer than in winter. All of 
these data are consistent with the above findings regarding conception and birth rates in northern 
countries. It has therefore been suggested that seasonal changes in daylight, through melatonin 
secretion, may affect female reproductive function. This involvement of melatonin was 
demonstrated by Voordouw, Euser, Verdonk, Alberda, de Jong, Drogendijk et al. (1992) in 
which the long-term daily administration of 300 mg of melatonin (n = 8) or combinations of 300 
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mg and 75 mg melatonin with 0.75 mg norethisterone (synthetic progestin), induced in the fourth 
month of treatment, a significant decrease in LH (with absence of the mid-cycle peak), estradiol, 
and progesterone plasma concentrations. Furthermore, a combination of 300 mg of melatonin 
with 0.15 mg of norethisterone or 75 mg of melatonin with 0.3 mg of norethisterone, 
administered for 21 days, was also reported to inhibit ovulation, suggesting an additive, or 
synergic effect of the two hormones.  
 Melatonin has also been reported to play a role in menstrual cyclicity (Aleandri et al., 
1996) and menstrual-cycle related mood disturbances (Parry, et al., 1997). This suggests possible 
ovarian steroid modulation of CNS circuitry responsible for affect, and suggests that circadian 
profiles warrant further investigation in those who experience menstrual-related somatic and/or 
mood disturbance such as women with PMDD. 
Response to L ight Therapy in SA D 
 Rosenthal, et al. (1984) were among the first to document the phenomenon of SAD, an 
illness characterized by a unique set of sleep anomalies and vegetative-like depressive symptoms 
occurring annually at the same time each year. In their study, Rosenthal et al. (1984) described 
29 patients who exhibited depressive symptoms conforming to a specific seasonal pattern. 
Although many of these patients had a bipolar affective disorder, potentially confounding the 
purity of the sample, their depressive episodes were generally characterized by hypersomnia, 
overeating, and carbohydrate cravings. The researchers noted that preliminary studies extending 
the photoperiod of these individuals with bright artificial light in the morning had an 
antidepressant effect in 11 of 29. This research led to the phase shift hypothesis proposed by 
Lewy, Sack, Singer, White, and Hoban (1988). According to this hypothesis, endogenous 
circadian rhythms in individuals with chronobiological mood disorders can be abnormally phase 
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advanced or phase delayed with respect to real time and real sleep (Lewy et al., 1988). If bright 
light is shown to individuals two hours before bedtime, it will delay their circadian phase, 
causing later sleep onset and later wake-up time. This delaying effect will persist until light 
exposure is given approximately five hours after usual bedtime. At this exposure time, the phase 
response will shift and the effect of bright light will no longer serve to delay the circadian phase, 
but rather advance it, initiating earlier wake up and sleep onset (Revell, Burgess, Gazda, Smith, 
Fogg, & Eastman, 2007).  Thus, the insomnia associated with many mood episodes can be said 
to mimic the effect of a phase delay, and bright light therapy in the morning has been shown to 
be an effective treatment for many individuals with mood disorders, as it serves to advance their 
circadian phases, thereby preventing them from sleeping late into the morning and allowing them 
to fall asleep at an earlier time in the evening. An increase in the effect of phase advance has 
been shown if the bright light treatment is augmented with afternoon melatonin administration 
(Revell et al., 2007). Although several studies have documented the beneficial effects of time of 
day exposure as effective in the treatment of mood disturbance, others have found time of day 
exposure to be irrelevant. Lee, Blashko, Janzen, Paterson, and Chan (1997) propose that it is the 
duration of time to which patients are exposed to light, rather than the time of day that accounts 
for the observed effects of morning-evening light treatments. They advocate a photon-count 
hypothesis that stems from the observation that a shorter winter photoperiod deprives susceptible 
individuals of sufficient quanta of light to maintain euthymia. In accord with this hypothesis, Lee 
et al. (1997), report that increases in the duration of phototherapy equivalent to two daily 
sessions  (e.g. morning and evening) lead to a longer total period of light exposure that may 
account for the antidepressant effects of light therapy in SAD.  
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Although employed as a treatment strategy less frequently than either cognitive or 
pharmaceutical techniques, sleep deprivation has been demonstrated to be effective in the 
amelioration of depressive symptoms. In a 2006 review, Peterson and Benca report that 
preventing sleep altogether during the night, can quickly reduce depressive symptoms within 
hours in 30 to 60% of patients reporting symptoms of a major depressive episode. Symptom 
improvement was defined as a 50% reduction of Hamilton Depression Rating Scale scores. The 
authors also state that similar levels of improvement have been observed using the technique of 
partial sleep deprivation, particularly during the latter part of the night.  
The effects of sleep deprivation on symptom improvement have also been observed in 
women with PMDD. Without discriminating between sleep stages, Parry et al. (2008) found that 
both early and late wake therapies produced improvements in mood symptoms in women with 
PMDD. Each type of sleep therapy, however, produced different effects on melatonin timing 
parameters. In addition to measuring mood changes during LL phase interventions with early 
wake therapy and late wake therapy, Parry et al. (2008) measured plasma melatonin levels every 
30 minutes between 18:00 and 09:00 h in 19 women with PMDD and 18 normal control women 
during the MF phase (days 6 to10 after the start of menses) and the LL phase (2 to 4 days prior to 
menses). During the treatment phase of early wake therapy, participants slept between 03:00 and 
07:00 h, while during late wake therapy, participants slept between 21:00 and 01:00 h. With 
respect to menstrual cycle phase, results indicated that melatonin offset was delayed (equivalent 
to that which would be observed during a phase delay), and duration of secretion was longer in 
the LL phase compared to the MF phase in both control and PMDD subjects. As well, late wake 
therapy, but not early wake therapy advanced melatonin offset, and shortened its duration. Both 
treatments were found to improve mood symptoms. Melatonin offset was associated with more 
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depressed mood in PMDD patients. Also, longer melatonin duration in the MF phase predicted 
greater mood improvement following late wake therapy. Parry et al. (2008) hypothesize that in 
women predisposed to depression, melatonin-timing alterations might exacerbate luteal phase 
depressive symptoms. The fact that melatonin duration also increased significantly in control 
subjects without worsening mood suggests that delayed luteal phase melatonin offset does not 
invariably lead to symptoms of depression in these women, however, PMDD patients may be 
more vulnerable to depression due to greater increases in melatonin offset duration in the LL 
phase. These findings suggest that sleep deprivation can alter sleep/wake cycles and melatonin 
patterns, and cause changes in mood in women with PMDD. The links between the above 
variables suggest that sleep architecture and the sensory parameters that mediate them may differ 
in women with PMDD. 
A longer duration of melatonin secretion also occurs in primarily female patients with 
SAD (Wehr, Duncan , Sher, Aeschbach, Schwartz, Turner, et al., 2001), postmenopausal 
depression (Tuunainen, Kripke, Elliott, Assmus, Rex, Klauber, et al., 2002) and other major 
depressive disorders (Blaicher, Speck, Imhof, Gruber, Schneeberger, Sator, et al., 2000), and 
there is high comorbidity in patients with PMDD and SAD (Praschak-Rieder, Willeit, 
Neumeister, Hilger, Stastny, Thierry et al., 2001; Portella, Haaga, & Rohan., 2006). As in animal 
models, depressed patients may be more sensitive to changes in melatonin duration, rather than 
to absolute levels. 
Shared deficiencies between SA D and Premenstrual Symptoms 
 In a 2001 study, Praschak-Rieder, et al. compared the point prevalence rates of PMDD in 
a sample of 46 premenopausal female patients suffering from SAD to a group of 46 healthy 
female controls. All participants completed semi-structured clinical interviews based on DSM-IV 
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criteria to ensure diagnosis of PMDD and also completed the Seasonal Pattern Assessment 
Questionnaire (SPAQ) (Rosenthal et al., 1984) to assess the presence of SAD. To verify the 
diagnosis of PMDD, all patients were followed up in stable summer remission using daily self-
rating scales for two full menstrual cycles. Results indicated that women with SAD met the 
diagnostic criteria for PMDD significantly more often than healthy controls (46% vs. 2%, 
respectively). These results indicate that those with SAD and PMDD may share a common 
underlying neurological mechanism.   
 Operating under the suspicion that a positive correlation between measures of seasonal 
and premenstrual symptoms could reflect an overlap in symptoms or a common depression 
history rather than the co-occurrence of two separate problems, Portella et al. (2006) conducted a 
study examining the comorbidity of SAD and PMDD symptoms in a general sample of 91 
female college students. The correlation between seasonality as measured by the SPAQ and 
premenstrual symptoms as measured by the Menstrual Distress Questionnaire (MDQ) (Moos, 
1968) was reduced when scores on a depressive symptom measure were statistically controlled, 
but remained positive and significant (r = .21; p = 0.045). This relationship persisted in a 
subsample of individuals with subsyndromal SAD on a screening measure (r = .48; p = 0.007). 
Although this correlation was reduced when depressive symptom severity was statistically 
controlled, it remained positive and significant. Each of these relationships suggests that the 
association between seasonal and premenstrual symptoms is not solely due to their overlap in 
depressive symptoms. That is, women who experience physical PMDD symptoms appear more 
likely to experience physical symptoms of SAD. 
 Given that the symptoms of atypical and seasonal depression are similar in nature to 
those of PMDD (irritability, tension, loss of concentration, increased appetite, hypersomnia, low 
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self-esteem and sensitivity to social rejection in the premenstrual week), Haffmans, Richmond, 
Landman, and Bloom (2008) examined whether women with PMDD respond to light therapy. 
They applied light therapy periodically to a small sample of women diagnosed with PMDD at 
periodic intervals during the late luteal phase. Symptom improvement was noted in all ten female 
participants as measured by two self-report measures of PMDD. However, in order to maintain 
this level of improvement, light therapy administration was required during all menstrual cycles.  
 In a randomized, double-blind, counter-balanced, crossover study spanning six menstrual 
cycles, Lam, Carter, Misri, Kuan, Yatham, and Zis (1999) examined the effect of dim versus 
bright light therapy in women with late luteal phase dysphoric disorder, now PMDD. Women 
collected baseline observations for two months, followed by two months of either a bright 
³ZKLWH´OLJKWHYHQLQJWUHDWPHQWFRQGLWLRQRUGLP³UHG´IOXRUHVFHQWOLJKWSODFHERFRQGLWLRQ%RWK
light conditions were administered through the use of lightboxes between 19:00h and 21:00h. In 
WKHEULJKW³ZKLWH´OLJKWFRQGLWLRQWKHOLJKWER[FRQVLVWHGRIFRRO-white fluorescent tubes rated at 
O[DWWKHOHYHORIWKHFRUQHDILWWHGZLWKDQXOWUDYLROHWILOWHU,QWKHGLP³UHG´OLJKWSODFHER
condition, red gel filters were installed in identical light boxes, such that they emitted 500 lx at 
the level of the cornea. The authors stated that a 500-O[LQWHQVLW\ZDVHPSOR\HGEHFDXVH³LWKDV
not had significant therapeutic effects in light box studies and does not appear to affect human 
circadiDQUK\WKPV´/DPHWDOS$OWKRXJKWHUPHGµGLP¶OLJKWXVHRIDOLJKWER[
rated at 500 lx is still of greater illuminance than office lighting and thus is a plausible treatment 
for patients. To further enhance plausibility, the authors reporteGXVLQJWKH³UHG´JHOILOWHU
EHFDXVHHDUOLHUVWXGLHVKDYHVKRZQWKDWORQJ³UHG´ZDYHOHQJWKVZHUHOHVVHIIHFWLYHDWUHGXFLQJ
6$'V\PSWRPVFRPSDUHGWRPLGGOH³JUHHQ´RUEURDGEDQG³ZKLWH´ wavelengths. Following two 
months in their initial condition, women were immediately crossed over into the other 
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experimental condition. During each month of treatment, light therapy was administered for 30-
minutes each day during the two-week luteal phase of the menstrual cycle. Outcome measures 
were assessed at the mid-follicular and luteal phases of each cycle using a variety of both self-
report and observer-rating measures. Participants were assessed twice per month throughout the 
course of the study. One visit was scheduled during the mid-follicular phase (days 6-13), and the 
other visit during the symptomatic luteal phase of the cycle (days 21-28). Results indicated that 
ERWKWKHDFWLYHEULJKW³ZKLWH´OLJKWFRQGLWLRQDQGUHGOLJKWSODFHERFRQGLWLRQUHGXFHGGHSUHVVLRQ
and pre-menstrual tension scores during the symptomatic luteal phase, compared to baseline. 
2QO\WKHEULJKW³ZKLWH´OLJKWWUHDWPHQWFRQGLWLRQSURGXFHGVLJQLILFDQWUHVXOWVKRZHYHU7KHVH
results indicate that bright, broad-band light therapy may be a viable treatment for women with 
PMDD in the luteal phase of their menstrual cycle.  
In a recent review article addressing the efficacy, protocol, safety, and side effects of 
light therapy for seasonal and non-seasonal depression, Terman and Terman (2005) report that 
despite mixed findings in the literature, and the need for larger well-controlled trials, the 
treatment protocol administered by Lam et al. (1999) is a viable option for the treatment of 
PMDD and PMS, especially in instances where women have not responded to pharmacological 
interventions. 
With respect to light therapy, Parry et al. (1997) attempted to replicate previous findings 
in which they discovered altered melatonin rhythms in PMDD subjects. In adults, dim light 
melatonin onset (DLMO) is defined as the time at which a salivary concentration of melatonin 
reaches a criterion of 4 pg/ml (Nagtegaal, Laurant, Kerkhof, Smits, van der Meer, & Coenen et 
al., 2002) and is considered to be normal when it occurs between 19:30 and 22:00 h. Phase 
response curves can be generated by using DLMO as a marker of circadian phase. Pandi-
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Perumal, Smits, Spence, Srinivasan, Cardinali, Lowe et al. (2007) report that, by convention, 
circadian time (CT) zero is defined as the wake-up time in visually normal individuals. During 
daylight hours, melatonin levels are nearly undetectable until CT 13 (13 hours following normal 
morning wake time) when concentrations rise to approximately 2 pg/ml (DLMO2), one hour later 
(CT 14) plasma concentrations are typically much higher, approximating 10 pg/ml (DLMO10). 
During nighttime hours, human plasma melatonin levels normally exceed 40 pg/ml. The phase 
advance zone (corresponding to the time intervals during which melatonin administration alters 
circadian phase) for melatonin extends from CT 6 to CT 18 while the phase delay zone extends 
from CT 18 to CT 6 (Pandi-Perumal et. al., 2007). Thus, in humans with a typical sleep-wake 
cycle melatonin rhythms are circadian in nature and characterized by a 24-hour cycle in which 
levels remain minimal until evening hours after which they begin to increase rapidly with the 
decline or absence of daylight and onset of sleep. 
 Parry et al. (1997) sought to determine whether light therapy might exert its therapeutic 
effects by altering the phase, amplitude, or duration of the underlying circadian clock as reflected 
in plasma melatonin levels. In 21 women with PMDD and 11 control women, the authors 
measured the circadian profile of melatonin during both the mid-follicular (day 8 ± 2 following 
onset of menses) and late luteal (day 12 ± 2 days following the LH surge) menstrual cycle 
phases, and after one week of light therapy administered daily, in a randomized crossover design. 
During three separate luteal phases, the treatments consisted of either: bright white morning light 
(administered between 06:30 h and 08:30 h), bright white evening light (administered between 
KDQGKRUGLP³UHG´HYHQLQJOLJKW:LWKUHVSHFWWRPHODWRQLQUK\WKPVDORQH
within group analyses revealed that in untreated PMDD women, melatonin onset time was 
delayed; duration was compressed (normal profiles are typically defined between 21:25 h ± 
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1:20h for DLMO10 and 05:37h ± 1:23 h at termination of secretion); and area under the curve 
(AUC) (referring to the amount of melatonin produced), amplitude (maximum concentration at a 
given time point), and mean melatonin levels were decreased in the luteal phase compared to the 
follicular menstrual cycle phase. No such effects were found in control women suggesting that 
altered circadian rhythms may play a role in the development of somatic and vegetative 
symptoms in the LL phase of the menstrual cycle in women with PMS or PMDD. 
 After morning light in PMDD women, melatonin onset and offset times were advanced, 
and both duration and midpoint concentrations were decreased with broad-band light compared 
WRWKH³UHG´OLJKWFRQGLWLRQ$IWHUHYHQLQJEURDG-band light in PMDD subjects, onset and offset 
times were delayed, midpoint concentration was increased, and duration was decreased as 
FRPSDUHGWRWKH³UHG´OLJKWFRQGLtion. By contrast, after light therapy in control subjects, 
duration did not change; but onset, offset, and midpoint concentration changed as they did in 
PMDD women. When onset and offset was compared, the authors found that in PMDD women, 
light shifted melatonin offset time more than onset time, and that morning light had a greater 
effect on shifting melatonin offset, whereas evening light had a greater effect in shifting 
PHODWRQLQRQVHWWLPH7KHVHILQGLQJVUHSOLFDWHWKHDXWKRUV¶SUHYLRXVREVHUYDWLRQWKDW nocturnal 
melatonin concentrations are decreased in women with PMDD, and suggest specific effects of 
light therapy on melatonin circadian rhythms that are associated with mood changes in patient 
versus control groups. The different changes in melatonin onset and offset times during the 
PHQVWUXDOF\FOHDQGLQUHVSRQVHWRPRUQLQJDQGHYHQLQJEULJKWOLJKWFRPSDUHGZLWK³UHG´OLJKW
support a two-oscillator (complex) model of melatonin regulation in humans in which an evening 
oscillator determines the rise of melatonin levels in evening hours, and a morning oscillator 
determines fall in melatonin in morning hours. This is in contrast to a one-oscillator model, 
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which predicts that onset and offset times shift together in response to photoperiodic changes. 
Parry et al. (1997) propose that the findings observed in PMDD women suggest tighter coupling 
between morning and evening oscillators, which increases resistance to photoperiodic changes in 
the late luteal phase of the menstrual cycle. These findings suggest that low or decreasing levels 
of reproductive hormones in the LL phase of the menstrual cycle affect the visuo-perceptual 
systems involved in the regulation of circadian rhythms, and that women susceptible to 
symptoms of PMDD may experience these effects to a greater extent than women who do not. 
Thus, re-stabilization of circadian rhythms over the menstrual cycle may decrease the 
vulnerability of PMDD women to the environmental and/or hormonal disturbances that are 
implicated in the experience of mood and somatic symptoms near the end of the cycle. 
Sleep in women with premenstrual symptoms 
 Data from polysomnographic and survey studies indicate that definitive differences in 
sleep architecture across the menstrual cycles of normal women are lacking, and that many 
results are conflicting or inconclusive (Moline, et al., 2003). Despite age restrictions and small 
sample sizes, however, there is some evidence that suggests that women afflicted with PMDD 
exhibit variations in sleep architecture (see review by Parry, Martinez, Maurer, Lopez, Sorenson, 
& Meliska, 2006). Sleep complaints, either insomnia or hypersomnia, constitute one of the 11 
criteria listed in the DSM-IV (APA, 1994) required to meet a diagnosis of PMDD. Although not 
all 11 criteria are required to qualify for diagnosis (APA, 2000) sleep disruption is a criterion that 
is supported by Mauri (1990) who reported that women with premenstrual symptoms tend to 
complain of insomnia, hypersomnia, tiredness, fatigue, disturbing nightmares or dreams, 
lethargy, and inability to concentrate. 
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 Parry, Mendelson, Duncan, Sack, and Wehr (1989) provided initial direct EEG evidence 
of variations in sleep architecture between PMDD and non-PMDD women. The authors 
compared eight women with moderate to severe PMDD symptoms to eight non-PMDD women 
(controls) twice per week across one menstrual cycle and found that the PMDD subjects 
exhibited a greater percentage of stage two sleep with a corresponding lesser percentage of REM 
sleep than non-PMDD controls over the course of one four-week menstrual cycle. No between 
group effects were observed, however, with respect to cycle phase, or timing of temperature 
minima (based on normal cycle body temperature), all additional common physiological metrics 
associated with the menstrual cycle. 
In a later study using a larger sample size, Parry, Mostofi, LeVeau, Nahum, Golshan, 
Laughlin et al. (1999) examined the differences in sleep architecture between those with (n=23) 
and without premenstrual symptoms (n=18). EEG recordings were taken during baseline MF and 
LL menstrual cycle phases (days 6-10 after menses and 2-4 days prior to the onset of menses, 
respectively) and after early (03.00 h to 07.00 h) and late (21.00 to 01.00 h) sleep deprivation. 
No differences were found on sleep EEG measures between PMDD and non-PMDD controls, 
however, for both groups, EEG measures differed significantly according to menstrual cycle 
phase. Both PMDD and non-PMDD women demonstrated significantly longer REM latencies 
(time to onset of REM) with decreased REM sleep (minutes and percent) in their luteal phases. 
Other studies have found significantly shorter REM latencies during the luteal versus the 
follicular phase, but still no significant differences between PMDD and non-PMDD women 
(Lee, Shaver, Giblin & Woods,1990). Lee et al. (1990), however, did report that PMDD 
individuals show significantly less delta sleep in both the follicular and luteal phases of the 
menstrual cycle. With respect to delta sleep, Shibui, Uchiyama, Masako, Kudo, Kim, Kamei et 
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al. (1999) reported that subjective daytime (09.00-16.30 h) sleepiness and the number of slow-
wave sleep (SWS) containing naps significantly increases during the luteal phase suggesting that 
the increased number of daytime SWS-containing naps reflects a greater physiological demand 
for non-REM sleep during the luteal phase. The above results make it difficult to conclude that 
there are any consistent differences in sleep architecture between women with and without 
PMDD.  
 Given the inconsistencies in studies examining differences in sleep architecture between 
those with premenstrual affective symptoms and controls that do not have the affective 
symptoms, it is of interest to investigate methods that could more objectively delineate and 
distinguish substrate operations between groups. Many of the studies to date have been 
confounded by methodological flaws such as small sample size, variability in methods, an 
absence of hormonal markers to define menstrual cycle phase, subjective reports of symptoms, 
or failure to use standard diagnostic criteria (e.g., Parry et al., 2006).  
Visual Learning, Memory Consolidation, and Sleep 
 During the past decade, research has supported a role for sleep in memory consolidation.  
In humans, there is evidence that sleep assists in the consolidation of memory with respect to 
procedural, non-declarative (implicit) task performance (Stickgold & Walker, 2005). Perceptual 
learning is no exception to this theory. Defined as a change in performance due to training 
(usually as a performance improvement), perceptual learning tends to persist over weeks to 
months, thereby distinguishing it from the transient performance characteristics of sensitization, 
habituation or priming (Fahle, 2005). Perceptual learning is often task specific, and does not lead 
to conscious insights that can be easily communicated.  It is therefore considered to involve 
information retention of the procedural or implicit type (Fahle, 2005). 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      58 
Performance on a visual texture discrimination task typically demonstrates marked 
improvement with practice (Karni & Sagi, 1991). It has also been shown to suffer as a result of 
both REM and SWS deprivation (Karni, Tanne, Rubenstein, Askenasy, & Sagi, 1994). If women 
with PMS symptoms exhibit differential sleep architecture across the menstrual cycle, their 
performance on a texture discrimination task that relies on overnight sleep might reflect this 
sleep architecture distinction. In the texture discrimination task developed by Karni and Sagi 
(1993) participants were presented with a small target texture consisting of three diagonal line 
elements (textons) embedded within a similar background of horizontal oriented textons, and 
asked to identify whether the target textons were aligned together in a horizontal or vertical 
direction. Performance was measured as the mean percent correct response for increasingly 
shorter time intervals between the briefly presented stimulus and a patterned mask (i.e., stimulus 
onset asynchronies, or SOAs, used to diminish iconic persistence). The patterened mask  
consisted of randomly oriented V-shaped micropatterns and a central compound pattern of 
UDQGRPO\URWDWHGµ)¶FKDUDFWHUVXVHGWRPDVNWKHIL[DWLRQRIDµ7¶RUµ/¶HOHPHQW3V\FKRPHWULF
curves (percent correct vs. SOA) are then plotted to monitor the effect of learning over time. A 
shift of this curve to the left is indicative of task improvement and learning. Karni and Sagi 
(1993) noted that in nine participants, a period of eight hours (latent phase) post learning was 
required before any gains in performance were noted. The following day after a normal night of 
sleep however, participants showed significant performance improvements. These performance 
gains were comparable to those who had been privy to additional practice sessions during the 
latent phase, indicating that additional training during this time between initial learning and 
subsequent testing offered no distinct advantage. What is more remarkable than the endurance of 
this learned task was that performance decay was not evident for a period of months following 
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REM consolidation. For example, one participant maintained performance gains for 32 months 
after initial training. Thus, it would appear that REM-dependent memory consolidation with 
respect to procedural, nondeclarative tasks such as texture discrimination is a robust 
phenomenon that resists decay months after initial learning.  
Karni and Sagi (1993) suggested that the time required to demonstrate improvement (6 to 
8 hours) upon the texture discrimination task might reflect an active process underlying the 
consolidation of experience-dependent plasticity within the adult visual cortex. If this was indeed 
the case, theirs would have been the first study to demonstrate a high degree of plasticity within 
the human primary visual cortex that is relevant to our ability to improve and develop perceptual 
skills (Stickgold & Walker, 2005). The model they proposed was Hebbian in nature, which 
specified synaptic activity enhancement in areas associated with texture perception. The 
purported mechanism for this action is believed to involve the local, retinal input-dependent 
modifications of neuronal connections between orientation selective cells and gradient sensitive 
cells in Brodmann area 17. This is particularly noteworthy if the post-primary V1 cortical areas 
that are responsive to texture discrimination involve the hippocampus²a structure that has been 
associated with spatial navigation and is well-known for Hebbian-type synaptic plasticity (e.g., 
Lange-Asschenfeldt, Lohmann, & Riepe, 2007).  
Using the same task with slight modifications, Stickgold, Whidbee, Schirmer, Patel and 
Hobson (2000) evaluated task performance in two separate experiments. In the first experiment, 
participants were tested either on the same day of task performance training or on the day after. 
When testing occurred on the same day as training, no significant improvements in performance 
were noted. In addition, no improvements were observed as a function of time between training 
and test, which ranged from 3 to 12 hours. When testing was carried out on the subsequent day, 
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however, significant overnight improvement was observed for intervals of 9, 13, and 22.5 hours. 
Noteworthy is the fact that 12 hours of awake time was insufficient for producing a significant 
difference, but nine hours of sleep time was. No improvement was seen unless participants 
acquired at least 6 hours of sleep. These findings suggest that sleep plays a role in memory 
consolidation that affects learning and performance on basic perceptual tasks such as texture 
discrimination. 
In a second experiment, 27 participants were brought back to the lab to examine the 
effect of sleep stage dependency on task improvement (Stickgold et al., 2000). Although task 
improvement was noted after an interval of sleep (as in experiment one), when the amount of 
improvement was associated with the amount of REM sleep acquired by participants in the lab, a 
strong correlation was observed. Specifically the amount of REM acquired in the last quartile of 
the night had the greatest effect on improvement in task performance. However, a positive trend 
was also observed between SWS and task improvement. The authors hypothesized that increases 
in performance following REM and SWS were not mutually exclusive. This is because 
participants deprived of either REM or SWS (but not both) did not exhibit as much improvement 
on the task as participants who acquired both stages of sleep. Given that the last quartile of REM 
appeared to exert the greatest influence on performance, these results led Stickgold et al. (2000) 
to propose a two-step model postulating that the amount of SWS acquired in the early evening, 
enhances REM-dependent memory consolidation in the last quartile of the night.  Their two-step 
model of memory consolidation posits that a sequence of neurological events must occur that is 
mediated by REM and SWS. 
Evidence derived from human and primate studies suggests that levels of circulating 
ovarian steroids can alter cognitive tasks. For example, in humans, several studies have reported 
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higher verbal fluency, but poorer spatial skills during periods of high estrogen levels, and 
improved spatial skills and lower verbal skills when estrogen levels are low (see review by 
Lacreuse, 2006). This seemingly contradicts previous rat and mice studies which showed that 
higher estradiol levels promote hippocampal dendritic arborization (e.g., Wooley, Weiland, 
McEwen. & Schwartzkroin,1997). However, compensatory or alternate mechanisms and/or 
interactions between estrogen and other neurotransmitter systems that exert their effects at higher 
levels within the brain (e.g. cortex) may account for these differences. It is also possible that 
subtle differences in the tasks used in the animal and human research may account for the 
differential findings.   
In a recent study examining the effect of ovarian suppression on cognition, Craig, 
Fletcher, Daly, Picchioni, Brammer, Giampietro, et al. (2008) induced a pseudo-menopausal 
state in 17 premenopausal healthy women using a gonadotropin hormone releasing hormone 
agonist (GnRHa). They then used event-related fMRI to examine the effect of GnRHa on visual 
working memory (VWM) as measured by the Delayed Matching to Sample (DMTS) test adapted 
from the Cambridge Neuropsychological Test Automated Battery (CANTAB). This test requires 
that participants match a complex abstract pattern (encoding phase) to one of four possible 
choices presented simultaneously (recognition phase) following a delay. Neuroimaging outcomes 
were assessed in experimental participants and age-matched controls at baseline and eight weeks 
after GnRHa treatment. Although no significant effects were found for recognition time, group 
interaction results revealed that GnRHa treatment was associated with attenuation of left 
parahippocampal and middle temporal gyri activation during the DMTS task. The results of this 
study indicate that ovarian hormone withdrawal may lead to reduced activation in these brain 
circuits among which includes the hippocampus. Thus, compared to controls, women who are 
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more sensitive to normal ovarian hormone fluctuations may exhibit changes in task performance 
involving memory and/or spatial navigation at different points in the menstrual cycle. 
 Task Performance and Premenstrual Symptoms 
Few studies have documented differences in task performance between women with and 
without PMDD or PMS, especially with respect to visuo-perceptual operations. With respect to 
cognitive performance, Reed, Levin, and Evans (2008) reported that compared to controls, 
women with PMDD showed impaired performance on the Immediate and Delayed Word Recall 
Task, the Immediate and Delayed Digit Recall Task, and the Digit Symbol Substitution Test in 
the luteal phase of the menstrual cycle. Other studies have found little difference between 
women with PMDD and normal controls on various neuropsychological tests (Resnick et al., 
1998). However, subtle differences have been reported in the areas of psychomotor speed.  
Resnick et al. (1998) evaluated neuropsychological functioning in women with and 
without PMDD across the domains of psychomotor speed, attention, and verbal learning and 
memory. The results of their study indicated that women meeting DSM-IV criteria for PMDD 
exhibit psychomotor slowing during the late luteal phase days of their menstrual cycles 
compared to their performances during the asymptomatic follicular phase (days 5 to 10 of the 
menstrual cycle). Psychomotor speed was assessed using five tests including the Digit Symbol 
Subtest of the Wechsler Adult Intelligence Scale Revised, the Grooved Pegboard Test , the Digit 
Vigilance Test, and the two-part (A and B) Trail Making Test. Furthermore, the trend of 
psychomotor slowing remained significant when the performance of women with PMDD was 
compared to that of women with subclinical (mild to moderate) PMS symptoms. 
Attentionally, women with PMDD have recently been found to exhibit lower levels of 
prepulse inhibition (PPI). PPI occurs when a relatively weak sensory event, or prepulse, is 
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presented 30±500 ms before a strong startle inducing stimulus, and reduces the magnitude of the 
startle response (Braff, Geyer, & Swerdlow, 2001). In humans, PPI occurs in a robust, 
predictable manner when the prepulse and startling stimuli are presented using either the same or 
different modalities (i.e., acoustic, visual, or cutaneous) (Braff et al., 2001). Kask, Gulinello, 
Backstrom, Geyer, and Sundstrom-Poromaa (2008) compared PPI in women with and without 
PMDD using the eyeblink component of the acoustic startle response. Their experimental 
protocol consisted of a 115 decibel (db), 40 millisecond (ms) noise preceded at a 100 ms interval 
by 20 ms prepulses that were either 72, 74, 78, or 86 dB. Their results indicated that women with 
PMDD exhibited a significantly higher startle response (lower PPI) than controls during both 
phases of the menstrual cycle. PMDD patients exhibited lower levels of PPI with 78 dB and 86 
dB prepulses compared to control subjects in the luteal, but not in the follicular, phase. 
Additionally, whereas non-PMDD participants displayed increased PPI during the late luteal 
phase compared to the follicular phase, PMDD women showed stable PPI magnitudes across 
their reproductive cycles. Relative to controls, PMDD patients displayed increased startle 
reactivity (lower PPI) across both menstrual cycle phases and significant deficits in prepulse 
inhibition of acoustic startle during the late luteal phase.  PPI deficits have been associated with 
perceptual abnormalities, increased anxiety, and difficulty inhibiting intrusive thoughts (Braff et 
al., 2001). The authors state that the observed PPI response in women with PMDD could be 
attributed to the combined effects of estrogen and progesterone and their interactions in the CNS. 
For example, they report that progesterone can be metabolized to GABA-active neurosteroids, 
such as allopregnanolone (ALLO), which then bind to the GABAA receptor.  Specifically, ALLO 
has been found to enhance inhibitory neurotransmission, consequently exerting anxiolytic, 
sedative, and antiepileptic effects (Kask et al., 2008).  Thus, these results may reflect an aberrant 
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response in the GABA mediated inhibitory system in women with PMDD. This disruption could 
manifest itself in several different ways including: deficiencies in overall levels of ALLO, or the 
enzyme responsible for the metabolism of progesterone to ALLO; reduced sensitivity to ALLO, 
down-regulation of the GABAA receptor, or disrupted binding of ALLO to the GABAA receptor. 
 The results of Kask et al. (2008), are consistent with those of Epperson, Pittman, 
Czarkowski, Stiklus, Krystal, and Grillon (2007) who examined acoustic startle response (ASR) 
in women with the added condition of emotional valence, which has been found to either 
augment or diminish the magnitude of its effects. Thus, women, both with and without PMDD, 
were shown pleasant, neutral, or unpleasant pictures while undergoing the ASR procedure.  
Testing took place at the mid-follicular (days 5 to 11 of the menstrual cycle) and mid-luteal (1 to 
7 days prior to the onset of menses) phases of the menstrual cycle. Results indicated that PMDD 
was associated with a clear increase in baseline startle magnitude in the luteal phase compared to 
the follicular phase, while healthy female controls did not show cyclic changes in this measure of 
physiologic arousal. The direction and degree to which picture viewing modulated the startle 
magnitude did not vary by group or menstrual cycle phase. The results of the ASR studies 
suggest that menstrual cycle phase exerts a modulatory effect on physiologic reactivity in women 
with PMDD, but not healthy women. Specifically, women with PMDD show more physiological 
reactivity during the late-luteal phase. Taken together, the results of the PPI and ASR studies 
indicate that lower or changing levels of reproductive steroids may interact with other 
neurotransmitter systems such as the GABAergic system in a way that interferes with the normal 
inhibitory actions of certain physiological and perceptual systems. 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      65 
The V isual Perceptual System in Brief 
As previously noted, the production and secretion of melatonin are mediated largely by 
postganglionic retinal nerve fibers, which themselves are largely responsible for the transmission 
of information regarding the daily pattern of light and darkness. Thus, mechanisms within the 
visual system are critical in regulating the availability of melatonin and the sleep/wake cycle. 
Given that sleep problems accompany mood disruptions in many psychological disorders 
including PMDD, it is plausible that individuals with these disorders also have functional 
distinctions associated with the visual system, both with the more vegetative, nonperceptual 
pathways (i.e., retinotectal and retinohypothalamic pathways) and those associated with higher-
end visual perception (i.e., retinogeniculostriate pathways). 
With regard to the latter, in human and non-human primates, it was previously espoused 
that two populations of retinal ganglion cells transmit signals to V1 by way of a relay through 
two sets of layers in the Lateral Geniculate Nucleus (LGN). Midget and parasol ganglion cells 
send separate projections to parvocellular (PC) and magnocellular (MC) layers of the LGN, 
respectively which in turn, innervate striate cortex (VI) (Hendry & Reid, 2000). 
Electrophysiological studies suggest that the MC streams communicate information relevant to 
higher-ordered movement and depth perception, while the PC stream communicates information 
relevant to higher-ordered shape, colour, and form perception (Livingstone & Hubel, 1988). 
More recently, a third visual stream with projections interleaved between PC and MC layers in 
the LGN has been identified (Hendry & Reid, 2000). 
 Research on this newly elucidated third visual stream, or koniocellular (KC) stream has 
begun to garner attention since its discovery (Hendry & Reid, 2000). The KC stream appears to 
EHLQYROYHGSULPDULO\ZLWKFRORXURSSRQHQF\DVLWVSHFLILFDOO\UHODWHVWR³EOXH-\HOORZ´FRORXU
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discrimination, although it may also provide feeds to other types of retinal circuitry that underlie 
a contribution to the cortical areas involved with motion discrimination (Calkins, 2001). Colour 
vision in humans can be attributed to the activation of three types of cone photoreceptors which 
are maximally sensitive to short, medium, and long wavelengths. Upon activation, signals from 
each of these cone types are relayed to retinal ganglion cells (RGCs) via cone-specific bipolar 
cells (Reid & Shapley, 1992). Signals for the KC system originate mainly from short-
wavelength-sensitive (S) cones, which have been shown to respond optimally to wavelengths 
ranging from 419 to 433 nm (see review by Calkins, 2001). Unlike the long-wavelength-
sensitive (L) and middle-wavelength-sensitive (M) cones, the opponent S-cones are less common 
and constitute only 5 to 10 percent of the total cone population (Curcio & Hendrickson, 1991). 
Retrograde tracing and intracellular recording techniques have revealed that the S-ON/(M+L)-
OFF signal input into the LGN originates from the small bistratified retinal ganglion cells (Dacey 
& Lee, 1994; Martin, White, Goodchild, Wilder, & Sefton, 1997), bypassing layers IV of V1 that 
UHFHLYHLQSXWIURP3&³UHG-JUHHQ´FKURPDWLFRSSRQHQWVLJQDOV7KHVHELVWUDWLILHG5*&VOLH
within and between the parvocellular and magnocellular layers, and have been shown in the 
macaque to project directly to the colour selective blobs in V1 (Martin et al., 1997). Dacey and 
/HHVWDWH³WKHGLVWLQFWLYHPRUSKRORJ\RIWKHVPDOOELVWUDWLILHGFHOOVVXJJHVWVDVSHFLILFQHXUDO
FLUFXLWU\WKDWPD\JLYHULVHWR³EOXH-\HOORZ´FRORXURSSRQHQF\´'DFH\	/HHS). 
Through these cells, S-cones are responsible for the S-ON component of the S-ON/(M+L)-OFF 
portion of colour opponency. The (M+L)-OFF process occurs when the signals from L and M-
cones converge at the ganglion cell level and offset the input from the S-cones (Dacey & Lee, 
1994).  
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*LYHQWKDWWKH.&VWUHDPLVUHVSRQVLEOHIRU³EOXH-\HOORZ´RSSRQHQF\DQGPD\EH
associated with a distinct neural circuit responsive to short wavelengths, advances in colour 
vision and theories tied to the neurological processes that underlie them have been greatly 
extended by the invention of short-wavelength automated perimetry (SWAP). SWAP, or "blue-
on-yellow" perimetry, is a visual field test designed to assess early visual field loss in several 
conditions including glaucoma, retinitis pigmentosa, and diabetes. As implied by the name, 
SWAP makes use of a short-wavelength target (i.e., 440 nm) to assess visual field loss. The use 
of a bright 100 cd/m2 "yellow" background saturates the rods as well as the L and M cones. 
Therefore, this test primarily activates only the S-cones and their associated small bistratified 
ganglion cells (Sample, 2000). In terms of psychophysical research, SWAP provides a valuable 
measure of S-FRQHRSHUDWLRQVDQGFRQVHTXHQWO\WKH³XSIURQW´.&VWUHDPKHalth and 
functionality. 
The tracking of visual stimuli is achieved via the concurrent coordination of the saccadic 
(SAC) and smooth pursuit eye movement (SPEM) systems. Srihasam, Bullock, and Grossberg 
(2008) report that the SAC eye movement system generates rapid, temporally spaced open loop 
processing signals that cancel the difference between an initial angle of gaze and the angle 
necessary to foveate a target, while the SPEM system generates continuous, moderate-velocity, 
closed-loop signals that prolong foveation of mobile goal stimuli by trying to match gaze 
velocity to stimulus velocity. For rapidly moving stimuli, prolonged foveation requires 
UHHQJDJHPHQWRIWKH6$&V\VWHPWRJHQHUDWHµµFDWFK-XS¶¶VDFFDGHV%RWKV\VWHPVPXVW
coordinate their actions such that the same target stimulus is selected and maximum visibility is 
achieved (Srihasam et al. 2008). An elegant summary of the neurophysiology and neuroanatomy 
of the SPEM system is provided by Lencer and Trillenberg (2008). During smooth pursuit eye 
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tracking, the retinal image of the stimulus target is encoded and projected from the LGN to 
neurons in V1 that respond to motion signals from moving objects. The receptive fields of 
neurons in V1, however, are small, and interpretation of target information requires the 
recruitment of neurons from both the middle temporal (MT) and medial superior temporal areas 
in MT (V5). While MT neurons have been found to respond to speed, acceleration, and direction 
of moving stimuli, neurons in MST are optimally active when an individual is performing 
smooth pursuit tasks (see review by Lencer and Trillenberg, 2008). Area V5 is therefore 
recognized as a key area responsible for control in smooth pursuit tasks. From V5, signals are fed 
forward to the frontal eye field (FEF) from which the occulomotor command for smooth pursuit 
tasks is generated. Thus, posterior brain regions such as V5 are responsible for stimulus detection 
and response to motion, while frontal areas, through control of ocular muscles, are responsible 
for the maintenance of pursuit, as well as smooth pursuit initiation and prediction. Pursuit-related 
neural activity is reliably observed in the rostral regions of superior colliculus (rSC) which 
contain cells that respond to both SPEM and SAC eye movements (Krauzlis, Basso, & Wurtz, 
2000). The cortical MT area sends strong excitatory projections to via rSC (Collins, Lyon, & 
Kaas, 2005), to the pontine nuclei, which in turn provide information to the cerebellum. Two 
cerebellar regions, the paraflocculus/flocculus and posterior vermis, involved in the coordination 
of pursuit and vestibular-ocular reflex and precise adjustments of the eye movements such as 
adaptation of pursuit information respectively then direct outputs to the motor neurons of the 
extra-ocular muscles in the brainstem (Ilg & Their, 2008). Thus, procedures such as eye tracking 
are of relevance in that they suggest specific neural networks that are potentially affected by 
hormones such as estrogen. 
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Estrogen and S-cone Functionality 
 In the last few years, evidence has accumulated indicating that estrogen may play a role in 
modulating the koniocellular visual stream. Using a desaturated D-15 test, a test that assesses 
fine colour discrimination for congenital and acquired colour vision defects, Gorin, Day, 
Constantino, Fisher, Redmond, Wickerham et al. (1998) reported that women who had used 
tamoxifen, an orally active selective estrogen receptor modulator (SERM), for many years 
tended to have poorer colour discrimination capabilities than women who had never used 
tamoxifen.  
 Additional studies have examined the effects of estrogen on the KC stream by using groups 
consisting of women with varying degrees of circulating estradiol. Eisner et al. (2004a) designed 
a study to evaluate the hypothesis that hormonal change can affect retinally-based lower level 
light-adaptation processes. Foveal visual sensitivities were measured across three consecutive 
menstrual cycles of four women not using hormonally acting medication and across three 
consecutive menstrual cycles of three women using the triphasic oral contraceptive, Ortho 
Tricyclen®. Ortho Tricyclen® is comprised of two synthetic hormonal agents, one of which 
varies in dose from week one to week three.  Women generally take one per day over a 28-day 
cycle. In one 28-day package, tablet numbers 1 to 21 each contain 0.035 mg ethinyl estradiol, 
while tablet numbers 1 to 7 each contain 0.180 mg of norgestimate, tablets 8 to14 each contain 
0.215 mg norgestimate, and tablets 15 to 21 each contain 0.250 mg norgestimate. Tablets taken 
from days 22 to 28 contain inert compounds. One woman, diagnosed with premenstrual 
syndrome (PMS), was a subject in both groups. Sensitivities were measured for a series of test 
wavelengths. During the testing procedure, both 2.0 and 4.0 log td background illuminances 
were employed. To assess threshold versus illuminance effects, the background illuminances 
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ranged from 1.2 log td through 4.4 log td in 0.4 log unit steps.  Test wavelengths of 440, 460, 
490, 510, 540, 580 and 640 nm were presented with 2.0 and 4.0 log td, 580-nm backgrounds. All 
test stimuli were presented at 1.5 Hz using a 50% square-wave duty cycle. Thresholds were 
detected using a method of limits in which the test illuminance was incremented in 0.06 log unit 
steps until women responded by pushing a button indicating that they detected the stimulus. 
After each threshold setting, test illuminances were decreased by 0.6 - 1.0 log units 
pseudorandomly. Of the six individuals tested, one had clear evidence of visual-adaptation 
changes occurring in phase with the menstrual cycle. Prior to using the oral contraceptive, this 
individual (the PMS subject) experienced S-cone sensitivity changes of up to 1.4 log unit on the 
4.0 log td background (580 nm). Her S-cone sensitivities tended to be highest near ovulation and 
lowest premenstrually, indicating that higher levels of estrogen may promote enhanced 
discrimination with respect to the S-cone system and that the magnitude of these changes may be 
affected by the use of triphasic hormonal contraceptives.  
 Additional evidence for the role of estradiol in altering visual stream functionality comes 
from studies on women taking tamoxifen. As previously described, tamoxifen is a selective 
estrogen receptor modulator (SERM) that is used as adjuvant therapy for early stage breast 
cancer. It acts by competitively binding to estrogen receptors on tumors and other tissue targets; 
thereby preventing stimulation at the nuclear level and the subsequent proliferation of steroid-
induced protein pURGXFWLRQV\QWKHVLVDQGVHFRQGPHVVHQJHUV\VWHPV2¶0DOOH\ 
The first study, conducted by Eisner and Incognito (2006), employed two groups 
consisting of women using tamoxifen as adjuvant therapy following successful treatment of early 
stage breast cancer (n=54; 30 reporting use for less than two years, and 24 reporting use for more 
than two years), and healthy amenorrheic peri-or post menopausal control subjects not using any 
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hormonally acting medications (n=32). A three-alternative forced-choice paradigm was used for 
assessing the perceived colour appearance of a 440 nm foveal test stimuli superimposed on a 
larger 3.6 log td, 580 nm background. In contrast to the control subjects, who indicated that the 
WHVWVWLPXOXVDSSHDUHG³ZKLWH´RIWKHWLme, 87.5% of long-term tamoxifen users indicated 
that the test-VWLPXOXVDSSHDUHG³ZKLWH´7KHVHUHVXOWVLQGLFDWHWKDWVLPSOHFRORXUSHUFHSWLRQ
processes may be altered in women with low levels of estrogen receptor binding. 
 Similarly, Yucel,  Akar, Dora, Akar, Taskin, and Ozer (2005) examined the effects of the 
PHQVWUXDOF\FOHRQVWDQGDUGDFKURPDWLFDQG³EOXHRQ\HOORZ´ILHOGDQDO\VLVRIZRPHQZLWK
migraine. Using standard achromatic automated perimetry (SAP) and SWAP, the authors 
examined both eyes of 73 normally menstruating women (31 subjects with migraine and 42 
healthy control subjects). Participants underwent a complete SAP and SWAP analysis in both the 
follicular and luteal phases of two consecutive menstrual cycles. In both groups, serum estradiol 
levels were significantly lower and serum progesterone levels were significantly higher during 
the luteal phase (one to two days prior to the onset of menses) than during the follicular phase 
(days 12-13 of menstrual cycle) as measured by basal blood samples drawn from the antecubital 
vein. For the non-migraine control group the mean sensitivity values with SWAP were 
significantly lower in the luteal than the follicular phase. A similar decrease was observed for the 
migraine group. The fact that estradiol levels were lower in the luteal phase provides additional 
evidence that low levels of estradiol are associated with decreased short-wavelength sensitivity. 
It also provides evidence for hormonal influences on retinal sensitivity given that visual field 
tests generally ascertain low-end functionality. This study differs from the present study, 
however, as the average age of participants was older (all aged between 30 and 39) and those 
with a history of severe PMS or PMDD were screened out. As well, women with migraine may 
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possess visual field anomalies not seen in control women or women without a history of 
migraine headaches. Thus, these findings make it somewhat difficult to infer hypotheses for the 
present study. 
It was previously assumed that retinal photoreceptors were the only structures that were 
capable of interpreting and transmitting signals related to wavelengths within the visual 
spectrum. This has been challenged based on the discovery of intrinsically photosensitive retinal 
ganglion cells (ipRGCs), a class of retinal ganglion cells that are capable of being activated by 
certain wavelengths without traditional photoreceptor input (e.g., Panda, Provencio, Tu, Pires, 
Rollag, Castrucci et al., 2003). These ipRGCs are not only believed to be the prime candidate for 
visual modulation of circadian rhythms based on neurophysiological, electrophysiological, and 
genetic studies, but they may also be critical to the production of melatonin (Rea, Figueiro, & 
Bulloch, 2005). Recent studies suggest that the classical photoreceptors may moderate output 
from ipRGCs (Brainard & Hanifen, 2005; Dacey, et al., 2005; Panda et al., 2003). Originally, 
this moderation was thought to occur at the retinal level or at various points of neural 
convergence along the visual streams. Among the classical photoreceptors, the S-cones are of 
particular interest as they share similar peak sensitivities (i.e., 440 nm) as ipRGCs. Moreover, 
cellular recordings have shown that when the S-cone bipolar is stimulated with short wavelength 
radiation, it contributes to the excitatory depolarizing response of the ipRGC through a bipolar 
RGC synapse in the proximal ON layer of the IPL. 
The moderating input of ipRGCs on known retinal photoreceptors (rods and cones) was 
shown by Panda and colleagues (2003). In this study, groups of genetically engineered mice 
were observed to respond disparately to artificial circadian conditions. Because there is evidence 
that suggests melanopsin-deficient mice retain most non-visual photic responses, the authors 
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hypothesized that either there is another class of photoreceptor present or, there are contributions 
from the classical photoreceptors to non-visual responses. To test this hypothesis, mice deficient 
in melanopsin and classical photoreceptors were engineered. These mice were then compared to 
wild type mice, mice lacking melanopsin only, and mice lacking classical photoreceptors only. 
The assessment of circadian entrainment was achieved by subjecting all groups of mice to a 24 
hour light-dark cycle (8 hours light and 16 hours dark) while monitoring wheel running activity. 
Wild-type mice, melanopsin-deficient mice, as well as mice lacking classical photoreceptors all 
entrained normally and consolidated their wheel running activity to the dark period of the 
prescribed cycle. Mice lacking both melanopsin and classical photoreceptors, however, failed to 
do so, and continued to exhibit free-running rhythms. Increasing the light photoperiod and light 
intensity also failed to produce entrainment in this group of mice. Panda et al. (2003) concluded 
that there must be at least partial functional redundancy between classical rods and/or cones, and 
the melanopsin containing ipRGCs, as mice lacking one of the two types of receptors were still 
able to transduce photic information to critical brain areas important for the measured rhythmic 
behaviors. The substantial overlap that exists between symptoms of SAD and PMDD, and the 
differential results observed in studies assessing biorhythmic profiles of women with PMDD 
(such as those examining melatonin rhythms) suggest that women with PMDD may possess 
visual perceptual deficits that could be assessed by further investigation of their visual pathways, 
specifically with respect to the S-cone (KC) pathway.  
Gender Differences in the V isual System 
 Although there are few studies examining gender differences on tasks specific to the 
visual functioning, there is some evidence that suggests morphological differences between 
males and females. Nuñez, Sodhi and Juraska (2002) reported that ovarian hormones introduced 
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after day 20 of the rat life cycle lead to an irreversible and critical loss of V1 cortical neurons, 
indicating an organizational effect of reproductive steroids during the peripubertal period in the 
binocular areas Oc1m and Oc1B. In an earlier study, Nuñez, Jurgens, and Juraska (2000) 
observed that neonatal androgens had an inhibitory effect on developmental cell death in rat 
primary visual cortex. Sexual dimorphism has also been observed in the retina. Salyer, Lund, 
Fleming, Lephart, and Hovarth (2001) showed than control male rats and female rats treated with 
testosterone had significantly larger retinal thicknesses than control female rats. The observation 
that estrogens are capable of exerting morphological changes throughout various levels of the 
visual system is interesting as it suggests a broader influence of reproductive steroids on the 
visual system and potential differences in perception as the result of hormonally mediated events 
such as the menstrual cycle, especially in those with PMS symptoms who may be suprasensitive 
to such changes.   
The Present Study 
The anomalous circadian responses observed with respect to melatonin release and 
secretion, and the differences in sleep parameters and sleep architecture sometimes reported in 
women with PMDD suggest that these women may suffer from a deficit in circadian 
entrainment. This hypothesis is further substantiated by the fact that patients with PMDD appear 
to respond to light therapy (Lam et al., 1999). The recent discovery of the short-wavelength 
sensitivity of the KC stream and the influence it may exert on ipRGCs suggests that these 
systems are worthy of examination in the PMDD population. Moreover, the performance of 
individuals with PMDD on tasks such as visual texture discrimination, which involves learning 
and plasticity contingent upon the acquisition of REM sleep, could serve to contribute to or 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      75 
clarify mixed findings with respect to data obtained solely from the examination of sleep 
architecture in this group of women.  
The present study sought to elucidate additional behavioral evidence implicating the 
potential neurological mechanisms through which hormonal levels (e.g. estradiol) and/or 
sensitivity may moderate visual perceptual functioning. We seek to test the theory that 
reproductive steroids such as estradiol exert functional or modulatory effects on the visual 
system using two groups of women. Given that women with PMS symptoms are hypothesized to 
be hormonally sensitive, we would expect that the visual systems of such women may respond 
differently to changes in hormonal levels that those of control women. Thus, in addition to 
examining the effects of hormonal changes on the visual system using menstrual cycle phase, we 
use a group of women with PMS symptoms to investigate whether any changes manifest 
differentially in a population that is hypothesized to be especially sensitive to such hormones.    
This was accomplished through the use of psychophysical tasks designed to examine both higher 
cortical perceptual and lower retinal functioning at two intervals across the menstrual cycle. At 
points in both the LF and LL phases, women with and without PMS symptoms were invited to 
FRPSOHWHPHDVXUHVRIFKURPDWLFFRQWUDVWVHQVLWLYLW\&&6EDVHGRQ³EOXH-\HOORZ´WULWDQ-
PDWFKHGDQG³UHG-JUHHQ´GHXWDQ-matched, near-isoluminant spatial patterns of varying spatial 
frequencies, (2) an assessment of SWAP, (3) measures of texture discrimination involving spatial 
tasks designed to assess steroidal influences on V1 plasticity, and (4) a smooth pursuit eye-
tracking procedure. The eye-tracking procedure was used as a tool to explore the potential link to 
REM disturbance in women with PMS symptoms, as well as to examine any deficiencies in 
retinal, extrastriate, and retinotectal smooth pursuit oculomotor operations. In addition to 
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completing the above tasks, measures of estradiol were obtained for the purposes of examining 
the influence of estradiol, and objectively determining menstrual cycle parameters. 
During the CCS procedure, neDULVROXPLQDQWELFKURPDWLF³EOXH-to-\HOORZ´RU³UHG-to-
JUHHQ´SHDNWRWURXJK sinusoidal gabor gratings were presented to assess cortical KC and PC 
stream functionality, respectively. Three different gabor orientations were also used to better 
isolate cortically-based chromatic orientation selectivity. We predicted that all groups would 
show increased chromatic contrast sensitivity in the LF phase as opposed to the LL phase (phase 
effect) (hypothesis 1), with women with PMS symptoms potentially exhibiting higher (overall) 
sensitivities than control women (group effect) (hypothesis 2). This would be in keeping with the 
findings of Wesner and Tan (2006) and Wesner and Pavlou (2008), whose results demonstrated 
heightened KC and PC contrast sensitivity in those with MDD and SAD. With respect to SWAP 
measurements, we hypothesized that both women with PMS symptoms and normal control 
women would exhibit lower short-wavelength sensitivity in the LL phase of the menstrual cycle 
when compared to the LF phase (hypothesis 3). In keeping with this hypothesis, however, it was 
further posited that women with PMS symptoms might exhibit differential sensitivities compared 
to control women in both phases (hypothesis 4), owing to a potentially heightened response to 
increases and decreases in levels of serum estradiol. Specifically, we hypothesized that that 
women with PMS symptoms would demonstrate higher S-cone sensitivity than controls during 
the peri-ovulatory, LF phase, and a lower short-wavelength sensitivity during the LL phase, 
when levels of estradiol decrease dramatically. 
Given that learning acquired during an initial session of texture discrimination 
demonstrates resistance to decay (Karni & Sagi, 1993), testing sessions after training occurred 
not on subseqXHQWGD\VEXWUDWKHURQGD\VPDWFKHGWRWKHSDUWLFLSDQW¶VDSSURSULDWHPHQVWUXDO
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cycle phase (e.g., LL and LF). Should REM sleep differ amongst those with PMDD, as was 
found by Parry et al. (1989), we predicted, similar to the observations of Stickgold et al. (2000; 
2005) and Stickgold and Walker (2006), that individuals with PMS symptoms might express 
deficiencies in overnight, texture-dependent learning tasks (group effect; hypothesis 5), thereby 
providing further support for a potential melatonin, and/or ovarian, steroid-based aberrant sleep 
cycle. Whether hippocampal modulatory differences, visual stream abnormalities, or 
combinations thereof mediate this was examined through the different hierarchical processing 
stages tied uniquely to the tasks described above. 
Finally, with respect to the eye-tracking procedure and in accord with the findings of 
Kask et al. (2008) and Epperson et al. (2007) we hypothesized that compared to controls, women 
with PMS symptoms would exhibit a deficit in eye-tracking performance that may be more 
pronounced during the LL phase of the menstrual cycle (group x phase effect; hypothesis 6). 
Although findings between women with and without PMS symptoms are mixed with respect to 
sleep architecture, the observation that women exhibit altered sleep parameters such as longer 
REM latency and less time in REM during the LL phase suggests that normal, phasic, hormonal 
changes may affect the neural circuits responsible for circadian functioning. The observation that 
women with PMS symptoms have been shown to exhibit lower PPI and psychomotor slowing on 
tests of neuropsychological functioning, as well as disruptions in rapid, lateral eye-movement 
(REM sleep) warrants investigation into oculomotor functioning and steroidal influences on 
underlying relevant smooth pursuit retinal and extrastriate pathways.  
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Method 
Participants 
One-hundred-and-eighty women (mean age = 21.16 years, SD = 5.23 years) from 
Lakehead University and the local community were recruited to participate in a study 
investigating :RPHQ¶V+HDOWKDQG9LVXDO)XQFWLRQLQJfollowing approval by Lakehead 
8QLYHUVLW\¶VUHVHDUFK(WKLFV%RDUG5(%. The majority of these women were students recruited 
from introductory and upper level psychology courses. Those in introductory psychology courses 
received one bonus point of course credit for participation in the screening phase of the study. 
Women meeting the criteria necessary to participate in the laboratory phase of the study received 
up to two additional bonus points (one per lab session). 
Based on information provided by the screening questionnaire, 34 women (mean age = 
22.37 years, SD == 6.42 years) ranging in age from 18 to 44 years were recruited for the 
laboratory phase of the study. These women were representative of two groups: (1) a group of 16 
women who reported the experience of adverse physiological and psychological symptoms 
approximately one week prior to the onset of menses (PMS group) and (2) a control group of 18 
women who reported a comparatively low level of such symptoms. Women were initially 
selected into the above groups based on their scores from the Menstrual Distress Questionnaire 
(MDQ) (Moos, 1968) and a questionnaire developed by the authors assessing DSM-IV criteria 
for PMDD, with women scoring highest selected into the experimental PMS group. Specific 
criteria for group classification are provided below.  Excluded from participation were: (1) 
women meeting criteria for a current major depressive episode as assessed by the Hamilton 
Rating Scale for Depression (HRSD) (details below), (2) women who reported the use of 
psychotropic medication(s) at the time of screening, (3) women with irregular menstrual cycles, 
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(4) women who were currently taking hormonal contraceptives or had taken them within the past 
six months, SUHJQDQWZRPHQZRPHQZKRWHVWHGDV³UHG-JUHHQ´RU³EOXH-\HOORZ´FRORXU
blind (assessed in laboratory session one), and (7) women with ophthalmological disorders (e.g., 
glaucoma, retinitis pigmentosa, optic neuritis, etc..). Women who endorsed a history of anxiety 
or depression, but who had not sought pharmacological or psychological treatment within the last 
six months were eligible for inclusion. All efforts were made to select women with regular 
(predictable) menstrual cycles (e.g. women for whom the onset of menses could be reliably 
predicted within one to two days) based on their responses to such a question on the 
questionnaire. All women had normal or corrected-to-normal near visual acuity. 
Measures 
 Screening Questionnaire (SQ). The screening questionnaire (SQ) (see Appendix A) 
included several different sections, but was primarily used to select the two groups of women for 
the study: (1) women reporting high levels of PMS symptoms, and (2) a control group of women 
reporting low levels or an absence of PMS symptoms; none of whom reported the use of 
hormonal contraceptives. Other sections of the SQ provided information regarding psychiatric 
diagnoses, demographics, reproductive history, contraceptive history, medical and health history, 
morning/evening preference, and caffeine consumption. Many of the questions were adapted 
from questionnaires developed for two previous projects on hormonal effects (Oinonen & 
Mazmanian, 2007; Oinonen, 2009), as reliability and validity statistics were available. The 
demographic section included questions relating to age and education. Medical and health 
history questions provided information regarding height, weight, known medical and hormonal 
conditions, medication use, and family history of hormonal medical conditions (e.g., thyroid 
disorders, diabetes, breast cancer) and fertility problems. Additionally, participants were asked if 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      80 
they had ever been diagnosed with a psychiatric illness; or treated with psychotherapy, 
pharmaceutical agents, or a combination of the two. Reproductive history was assessed with 
questions regarding age of menarche, parity, length of menstrual cycle, length of menses, 
premenstrual symptoms, time of last menstrual period, and cycle regularity. The contraception 
section contained questions about contraceptive use (e.g., type), and duration of use, as well as 
specific questions concerning the experience of certain OC side effects, including positive and 
negative mood change.  
Symptoms of PMS were assessed using the Menstrual Distress Questionnaire (MDQ) 
(Moos, 1968) and a 33-item measure of PMS severity created for this study: The Lakehead 
Inventory of Premenstrual Symptoms (LIPS). In order to ensure that the two groups were not 
confounded by additional current diagnoses, the Hamilton Rating Scale for Depression 
(Hamilton, 1960) was included to screen for Depression. Scores from the Beck Anxiety 
Inventory (BAI) (Beck, 1990) were also examined as a post-hoc check to ensure groups did not 
differ in terms of anxiety, but were not used initially to screen women into groups. Participants 
meeting criteria for depression at the time of screening were excluded from experimental 
procedures. Finally, the Seasonal Assessment Pattern Questionnaire (SAPQ) (Rosenthal et al., 
1984) was included to collect information on seasonal patterns of mood disturbance. Items from 
this questionnaire will be correlated with items on both measures of PMS for use in subsequent 
investigations.  
Menstrual Distress Questionnaire (M D Q). The MDQ (Moos, 1968) consists of 47 
items, each of which is rated on a five-point scale from 0 (no experience of the symptom) to 4 
(present/ severe) with respect to either current experiences (MDQ-T) or experiences during three 
phases (menstrual, intermenstrual, premenstrual) of the most recent cycle (MDQ-C). The MDQ 
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consists of eight scales derived from empirically distinct, although correlated, sets of symptoms. 
Based upon principal components analysis with orthogonal rotation it has been established that 
these clusters consist of: pain, concentration, water retention, behavior change, negative affect, 
autonomic reactions, arousal and control.  A more recent examination of the factor structure of 
the MDQ revealed that the original eight factors identified by Moos (1968) effectively represent 
the structure of menstrual cycle symptoms (Ross, Coleman, & Stojanovska, 2003). Furthermore, 
they reported that these factors appear to be replicable across different samples and across 
different methods of data collection. For the purposes of the present study, women were 
administered the MDQ-C, and asked to rate each item on a five-point Likert scale. 
Lakehead Inventory of Premenstrual Symptoms (L IPS). This 33-item scale developed 
by the authors was designed to thoroughly assess the extent to which participants meet the 
$3$¶VSUHOLPLQDU\'60-IV criteria for PMDD (APA, 2000). For each of the eleven criteria 
listed in the DSM-IV, participants were asked three questions assessing: (1) the frequency with 
which each set of symptoms is experienced; (2) the degree to which each symptom impairs work, 
school or interpersonal performance/functioning; and (3) the severity with which each symptom 
is experienced. All questions were rated using seven-point likert scales anchored by 0 (not at all) 
on one end, and 6 (extremely) for the latter two categories of questions, and 6 (frequently) for the 
first category. All questions asked women to estimate whether the described symptoms have 
occurred in more menstrual cycles than not over the past 12 months. Possible scores on this 
measure range from 0 to 198, with higher scores indicating an increased severity of symptoms 
and a greater degree of impairment.  
Hamilton Rating Scale for Depression (H RSD). The HRSD (Hamilton, 1960) is used 
widely to assess current symptoms of depression in both clinical and research settings (Dozois, 
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Dobson, & Henny 2004). The core scale consists of 21 items, scored from 0 (not at all) to 4 
(marked or severely) with items 18 to 21 assessing patterns of diurnal variation, 
depersonalization, obsessions/compulsions, and paranoia. For this study, the 28-item HRSD was 
employed. This form includes an additional seven items reflecting atypical and vegetative 
symptoms. In accordance with Wesner and Tan (2006), who used the HRSD to screen for 
participants with Seasonal Depression, efforts were made to exclude women scoring 20 or 
higher. Given the previously described overlap between symptoms of PMS and Seasonal 
Depression, scores on this measure allowed for the examination of depressive symptoms and the 
evaluation of potential confounds between depressive and PMS symptoms.  
Beck Anxiety Inventory (B A I). The BAI measures the severity of self-reported anxiety 
(Beck & Steer, 1990).  It consists of 21 descriptive anxiety symptoms that are rated on the 
following four-point scale: 0 (not at all), 1 (mildly, it did not bother me much), 2 (moderately, it 
was very unpleasant, but I could stand it), and 3 (severely; I could barely stand it). Analysis has 
revealed that the BAI correlates highly with other measures of anxiety, including the Hamilton 
Anxiety Scale Revised (r = .51) and the anxiety subscale of the Cognition Check List (CCL-A) 
(r = .51) (Beck, Epstein, Brown, & Steer, 1988).  The BAI was constructed to measure 
symptoms of anxiety that are minimally shared with those of depression (Beck & Steer, 1990).  
With their diagnostically mixed sample of 160 outpatients, Beck et al. (1988) reported that the 
BAI had a high internal consistency (Cronbach coefficient alpha = .92).  This same study 
reported a test retest reliability of .75. The maximum score on this measure is 63. Scores on this 
measure were collected to use as a check to ensure the groups did not differ in terms of anxiety, 
as well as for use in future investigations. 
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Seasonal Assessment Pattern Questionnaire (SAPQ). For the Seasonal Pattern 
Assessment Questionnaire (Rosenthal et al., 1984), participants are asked about seasonal 
variations in mood, weight, appetite, sleep length, social activity, concentration, and energy. This 
assessment has been shown to be high in internal consistency and test-retest reliability 
(Magnusson, Friis, & Opjordsmoen, 1997), and has an estimated identifying efficiency of 57% 
(Raheja, King, & Thompson, 1996). It is the most commonly used measure in the identification 
RI6$'6XOOLYDQ	3D\QH7KH6$34LVVFRUHGE\DGGLQJXSWKHSDUWLFLSDQW¶VUDWLQJVRQ
items assessing seasonal change in terms of alternations in the depressive symptoms and the 
degree to which they feel that the changes affect their lives. A total rating score of 12 or higher, 
out of a possible score of 24, is generally indicative of a set of symptoms consistent with SAD 
(Rosenthal et al., 1984; Sullivan & Payne, 2007). Scores on this measure will be correlated with 
scores on the two measures assessing PMS symptoms in later studies. 
 Conscientiousness Scale from The Revised N E O Personality Inventory (N E O-PI-R). 
The NEO-PI-R (1994) is a 240-item questionnaire designed to assess the traits of Neuroticism, 
Extraversion, Openness, Agreeableness, and Conscientiousness. Questions are rated on a five-
point likert scale ranging from strongly disagree (0) to strongly agree (4). Each of the five scales 
is further divided into six facets. Internal consistency (reliability) coefficients are reported to 
range from .86 to .95 for domain scales, and from .62 to .82 for facet scales (Costa & McCrae, 
1994). The NEO-PI conceptualizes conscientiousness as subsuming both proactive and inhibitive 
aspects, with proactive aspects dealing with behaviors relating to success at work (e.g., the need 
for achievement and commitment to work), and inhibitive aspects relating to self-control and 
cautiousness (Costa, McRae, & Dye, 1991). These aspects are encompassed by the six facets of 
dutifulness, achievement striving, competence, order, self-discipline, and deliberation. According 
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to the authors, dutifulness reflects the propensity to honor and uphold commitments to social 
justice and social obligations, often found in work contexts; achievement striving reflects the 
propensity to be hard working and driven; competence refers to one's sense of being capable, 
effective, and sensible; order refers to one's propensity to be well organized, neat, and clean; self-
discipline is the ability to carry tasks through to completion despite boredom and other potential 
distractions; and deliberation reflects impulse control, patience, and maturity (Costa & McCrae, 
1994). This measure was included to potentially control for differences in perceived obligation, 
stamina, and/or responsibility between women with and without PMS symptoms, as those 
scoring higher on such traits may exhibit a tendency to persist at difficult tasks despite 
experiencing feelings of discomfort (e.g., during the lab session occurring in the LL phase).  
 Horne-Ostberg Morningness-Eveningness Questionnaire (M E Q). Developed by 
Horne and Östberg in 1976, the MEQ is a 19-item measure designed to determine whether 
people function more effectively in the morning or evening hours. Questions assess preferences 
pertaining to habitual rising and bed times, preferred times of physical and mental performance, 
and subjective alertness after rising and before going to bed. It yields scores on a single scale of 
³PRUQLQJQHVV

YV³Hveningness'' ranging from 16 to 86. Higher scores suggest greater 
³PRUQLQJQHVV

/RZHUVFRUHVLQGLFDWHJUHDWHU³HYHQLQJQHVV

LHDSUHIHUHQFHWRVOHHSODWHUDQG
for evening activities). The MEQ classifies participants as follows: 70-86 Definitely Morning 
Type, 59-69 Moderately Morning Type, 42-58 Neither Type, 31-41 Moderately Evening Type, 
and16-30 Definitely Evening  Type. This questionnaire was used to collect data for future 
studies.  
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Laboratory Measures and Materials 
 Laboratory Questionnaire. Prior to completing laboratory procedures, participants were 
asked to complete a brief laboratory questionnaire (see Appendix B) designed to assess their 
current affective state and level of cycle-related discomfort. Women were also asked to indicate 
whether they had taken any pain medication or consumed any caffeine. They were further asked 
to indicate the amount of sleep they acquired the previous evening. 
Positive and Negative Affect Scale (PANAS). The PANAS (Watson, Clark, & Tellegen, 
1988) was included in the laboratory questionnaire. The PANAS consists of two scales: one for 
positive affect (PA), and one for negative affect (NA).  High positive affect reflects a state of 
high energy, full concentration, and pleasurable engagement; whereas low PA is characterized by 
sadness and lethargy. In contrast, NA is a general dimension of subjective distress and 
unpleasant mood states, including anger, contempt, and disgust.  Low NA indicates a sense of 
calm and security. The PA PANAS items include attentive, interested, alert, excited, 
enthusiastic, inspired, proud, determined, strong, and active; while the PANAS scale for NA 
includes the items distressed, upset, guilty, scared, hostile, irritable, ashamed, nervous, jittery, 
and afraid. For the current study, participants were asked to indicate how they felt at the moment 
they were completing the surveys. They were asked to rate each adjective on a five-point 
response scale ranging from 1 (very slightly or not at all) to 5 (extremely). These ratings will be 
used for exploratory analyses in subsequent studies.  
Menstrual Distress Questionnaire (MDQ). In order to prospectively assess menstrual 
cycle related pain and/or discomfort, three scales from the MDQ were included in the Laboratory 
Questionnaire. These included the pain (six questions), water retention (four questions), and 
negative affect (8 questions) scales. Scores on these scales were collected to be used as potential 
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covariates in analyses comparing performance across the menstrual cycle or between groups. 
The scales were also used as a prospective confirmation of PMS symptomatology for the two 
groups of women. 
 Visual screening. A Freiberg visual acuity task (FrACT; Bach, 1996) was used to 
PHDVXUHSDUWLFLSDQWV¶QHDUYLVXDODFXLW\IRUDFPGLVWDQWVWLPXOXV/DQGROWµ&¶VWLPXOLZHUH
presented on a 27 cm CRT monitor and participants were required to select the proper orientation 
oIWKH&¶VJDS²a gap whose degrees visual angle systematically varied from a 5° subthreshold 
to a 1° suprathreshold size. The orientation responses were made using a number pad on a 
standard keyboard. A total of eight possible orientations were presented with the test adapting to 
the responses of the participants. Participants were positioned with a chin rest to ensure constant 
viewing distance and stimulus visual angles.  
Color vision was also assessed using the Ishihara pseudoisochromatic plate test, 24-plate 
edition (Ishihara, 1993). Participants showing deviations along the protan, deutan or tritan lines 
(e.g., colour blindness) were excluded from the study. Ishihara plates consist of a series of 
colour-defined numbers embedded within different coloured dots. The plates were always 
SUHVHQWHGXQGHUDVWDQGDUG'³GD\OLJKW´ODPS7KHSODWHVDUHGHVLJQHGVRWKDWJURXSLQJRI
dots by colour causes a number to emerge from the background that can be recognized correctly 
by people with normal colour vision, but in the absence of normal colour signals, all of the dots 
appear falsely of the same colour (pseudoisochromatic). Therefore, colour-deficient observers 
either fail to see the number altogether or make mistakes in recognizing it correctly. Using the 
above screening procedures, all women participating in the laboratory sessions reported normal 
or corrected-to-normal near acuity and no deficits in colour vision.  
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Spatial chromatic contrast sensitivity (C CS) measurements. CCS was measured using 
near isoluminant, KHWHURFKURPDWLF³UHG-to-JUHHQ´DQG³EOXH-to-\HOORZ´SHDN-to-trough gabor 
gratings with center-spatial frequencies at 0.5, 1.5 and 4.0 cycles per degree (c/deg). These 
bichromatic gabors were presented within a 1000 msec temporal Gaussian window. Gabors are 
spatially discrete patterns composed of sinusoidal gratings that are convolved with a spatial 
gaussian blur.  In this study, three different near isoluminant gabors were used, each consisting 
of either a vertical, horizontal, or 45° oriented sinusoidal pattern. All gabors were presented on a 
gamma corrected Viewsonic G225 21-inch monitor for one second either to the left or right of 
a center-positioned 0.38° white crosshair (18.00 cd/m2). Near isoluminance was used to 
minimize the influence of luminance stream operations in the determination of threshold. The 
chromaticities were derived from a hue scaling study conducted by DeValois, DeValois, 
6ZLWNHV	0DKRQ7KH³UHG-to-JUHHQ´5*JDERUZDVXVHGWRDVVHVV3&SURFHVVLQJ
ability.  The relative initial contrast of the gabor ZDVVHWWRIRUWKHPD[LPXPDOORZDEOH³UHG´
SHDNDQG³JUHHQ´WURXJKZKLOHVWLOOPDLQWDLQLQJQHDULVROXPLQDQFH,Q&,(FRRUGLQDWHV 
WKH³UHG´SHDNZDV[ DQG\ DQGWKH³JUHHQ´WURXJKZDV[ DQG\= .3772. 
)RUWKH³EOXH-to-\HOORZ´%<JDERUWKHrelative initial contrast was set to 1.0 as well for the 
PD[LPXPDOORZDEOH³EOXH´SHDNDQG³\HOORZ´WURXJK7KLVQHDU-isoluminant gabor was 
GHVLJQHGWRSUREHWKH.&FRUWLFDOVWUHDPZLWKWKHLQLWLDO³EOXH´VHWWR[ DQG\ 
DQGWKHLQLWLDO³\HOORZ´VHWWR[ DQG\ LQ&,(FRRUGLQDWHV$QLOOXVWUDWLRQ
showing these endpoints within the 1931 CIE space is shown in Figure 2. Our spectroradiometric 
measurements confirmed near isoluminance of the stimuli, with luminance values corresponding 
to 35.3 cd/m2 ³UHG´FGP2 ³JUHHQ´FGP2 ³EOXH´DQGFGP2 ³\HOORZ´
Luminance for the background screen was 36.8 cd/m2 IRUWKH³UHG-JUHHQ´FRQGLWLRQDQG
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cd/m2 IRUWKH³Elue-\HOORZ´FRQGLWLRQ([DPSOHVRIERWKVHWVRIFKURPDWLF5*DQG%<JDERUV
at the above frequencies are illustrated in Figure 3. 
 The stimuli were presented binocularly with the participant seated 75 cm from the 
display. Testing began after a seven-minute dark adapt followed by a three minute light adapt to 
the background. Chromatic contrast thresholds were assessed using a spatial, two-alternative 
forced choice (2AFC), 2-interleaved staircase procedure. Chromatic contrast was defined along 
either the deuWDQ³UHG-to-JUHHQ´RUWULWDQ³EOXH-to-\HOORZ´FRQIXVLRQOLQHVLQ&,(VSDFHWKDW
is, modulation of the relative chromatic contrast for the R/G or B/Y gabors was configured along 
these two dichromatic confusion axes, respectively. Relative chromatic contrast modulations 
were made starting from the near isoluminant endpoints towards the neutral background.  This 
was done by incrementing or decrementing chromatic contrast in 0.1 logarithmic (gamma 
corrected) steps in which the iterations were based on a relative Michelson periodic contrast of 
RUVHWWRWKHPD[LPXPSHDNDQGWURXJK5*%HQGSRLQWYDOXHVIRU³UHG-to-JUHHQ´DQG
³EOXH-to-\HOORZ´PRGXODWLRQV7KHXVHRIrelative contrast iteration ensured proper near-
isoluminant modulation along the CIE deutan and tritan confusion lines.  It is important to point 
out again that the thresholds obtained, and therefore the CCS, are not absolute but relative 
measures within each chromatic condition. Three correct responses were necessary for an 
increase and one incorrect response for a decrease in contrast. Each staircase terminated after 
four practice and six experimental trial reversals. The arithmetic and geometric means of both 
staircase experimental reversals defined the chromatic contrast threshold (both values were used 
in the analyses) for each spatial frequency condition while the inverse of the arithmetic threshold 
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defined CCS.1 Using either the left or right mouse buttons, participants were asked to choose 
ZKLFKVLGHRID³ZKLWH´&,(FKURPDWLFity of x = .3050, y = 0.3275, and luminance value 
of 18 cd/m2) crosshair the gabor appeared on (left or right side).  
Short-wavelength automated perimetry (SW AP). Following the screening procedures 
and completion of the laboratory questionnaire, SWAP measurements were collected for all 
participants. SWAP, or "blue-on-yellow" perimetry, is a visual field test designed to assess early 
visual field loss and is used to assess S-cone sensitivity. SWAP makes use of a short-wavelength 
target (i.e., 440 nm) superimposed on a 580-nm, 100 cd/m2 "yellow" background, the latter of 
which saturates the L and M cones and rods, thus ensuring that the 440-nm test spots activate 
only the S-cones and their associated connected KC streams (Sample, 2000). In terms of 
psychophysical research, SWAP provides a valuable measure of early retinal S-cone operations. 
KC stream functionality can also be inferred using the SWAP coupled with higher-ordered 
psychophysical measures such as B/Y orientation-specific contrast sensitivity measurements (see 
above). 
SWAP measurements were made with an AP200BY Automated Perimeter (Opto-Global, 
$GHODLGH6RXWK$XVWUDOLDXVLQJWKHSDUWLFLSDQW¶VGRPLQDQWH\HWKHQRQ-dominant eye was 
patched).  Right or left eye dominance was determined by having participants indicate which eye 
they favored during the performance of a monocular task. Following the determination of eye-
dominance, participants were positioned on a chin-rest situated in front of a stimulus bowl, 
extending a 100q monocular visual angle. Following a five-minute dark adaptation, participants 
were required to focus on a 640-QP³UHG´IL[DWLRQSRLQWIRUDSHULRGRIPLQXWHVWRHQVXUH
proper retinal light adaptation and ocular position. Following light adaptation, participants were 
                                                 
1 NOTE: Statistical and plot analyses revealed no difference between the arithmetic- or 
geometric-derived CCS.  We therefore only report the arithmetic means in this paper. 
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passed a joystick and asked to depress the top button to indicate when a target stimulus was 
detected. The target stimulus consisted of a Goldmann Size V 440-QP³EOXH´FLUFXODUSRLQW
(1.72º) that was randomly presented along 162 points across the visual field. Results from this 
H[SHULPHQWSURYLGHGDPDSRIWKHSDUWLFLSDQW¶VVHQVLWLYLW\WRWKHWDUJHWVWLPXOLDFURVVWKHYLVXDO
ILHOG7KURXJKRXWWHVWLQJWKHDXWRPDWHGSHULPHWHUWUDFNHGWKHZRPHQ¶VSXSLOSRVLWLRQXVLQJDQ
infrared eye-tracking camera ensuring proper foveal fixation and target imaging at designated 
retinal positions. Participant responses were not recorded if the eye position moved, or was out 
of alignment. 
Texture discrimination task (T D T). Spatial learning properties were assessed across 
groups and over menstrual cycle phases using a texture discrimination task adapted from Karni 
and Sagi (1991). During the TDT, participants were presented with computer-generated textures, 
consisting of a foreground target of three 566-QP³JUHHQ´HOHPHQWVWH[WRQVGLIIHULQJonly in 
orientation from a background of horizontal elements. The grouping of the three-element textons 
was presented randomly as either three vertically stacked textons or three horizontally 
positioned, side-by-side textons. This texton arrangement was always presented in the same 
quadrant per participant.  That is, every participant, during training and testing, was always 
presented with the texton groupings in Quadrant I, II, III or IV (position was based on standard 
Cartesian coordinate system).  This was done to maintain retinotopic consistency for each 
participant.  To guarantee proper central fixation, Dµ7¶RUµ/¶ZDVSUHVHQWHGLQWKHPLGGOHRIWKH
monitor at the same time as the texture element. All participants were asked to first identify the 
target letter (fixation) followed by the orientation of the target texton group (horizontal or 
vertical).  Following presentation of this target display and a brief inter-stimulus blank, a 
patterned mask was presented. The inter-stimulus blank, known as the stimulus-to-mask onset 
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asynchrony (SOA), varied in duration ranging (in order) from 360 to 20 ms. Specific SOA 
iterations were dependent on the lab session and trial block. 
The 22.0 cd/m2´JUHHQ´OLQHVHJPHQWVLQWKHLQLWLDOSUHVHQWDWLRQZHUHDUFPLQXWHV in 
OHQJWKVSDFHGRUDUFPLQXWHVDSDUW7KHOLQHVHJPHQWVZHUHµMLWWHUHG¶WRHFFHQWULF
from central fixation on a black background. Jittering was done within a 19 x 19 element lattice 
that was 13.5° wide x 13° high. The spatial averaged luminance of the target display with all the 
elements was 38 cd/m2. 
)ROORZLQJHDFKWULDODPVPDVNFRQVLVWLQJRIUDQGRPO\URWDWHGµJUHHQ- FRORXUHG¶
µ9¶FKDUDFWHUVµMLWWHUHG¶RQDEODFNEDFNJURXQGSUHVHQWHGLQWKHVDPH[HOHPHQWODWWLFHDV
the test session. All characters within the mask were 22.5 cd/m2 and spaced 15 arc-minutes apart. 
The overall space-averaged luminance of the mask display was 30.0 cd/m2 with a peak 
wavelength of 566 nm. The top panel of Figure 4 illustrates the presentation of a single trial in 
ZKLFKWKHFHQWUDOIL[DWLRQWDUJHWLVDURWDWHGOHWWHUµ7¶DQGWKHWH[WXUHHOHPHQWLVIRXQG
simultaneously in the top left-hand panel (Quadrant II). The lower panel of Figure 4 shows the 
mask pattern presented for all trials at a given SOA. 
All trials began with the 250 ms presentation of a small fixation cross subtending 15.5 
arc-minutes. A FXVWRPUHVSRQVHSDGZLWKIRXUEXWWRQVZDVXVHGWRUHFRUGSDUWLFLSDQWV¶
responses. The buttons were arranged in a diagonal pattern to eliminate handedness confounds 
and reduce response position bias (e.g., Simon, 1969). One pair of buttons was designated for 
each of the possible fixation targets (T or L); the other pair was used to indicate the texton 
arrangements (horizontal or vertical). Women were notified via an audible beep if an incorrect 
response was indicated for the fixation letter, but no feedback was given for an incorrect 
identification of texton arrangement.  This was necessary to ensure proper central fixation of the 
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participants throughout the trials, thereby guaranteeing consistent retinal quadrant positioning of 
the target textons. Again, as mentioned above, measuring potential plasticity changes demands 
this kind of spatial consistency in the retinotopic maps of V1. Performance was measured as the 
mean percent correct response for different SOAs. Reaction times (in msec) were also measured.  
$OOVWLPXOLZHUHSUHVHQWHGRQD´,PDJH6\VWHPV&RUSRUDWLRQPRQLWRUPRGHO0/-0332 
(subtending 20 degrees visual angle) that used a monochrome p46-phosphor tube with a 290 ns 
response time. This ensured accurate timing as well as the elimination of ghosting artifacts. 
Participants were positioned with a chinrest so that their entrance pupils were 110 cm from the 
high-speed (200.4 Hz refresh rate) monitor. 
Participants completed 16 to 20 blocks of trials (stimulus presentations) with 50 trials in 
each block, constituting a presentation of approximately 1000 stimuli per session. The first lab 
session conducted (either during the LF or LL phase) was designated as a training session, and 
consisted of six SOAs decreasing progressively from 360 to 40 ms. The second lab session 
(testing session) was conducted during the other menstrual cycle phase (either LF or LL 
depending on the first phase) and consisted of seven SOAs decreasing progressively from 300 to 
20 ms. 
Smooth pursuit eye tracking task . The eye tracking procedure was adapted from that of 
Smyrnis, Evdokimidis, Mantas, Kattoulas, Stefanis, Constantinidis et al. (2007) using a 
Cambridge Systems, infrared eyetracker [Cambridge Research Systems (CRS), Rochester, UK]. 
A 22-inch Mitsubishi Diamond Pro 2070 monitor powered by a CRS ViSaGe stimulus generator 
with a 14-bit resolution per colour channel and 200 Hz frame rate displayed the sinusoidal 
movement of the stimulus. The monitor was driven by a Dell Precision Workstation with a 
Pentium 4 processor running at 3.6 GHz. Calibration and gamma-correction of the software and 
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monitor was conducted using a Minolta colorimeter and calibration software provided with the 
ViSaGe system.  
Each participant began the experiment by performing a calibration procedure with their 
dominant eye in which system-specific software calculated the correlation between measured 
Purkinje glints in the camera image to specific eye positions. During the calibration procedure, 
ZRPHQZHUHDVNHGWRIRYHDWHXSRQD³ZKLWH´FURVVKDLUq x 0.5°) while the computer 
measured Purkinje glints.  Different crosshairs were presented at a series of different screen 
positions. Following completion of the measurement at one position, the crosshair was removed 
and immediately replaced by another crosshair at a different area on the screen.  Twenty such 
measurements were made, forming a 4 x 5 lattice covering the entire viewing area of the 
monitor, allowing for interpolation of any recorded eye position to a particular screen region. 
The visual angle extended from left to right and top to bottom extended 26q and 15q visual angle 
respectively. 
During the experimental procedure, participants were instructed to follow a horizontally 
moving circular, 89.2-cd/m2, ³\HOORZ´WDUJHWGRPLQDQWZDYHOHQJWKRIQPVXSHULPSRVHG
XSRQD´JUD\´EDFNJURXQGPHDQOXPLQDQFHRIFGP2). The angular subtense for the full 
horizontal excursion was13.3° from fixation center, with a horizontal motion conforming to a 
sinusoidal (right to left) pattern of acceleration and deceleration. The velocity of the target varied 
between 0 deg/sec at maximal excursion and 10.43 deg/sec to 83.29 deg/sec, depending upon the 
frequency of the trial. Target frequencies were presented in the same ascending order for all 
participants: 0.25 Hz, 0.5 Hz, 1.0 Hz, 1.25 Hz and 2.0 Hz. For each frequency condition, 
participants pursued the target for five complete 360° cycles, forming a total of 25 tracked cycles 
for the entire experiment. Trials began with a five second presentation of a fixation crosshair at 
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the center of the monitor. Two seconds following the removal of the fixation crosshair, the target 
was centrally presented and immediately began to move.  Target movement began at the center 
of the screen towards the extreme left, 13.3° angular subtense position, which we identify as a 
90° excursion phase, and then towards the extreme right, -13.3° angular subtense position, which 
we identify as a 270° excursion phase. Central position is therefore identified as 0° phase at start, 
180° phase halfway through the first half of a complete cycle, and 360° phase at the end of the 
complete cycle. Following completion of the five cycles, the target ceased movement and was 
removed from the screen revealing, once again, only the grey background. Participants were 
cued as to the initiation of a subsequent trial. To avoid excessive local memory demands on the 
Dell computer hard drive, infrared Purkinje-image positions were acquired as x,y ASCI files and 
downloaded to a large memory Apple storage facility (RAID system) linked to a network 
server.  Given the convergent evidence for depressive and reproductive cyclic influences on 
oculomotor physiology, we were particularly interested in onset and offset latency, and the 
amplitude and smooth pursuit tracking accuracy for the different cycle phases and frequencies.  
 Salivary Estradiol Collection. The collection of saliva for estradiol measurement was 
accomplished via the use of a passive drool technique. Upon initial contact with participants in 
the orientation session, instructions (as per Salimetrics protocol) were given asking all women 
to avoid the following prior to attending their laboratory appointment: (1) brushing teeth within 
one hour, (2) using salivary stimulants such as chewing gum, lemon drops, granulated sugar, or 
drink crystals, (3) consuming a major meal within one hour, (4) consuming alcohol for twelve 
hours, or (5) consuming acidic or high sugar foods within 20 minutes. One 2 ml sample of saliva 
was collected within each lab session and the sample was collected across three different times 
within the 3-hour session. Women were offered distilled water following the collection of the 
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first two salivary samples allowing for an adequate amount of time to pass prior to collection of 
the final sample at the end of the laboratory session.  During collection, participants were given a 
straw approximately five cm in length and one Cryovial. Prior to their testing session, 
participants were asked to rinse their mouths out with distilled water. In order to collect the 
samples, participants were instructed to imagine eating something palatable and allow saliva to 
pool in their mouths. With heads tilted forward, participants salivated down the straw allowing 
for the collection of saliva in the cryovial. In order to ensure accurate hormonal measurements 
and to attempt to control for the pulsatile release of steroids, this procedure was repeated three 
times during each laboratory session until approximately 2 ml of sample was collected in the 
same tube (see Salimetrics® Specimen Collection protocol in Appendix C). That is, participants 
were asked to contribute saliva to one test tube at three times during each session, resulting in 
one test tube of two mL of saliva that was collected over a three hour period. Samples were 
provided at the beginning and end of each session as well as after the first experimental 
procedure (SWAP) corresponding to approximately one hour into the session. This procedure 
was used in order to obtain a saliva sample that contained a level of estradiol that was 
representative of the levels present during the actual testing session and at that particular cycle 
phase. Such a procedure controlled for the fluctuations in estradiol levels over time due to the 
pulsatile release of gonadal steroid hormones (Hampson & Young, 2008). Samples were 
refrigerated between collection intervals. All women completed the laboratory sessions between 
three and three-and-a-half-hours.  Following collection, samples were frozen at -21º C until the 
time of analysis. Samples were analyzed via the use of enzyme linked immunosorbent assay 
(ELISA), to detect optical density (Groschl, 2008). Following the collection of all samples, 
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analyses were undertaken at the Lakehead University Centre for Biological Timing and 
Cognition Bioassay Laboratory.  
 Ovulation Test Strips. To corroborate self-report information, and position within the 
menstrual cycle, the determination of ovulation was accomplished via the use of generic 
ovulation test strips purchased from a bulk medical supply source. (http://www.early-pregnancy-
tests.com/) (e.g. Claydon, Younis, & Hainsworth, 2006; Johnson, Shaw, Parkinson, Ellis, 
Buchanan, Zinaman et al., 2011). These strips are sensitive to the pre-ovulatory LH surge and 
change colour when the presence of the hormone is detected in urine. The strips are sensitive to 
25 mIU/mL of LH, as per kit instructions. This LH test was used to ensure that the menstrual 
cycle in question was indeed an ovulatory cycle and that women were invited into participate in 
lab sessions targeting the LF phase at the appropriate time (i.e., just after the LH surge).  
Depending on the reliability of their cycle, women were asked to test for a spike in LH between 
days -20 to -13 of their menstrual cycles (based on a method of reverse-count). Participants were 
asked to test between the hours of 10:00 h and 20:00h, when the presence of LH can be detected 
in urine (see test strip instructions in Appendix D). In order to achieve a result, women were 
required to direct the test strip into a collected sample of urine for seven to ten seconds. Collector 
cups facilitating the positioning of test-strips were provided to all women during the laboratory 
orientation. Results were indicated by the appearance of coloured bands in the control (C), and/or 
test (T) regions of the strip. The appearance of one colour band in the control C region or a 
lighter appearance of the T band is indicative of a negative result for the presence of LH. The 
appearance of a T band equal to, or darker than the C band indicates the presence of LH, and the 
likelihood of ovulation occurring within 24 to 48 hours. The absence of a control band is 
indicative of an invalid test, which can occur if an insufficient volume of specimen is added to 
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the test strip. A trained female researcher provided instructions to all participants on the use of 
the test strips as well as their interpretation during their orientation session. All women were 
provided with five collector cups, five ovulation test strips, and a set of printed instructions 
following the orientation session. 
Procedure 
 Screening Phase. Following recruitment, all participants were directed to a website 
where they read a brief overview (letter) of the study and what would be required of them in all 
phases. After reading this letter (see Appendix E) and completing Consent Form A (see 
Appendix F), women were immediately guided to the online screening questionnaire. Following 
the completion of the screening questionnaire, all women were provided with Debriefing Form A 
(see Appendix G) that included the contact information of all researchers involved in the study. 
Subsequently, participants meeting criteria for the study (described above) were contacted by 
telephone or email and invited to participate in the laboratory phase of the experiment. Prior to 
scheduling the initial sessions, participants were asked to attend an orientation session in which 
they were asked to provide information regarding their menstrual cycle, including the date of 
their last menstrual period and the usual duration of their menstrual cycle. Criteria for 
establishing the presence or absence of PMS symptoms are defined below. 
Laboratory O rientation. After responding to an initial request to participate in the 
study, all women were invited to the laboratory for an explanation of experimental tasks and 
scheduling of sessions. During this session, current menstrual cycle day was determined using 
calendars and self-report information. Women were told that one laboratory session was to be 
undertaken in the LF phase, just after the LH surge, when estradiol concentrations were rising or 
high, and a second session was to be undertaken later in the LL phase prior to the beginning of a 
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subsequent cycle. All women were provided with five ovulation test-strips and instructed on their 
use and interpretation of results. The primary researcher or a trained assistant always explained 
the difference between positive and negative test results. Printed copies of test instructions with 
photos and step-by-step directions for interpreting LH test results were provided to all women to 
take home. While in the lab, they also watched a demonstration video illustrating proper use and 
interpretation of test results. Women were asked to begin using the LH strips beginning on day -
17 or -18 of their cycle and to continue using the strips until a positive result was achieved. If 
necessary, additional strips were provided at their request.  
While in the orientation session, women were preliminarily scheduled for a laboratory 
session corresponding to their current position within the menstrual cycle. Those who were 
uncertain of their cycle-day while in the lab were not scheduled immediately and instead asked 
to make note of the first day of their subsequent cycle and contact the primary researcher upon 
reaching it. If women, who were preliminarily scheduled, obtained a positive test result using the 
ovulation test strips prior to the scheduled session, they were instructed to contact the researchers 
immediately to reschedule their session to within 24 hours of the achievement of the positive 
result. The LL phase was confirmed retrospectively by asking all women to contact the 
researchers upon the start of their next menstrual period. Counting backwards from this day 
provided information which served to corroborate both participant self-reports of cycle 
regularity, as well as the approximate day of the cycle on which participants were initially tested. 
This information was also used to book second laboratory sessions if necessary. At the end of the 
initial laboratory session, a subsequent laboratory session was scheduled corresponding to 
SDUWLFLSDQWV¶FXUUHQWSRVLWLRQLQWKHPHQVWUXDOF\FOHDs described above, these appointment times 
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may have been altered slightly following contact with participants indicating day one of a 
subsequent cycle).  
For each group of women (PMS and control groups), descriptive data including mean 
cycle day at the time of laboratory testing in both menstrual phases, range of days tested during 
each phase, and phase at time of session one, is found in Table 1. Information provided in Table 
1 is based on the method of reverse counting in which the LF and LL cycle phases are measured 
in relation to day one of the menstrual cycle, thereby controlling for cycle length (Jöchle, 1973). 
Thus, for the purposes of reporting, day counts were established by counting backwards from 
day one of menses. This method has been found to be more reliable than forward counting, as 
research has shown greater variability in follicular phase duration than that of the luteal phase. In 
other words, the number of days in the luteal phase is more consistent than the number of days in 
the follicular phase, and variability in the follicular phase therefore accounts for most of the 
variation in total cycle length (e.g., Pillsworth, Haselton, & Buss, 2004). Using the day counts, 
two independent samples t-tests were employed to assess differences between groups at the time 
of testing in each phase. These tests revealed no differences between control women and women 
with PMS symptoms at the time of testing in either the LF, t(32) =  -0.30,  p = .77, or LL, t(32) = 
-0.15, p = .89, phases of the menstrual cycle. As well, no differences were indicated between 
control (M = 157.41, SD = 7.83) women and women with PMS symptoms (M = 157.56, SD = 
8.37) in terms of conscientiousness scores, t(31) = -0.05, p= .96. Finally, no differences were 
observed between women in control (M = 6.28, SD = 10.55) and PMS (M = 7.19 SD = 9.13) 
groups in terms of general anxiety, t(32) = -0.27, p = .79. 
Laboratory Sessions. Prior to beginning testing, and upon completion of the laboratory 
questionnaire, participants were asked to complete Consent Form B (see Appendix H). 
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Table 1  
 
Mean Cycle Day at Time of Laboratory Testing in the Late Follicular (LF) and Late Luteal (LL) 
Phases of the Menstrual Cycle for Women in Control (N= 18) and PMS (N = 16) Groups, Range of 
Testing Days in Each Phase, and Number of Participants Tested in Session One for Each Phase 
 
 
 Group 
________________________________________________ 
Menstrual Cycle Parameter Control (N= 18) PMS (N= 16) Total (N= 34) 
Mean Cycle Day at LF Testing -14.67 -14.44 -14.56 
Range of LF Testing Days -11 to -20 -10 to -19 -10 to -20 
Mean Cycle Day at LL Testing -4.22 -4.13 -4.18 
Range of LL Testing Days -1 to -8 -1 to -7 -1 to -8 
Number of Participants in LF 
Phase at Session One 13 9 22 
Number of Participants in LL 
Phase at Session One 5 7 12 
Number (Percentage) of 
Women testing Positive for 
LH Surgea 
13 (72) 11 (69) 25 (74) 
 
____________________________________________________________________________ 
Note. Cycle day counts are based on a method of reverse count to the Luteinizing Hormone (LH) 
surge 
aAll women testing positive for the LH surge were tested within 24 hours following the result. 
Women not reporting a positive result (N=9) were included in analyses given that their reverse count 
testing day was within the appropriate phase. 
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Following the completion of Consent Form B, all participants underwent the visual screening 
protocol (i.e., the FrACT and the Ishihara pseudoisochromatic plate test). They then provided the 
first of three portions of the salivary estradiol sample. Each laboratory session involved the 
assessment of S-cone and L+M cone functionality via the use of both SWAP and CCS 
procedures. Additionally, participants were administered the TDT, and asked to participate in the 
eye-tracking procedure.  While in the lab, the order of tasks administered to all women following 
the SWAP procedure was counterbalanced. The remainder of the salivary sample was collected 
at two intervals during the lab session: once following the SWAP procedure and again after 
completing all of the experiments. Samples were refrigerated during collection intervals and 
frozen at -21qC following the final collection and completion of the lab session. Upon 
completion of the study, all women were provided with Debriefing Form B (see Appendix I). In 
order to attempt to control for time of day effects, efforts were made to schedule each 
SDUWLFLSDQW¶VWZRODEVHVVLRQVDWURXJKO\WKHVDPHWLPHRIGD\:LWKWKHH[FHSWLRQRIWZR
participants whose lab sessions were scheduled five and six hours apart, the remainder of 
SDUWLFLSDQWV¶VHVVLRQVZHUHVFKHGXOHGZLWKLQWKUHHKRXUVRIHDFKRWKHU$QDO\VLVRIWKHWLPHRI
day data revealed that the average time of testing for laboratory sessions was in the early 
afternoon. Independent samples t-tests revealed no differences between the time of testing in 
either the LF or LL phase for control women t(31) = -0.10, p = .99 (LF: M = 14:07, SD = 2:03, 
LL: M = 14:07, SD = 2:11), women with PMS symptoms, t(30) = -0.84, p = .41 (LF: M = 13:32, 
SD = 2:32, LL: M = 14:27, SD = 3:36), or the overall sample of women, t(63) = -0.70, p = .49 
(LF: M = 13:50, SD = 2:17, LL: M = 14:17, SD = 2:56). Thus, time of day is not a potential 
confound for the interpretation of group differences in either phase or between groups.   
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 Salivary Estradiol Assay. Saliva samples were analyzed using a standardized 
Salimetrics protocol (for a detailed overview of this protocol, see Appendix C). Plate 
arrangements were determined a priori and samples were thawed, vortexed, and centrifuged at 
1500 g for 15 minutes.  Five microcentrifuge tubes were filled with 300-mL assay diluent and 
labeled 2 through 6 respectively. The 32 pg/mL standard (tube 1) was then serially diluted 2x by 
removing 300 ml and adding it to tube 2. This procedure was repeated for tubes 3 through 6 
creating final standard concentrations of 32 pg/ml, 16 pg/mL, 8 pg/mL, 4 pg/mL, 2pg/mL, and 
1pg/mL for tubes 1 through 6 respectively.  Adhering to the plate layout determined a priori, 100 
ml of standards, unknowns, and controls were pipetted into corresponding wells. All samples 
were assayed in duplicate. One-hundred ml of assay diluent was used in each non-specific 
binding (NSB) well. Using a 1:800 dilution, 100 ml of enzyme conjugate, (15 ml of enzyme 
conjugate and 12 mL estradiol assay diluent) was added to each well using a multi-channel 
pipette. The plate was then covered with adhesive covering and mixed on a Bokel Scientific 
Model 130000 plate rotator for five minutes at 500 rpm and incubated at room temperature for 
115 minutes. Following incubation the plate was washed with a Molecular Devices Skan Washer 
400 plate-washer four times with 1x wash buffer. Two-hundred mL of tetramethylbenzidiene 
(TMB) solution was then added to each well using a multichannel pipette. The plate was then 
mixed on a plate rotator for five minutes at 500 rpm and incubated in the dark at room 
temperature for 25 minutes. Fifty mL of stop solution was then added using a multichannel 
pipette. Samples were subsequently mixed on a plate rotator for three minutes at 500 rpm. 
Finally, samples were read in a Molecular Devices SPECTRA max 384 plus plate reader at a 450 
nm setting for concentration count and 660 nm setting for zero optics calibration. Final 
calculations were computed by subtracting the average optical density (OD) for the NSB wells 
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from the average OD of the zero, standards, controls, and unknowns. Percent bound for 
standards, unknowns and controls was calculated by dividing the average OD by the average OD 
for the zero. Concentrations of controls and unknowns were determined using SoftMax Pro 
software through interpolation with a 4-parameter sigmoid minus curve fit.  
Data Analysis 
 F inal group assignments. As noted above, women were initially screened using 
retrospective reports of PMS symptoms in the LL phase of the menstrual cycle as assessed by all 
8 scales on the MDQ. However, final group assignments for the PMS and control groups were 
determined using: (1) retrospective menstrual cycle data provided by six MDQ scales found 
within the screening questionnaire (pain, concentration, behaviour change, autonomic reactions, 
water retention, and negative affect), (2) prospective data provided by three MDQ scales (pain, 
water retention, and negative affect) within laboratory questionnaires completed during 
experimental sessions corresponding to both menstrual cycle phases, and (3) scores on the LIPS 
questionnaire, a measure of pre-menstrual symptoms created by the authors. 
Five criteria were used to categorize women into either PMS or control groups. Women 
were assigned values of either 0 or 1 (corresponding to a control or PMS assignment) 
respectively for each of the five criteria listed below, resulting in a possible summed score 
ranging from 0 to 5. After assessing information provided by each woman for each criterion, 
women with scores of three or more were assigned to the PMS group, while those with scores 
less than three were assigned to the control group. The five criteria used are as follows: (1) 
retrospectively reported mean premenstrual phase MDQ scores for the entire sample of women 
who completed the screening questionnaire (N= 188) (i.e., the mean of the sum of scores for the 
PMS symptoms four days prior to the onset of menses for the entire sample). Women with a 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      104 
score above the mean were coded as 1 while those with a score below were coded as 0; (2) The 
second criterion used was the retrospectively reported change in MDQ score for each woman 
between the late luteal phase of the menstrual cycle and the remainder of the menstrual cycle. 
Percent change was used to examine the increase in scores for all women who participated in the 
study. Those whose scores increased (or changed in a positive direction) from the non-late luteal 
to the late luteal phase were coded as 1, while those whose scores remained the same or 
decreased were coded as 0; (3) Prospective data on PMS symptoms provided during the sessions 
by the laboratory questionnaires were used to create a late luteal phase MDQ score based on the 
sum of the three scales (i.e., pain, water retention, and negative affect). The mean score for all 
participants was then calculated. Using this information, women with scores higher than the 
mean were coded as 1, while those women with scores equal to or lower than the mean were 
coded as 0; (4) Percent change in prospectively measured PMS symptoms between the LF and 
LL phase laboratory sessions was used as criterion four. The aggregate score based on the three 
MDQ scales for both sessions was examined. Women with an increase in symptoms between the 
late follicular phase and the late luteal phase were coded as 1 while those whose score decreased 
or remained the same were coded as 0; (5) Finally, the mean score on the LIPS for the entire 
group of women who completed the screening questionnaire (N=188) was used as a fifth 
criterion, with women scoring above the mean coded as 1, and women with scores falling at or 
below coded as 0. Using these five criteria, 18 women were grouped as controls and 16 women 
were grouped as having PMS symptoms. A final total score consisting of the sum of z-scores for 
criteria 1 to 5 (PMS 5) was also created, given evidence that aggregate scores are most reliable 
(Ossenkopp & Mazmanian, 1985). Means and standard deviations for control and PMS groups 
for all classification parameters are found in Table 2. In order to examine group differences on 
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Table 2 
Means and Standard Deviations of Classification Parameters for Women in Control (N= 18) and 
PMS Groups (N=16). Parameters Included: 1) Retrospective Menstrual Distress Questionnaire 
(MDQ) Scores (6 Scales) Four Days Prior to the Onset of Menses, 2) Percent Change in 
Retrospective MDQ Score Between the Remainder of Cycle and Four Days Prior to the Onset of 
Menses, 3) Prospective MDQ Ratings (3 Scales) Obtained During the Laboratory Session Conducted 
in the Late Luteal Phase of the Menstrual Cycle, 4) Percent Change in Prospective MDQ Scores 
from Laboratory Sessions in the Late Follicular (LF) and Late Luteal (LL) Phases of the Menstrual 
Cycle, and 5) Scores on the Lakehead Inventory of Premenstrual Symptoms (LIPS).     
 
         Group 
 
Classification Measure     Control M (SD)  PMS M (SD) 
             (N=18)         (N=16) 
 
 
1. Retrospective MDQ Scores Four Days Prior  41.94 (12.53)         67.47 (25.38) 
to the Onset of Menses*** 
 
2. Percent Change in Retrospective MDQ   0.74 (11.06)         18.04 (19.36) 
Scores Between the Remainder of Cycle  
and Four Days Prior to the Onset of Menses** 
 
3. Prospective MDQ Scores During    7.17 (5.71)         16.53 (10.58) 
the Late Luteal Phase Laboratory Session** 
 
4. Percent Change in MDQ Scores Between   -29.47 (84.41)         13.12 (59.98) 
Laboratory Sessions  
 
5. Scores on the Lakehead Inventory    11.83 (5.59)          22.53 (9.65) 
of Premenstrual Symptoms (LIPS)**    
 
____________________________________________________________________________ 
 
PMS 5 Score      -4.47 (20.05)      12.92 (18.67) 
 
_____________________________________________________________________________ 
NOTE: The PMS 5 score is based on the summation of the z-scores of the five numbered 
classification variables  
 
t p < .10, *p p p  
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the five classification parameters, a MANOVA was calculated in which the five classification 
variables were entered as dependent variables, and group (control or PMS) was entered as the 
EHWZHHQVXEMHFWVYDULDEOH)RUWKLVWHVW%R[¶VWHVWRIHTXDOLW\RIYDULDQFHZDVUHWXUQHGZLWKLQ
acceptable limits (p >.05). The MANOVA revealed a significant overall effect indicating group 
differences in classification scores between control and PMS women, F(5, 28) = 51.69, p = .011, 
K2 =.40, observed power = .87.  Follow-up ANOVAs revealed that women with PMS symptoms 
exhibited significantly: (1) higher scores on retrospective reports of PMS symptoms four days 
prior to the onset of menses, F(1, 32) = 13.17, p = .001, K2 =.29, observed power = .94, (2) a 
higher amount of change on retrospective scores between the LF and LL phases of the menstrual 
cycle, F(1, 32) = 11.54, p = .002, K2 =.27, observed power = .91, (3) higher scores on prospective 
ratings of symptoms of premenstrual syndrome in the laboratory session conducted in the LL 
phase, F(1, 32) = 9.54, p = .004, K2 =.23, observed power = .85, and (4) higher scores on the 
LIPS, F(1, 32) = 14.35, p = .001, K2 =.84, observed power = 1.00. No group difference was 
found for the change in prospective symptom ratings between the two laboratory sessions, F(1, 
32) = 2.19, p = .15, K2 =.06, observed power = .30, although the direction of the means was 
consistent with the PMS group having more symptoms in the LL phase. Finally, significant 
between group differences were observed on the PMS 5 variable, t(32) = -2.32, p =.027. 
 Data reduction and organization. The testing of women in two groups at two distinct 
phases of the menstrual cycle created a nested model in which the data produced was organized 
at more than one level. For all experiments, menstrual cycle phase constituted a within subjects 
independent variable (IV) and group constituted a between subjects IV. Each experimental 
procedure contributed a unique set of dependent variables (DVs) represented by task-
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performance. This design allowed for the examination of group effects, phase effects and group x 
phase effects. 
 Chromatic contrast sensitivity (C CS). &KURPDWLF³UHG-JUHHQ´5*&&6DQG³EOXH-
\HOORZ´%<&&6IXQFWLRQVZHUHH[DPLQHGDFURVVWKUHHVSDWLDOIUHTXHQFLHVDQG
cpd) presented at three orientations (0q, 45q, and 90q) in each menstrual cycle phase for each 
participant.  
In order to establish the unique properties of each visual stream, as well as to examine 
initial and overall effects of group and phase for CCS, a four factor repeated-measures ANOVA 
was conducted in which colour (2-levels), menstrual cycle phase (2-levels), frequency (3-levels), 
and orientation (3-levels) were entered as within subjects factors (IVs) and group was used as the 
between subjects factor (IV). Following this analysis, two additional three-factor repeated 
measures ANOVAs were conducted to examine effects unique to each visual stream. As with the 
overall analysis, phase, frequency and orientation constituted the within subjects IVs and group 
represented the between subjects IV. 
Mean CCS values corresponding to unadjusted data were plotted to compare between-
subjects groups. Curves were fit according to a double exponential template (Movshon & 
Kiorpes, 1988), with error bars expressing the standard error of the means.  Of note, significant 
effects involving only spatial frequency variables were omitted from the Results section for 
brevity and because the observed effects conformed to expected, nonlinear, frequency-dependent 
low or band-pass CCS functions that are unrelated to the questions posed in the current study. 
For example, significant main effects of spatial frequency on contrast sensitivity across the range 
of 0.5 to 4.0 cpd were expected, and found, for all groups of participants. Of course, significant 
interactions of spatial frequency with any of the between-subjects group and/or within menstrual 
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cycle phase variables were reported in the Results sections, as were significant main effects for 
group and cycle phase. 
The influence of estradiol on CCS was examined using a series of hierarchical 
regressions in which concentrations of estradiol in each of the LF and LL phases were entered at 
step one, and percent change in estradiol between phases was entered at step two. These analyses 
were performed for the pooled sample of women and women in each of the control and PMS 
groups for all three conditions of orientation (0q, 45q, and 90q), and for both R/G and B/Y 
presentations.  
 Short-wavelength automated perimetry (SW AP). S-cone sensitivity was assessed 
qinitially within three radial zones of retinal eccentricity: central, paracentral, and peripheral. In 
order to further elucidate more localized areas of sensitivity, these regions were subdivided 
further into five hemiretinal zones: central, superior nasal, inferior nasal, inferior temporal, and 
superior temporal.  As with the CCS measurements, initial measurements of S-cone sensitivity 
were assessed using two repeated measures ANOVAs. The first set of analyses divided the retina 
into three zones according to eccentricity, with the central zone referring to 1°- 6° of visual 
angle, the paracentral zone referring to 10°- 22° visual angle, and the peripheral zone referring to 
30°- 50° visual angle. The second set of analyses divided the retinal area into five hemiretinal 
locations involving a central section (1°- 6°) and four outer quadrants (10°- 50°) corresponding 
to the superior nasal, inferior nasal, inferior temporal, and superior temporal sections. For both 
analyses, menstrual cycle phase (LF or LL) was entered as a within subjects IV, and group 
(control or PMS) was used as a between subjects IV. Subsequent to these analyses, a series of 
forced entry linear regressions was used to investigate the influence of estradiol levels on S-cone 
sensitivity in six areas of retinal eccentricity. For these analyses, concentrations of estradiol in 
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each phase were used as predictors, while the total sensitivity scores for each region in each 
phase were used as DVs. Finally, the relationship between S-cone sensitivity and changes in 
estradiol across the cycle was examined for the pooled sample of women and for each group 
using a series of bivariate correlations. 
 Texture discrimination task (T D T). With respect to the TDT task, all women were 
trained in their first laboratory session irrespective of whether they were in their LF or LL 
menstrual cycle phase. Although optimal conditions would have allowed for complete 
counterbalancing of training and testing sessions such that women were trained and tested in 
each phase (creating a total of four sessions), practical constraints such as timing, scheduling, 
and participant availability as well as task specific confounds such as the retinotopic nature of 
the TDT paradigm, and practice effects prohibited this. Thus, in order to examine the influence 
of group and cycle phase at the time of training and testing, performance at each level of SOA 
was examined using a two-level repeated measures ANOVA. For this ANOVA, group (control 
or PMS) and training-testing order (LL-LF or LF-LL) were used as between subjects IVs and 
relative training-testing change scores for the five levels of SOA were used as DVs. Finally, as 
with the CCS and SWAP analyses, five multiple regressions (one for each level of SOA) were 
performed to examine the influence of session order and estradiol levels in each phase on the 
proportion of improvement in scores between training and testing for each SOA. For these 
regressions, the five proportion improvement scores corresponding to each level of SOA, were 
used as DVs and concentrations of estradiol in the LF phase, concentration of estradiol in the LL 
phase, and session order were employed as the three predictors. These regressions were 
performed separately for each group of women as well as for the pooled sample of participants. 
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 Smooth pursuit eye tracking. During the eye-tracking procedure, all women tracked 
with their dominant eye for 10 complete cycles for each of 5 temporal frequencies: 0.25 c/sec or 
hertz (Hz), 0.5 Hz, 1.0 Hz, 1.25 Hz, and 2.0 Hz. Following completion of all trials, the 10 cycles 
were reduced to an average sinusoidal function for each participant with the assumption that the 
DJJUHJDWHVFRUHZRXOGEHVWFDSWXUHZRPHQ¶VDYHUDJHH\HWUDFNLQJDFFXUDF\HJ2VVHQNRSS	
Mazmanian, 1985). Sinusoidal gaze patterns were created during the procedure as participants 
IROORZHGWKH³\HOORZ´FLUFXODUVWLPXOXVIURPFHQWHUWROHIWDQGEDFNWKURXJKFHQWHUWRULJKWRQ
the computer monitor. The left and right positions made up the sinusoidal pattern with extreme 
left and right position excursions defining the peaks and troughs.  Excursions of the stimulus and 
the registered eye movements were made in degrees visual angle: left being positive and right 
being negative. The extreme left and right positions minus the center position defined the 
amplitudes of the sinusoidal smooth pursuit pattern (i.e., ±13.3°).  In order to facilitate data 
analysis, the final averaged sinusoidal function for each woman was deconstructed into five 
positional phases at 0q, 90q, 180q, 270q, and 360q allowing for examination of gaze at several 
points.  Again, 0°, 180° and 360° defined the center position from start to completion of an entire 
cycle.  Ninety and two-hundred-and-seventy degrees defined left (peak) and right (trough) 
positions, respectively. Following the averaging of 10 complete cycles, the five phase eye 
positions were entered into a three-factor mixed ANOVA using menstrual cycle phase, 
frequency, and position as within subjects IVs and group as a between subjects IV. As with all 
other experiments, the two levels of analysis for menstrual cycle phase were represented by the 
LF and LL positions. Frequency and position were each defined using five levels as indicated 
above. 
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Results 
Data Screening 
 Prior to conducting all analyses, the dependent variables (DVs) were examined as a 
function of group for the presence of univariate and multivariate outliers (e.g., Tabachnick & 
Fidell, 2007), as well as for skewness and kurtosis. Examination of Mahalonobis distances 
revealed no multivariate outliers; however, a number of univariate outliers were noted (see 
below). 
With respect to the salivary estradiol measurements, three univariate outliers were 
detected. Two of these were for the same participant in the PMS group in each of the LF (25.85 
Ug/mL) and LL (20.61 Ug/mL) phases of the menstrual cycle, with the third outlier found for a 
women in the PMS group in only the LL (10.85 Ug/mL) phase. Consultation with the literature 
(e.g. Hampson, 2008; Rosoen & Lopez, 2009) revealed that although the shift in concentration 
was appropriate between phases (e.g., estradiol concentration higher in late follicular than late 
luteal phase), the participant with two outliers had concentrations of estradiol higher than what is 
typically observed in women of the same age. Similarly, the third outlier was slightly outside of 
the range of reported estradiol levels during the LL phase of the menstrual cycle. Comparison 
with the estradiol values of pregnant women suggests that it is highly unlikely that the high 
estradiol levels were due to pregnancy. It is more likely that the higher values are due to 
contamination of the sample. Thus, these three estradiol values were not used in any analyses, 
\HWWKHUHPDLQGHURIWKHSDUWLFLSDQWV¶GDWDZDVUHWDLQHG 
Using the criteria of standard error (SE) skewness/skewness and examination of 
histograms with normal curves (e.g. Tabachnick & Fidell, 2007), the relative CCS data was 
revealed to be significantly skewed. This was not surprising, given the inherent nonlinear nature 
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of human CCS. Logarithmic transformation of this data improved the shape of the distributions, 
however, a proportion of univariate outliers were still noted. Of the 1224 CCS values recorded 
across 36 unique spatial frequency, orientation, and chromatic conditions measured in each 
menstrual cycle phase, 55 (4.5%) cases were identified as extreme values based upon 
interquartile range distances, z-scores, and box plots. Given the potential influence of these 
extreme scores in data analysis, the transformed values were winsored at a z-score of +/- 3.29 (or 
p = .001) of the mean value for the respective condition. Thus, they retained their rank order and 
some distance from the remainder of values, but the possible effect of their separation was 
reduced. These points were distributed across 9 women in the control group and 16 women in the 
PMS group. Given the heterogeneity of conditions in the CCS study and the fact that none of 
these women demonstrated a greater than one log unit separation between their data and that of 
the rest of the sample for any given condition, it was unlikely that the adjustment of their scores 
would lead to artificial effects of phase. Thus, the decision was made to make an adjustment in 
favour of correcting the skewness of the distribution.  
Similar screening and adjustment procedures were employed with SWAP data, resulting 
in modification of 12 (2.5%) extreme cases among 476 total observations. Following these 
adjustments, the distributions of contrast sensitivity and S-cone sensitivity values within groups 
and across conditions fell within acceptable limits of normality. Examination of the changed data 
points indicated that for each of the control and PMS groups one participant accounted for 10 of 
12 (4 for the control women and 6 for the women in the PMS group) of these changes and that 
the data was split evenly between phases. Thus, given that these women tended to operate in the 
extreme range of sensitivities across both phases, it is less likely that a phase effect would be 
artificially detected. 
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For the TDT task, participant data was screened using two criteria. First, only women 
who completed both training and testing sessions were included. Second, results were included 
in analyses only if women were able to discriminate the T/L fixation in the majority of 
conditions in both testing and training conditions. Discrimination of fixation was defined as the 
ability to correctly identify 60% or more of the initial letter presentations. This was especially 
relevant at the beginning of the task at higher SOA levels. As women progressed through the 
procedure and the SOAs decreased accordingly, some women were also unable to reach the 60% 
fixation discrimination. Those, however, whose data fit a profile indicating an ability to 
discriminate at higher SOA levels, thereby implying an understanding of the task, but who could 
not reach 60% discrimination at lower, more difficult SOAs were nonetheless included. For the 
training data, 14 fixation averages below 60% between SOA 80 and SOA 40 were included, 
while for the testing data 8 fixation averages below 60% corresponding to either SOA 60 or SOA 
40 were included. These two criteria resulted in the removal of seven women from the final 
analysis. Finally, as most women were performing at or below chance at SOA 20 in the testing 
phase, this condition was removed from the final analysis. 
With respect to the eye-tracking procedure, each woman completed 10 cycles at each of 
five target oscillating frequencies (in order): 0.25, 0.5, 1.0, 1.25, and 2.0 Hz. All eye movement 
data were fitted with sinusoidal wave functions corresponding to the sinusoidal movement of the 
stimulus. For each cycle, eye position was measured continuously at a temporal resolution of 20 
msec. Precision of timing sequence and target position was confirmed with high-speed video 
synchronized with oscilloscopic tracings of a voltage signal marker generated by the VISage 
program every 20 msec. Smooth pursuit eye movements (averaged across 10 cycles) were 
plotted with the target movement in degrees visual angle as a function of time (in msec). 
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Saccades and missed tracks (e.g., blinking) were filtered using a cutoff amplitude of ±20q visual 
angle. Women with values exceeding these filter constraints at all tracked positions were 
assigned a value of zero degrees for that point within the function. This was done for all cycle 
values prior to the 10-cycle averaging.  Those women who showed extreme eye positions and 
exceeded the filter parameter more than 6 times across the 10 tracked cycles were not included in 
the final grand means used across clinical groups. This procedure resulted in six women being 
omitted from the control group and three women being omitted from the PMS group. 
Salivary Estradiol Assay 
 Results of the salivary estradiol assay were initially examined using a 2 x 2 ANOVA with 
estradiol levels in each menstrual phase (LF and LL) used as within subjects variables, and group 
(control or PMS) used as the between subjects factor. The means and standard deviations for the 
estradiol leYHOVDUHUHSRUWHGLQ7DEOHDVDIXQFWLRQRIJURXSDQGSKDVH)RUWKH$129$%R[¶V
test of equality of covariance was returned within normal limits. The ANOVA did not indicate an 
effect of group, F(1, 30) = 0.008 , p = .93, K2 = .00, observed power = .05. However it did reveal 
an overall effect of phase F(1, 30) = 6.12 , p = .019, K2 = .17, observed power = .67, with higher 
estradiol in the LF than LL phase; as well as a trend for a group x phase effect, F(1, 30) = 3.34, p 
= .078, K2 = .10, observed power = .42.   
In order to further examine these findings, paired samples t-tests were used to examine phase 
effects within the two groups.  Differing results were found for the PMS and control groups. For 
the PMS group, a paired samples t-test revealed no differences between estradiol concentrations 
in the LF and the LL phases, t(14) = 1.00, p = .33. For the control group, however, a paired 
samples t-test revealed significantly higher estradiol concentrations in the LF than the LL phase 
of the menstrual cycle, t(17) = 3.48, p = .003. Thus, these analyses revealed that, unlike the 
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Table 3 
 
Means and Standard Deviations of Estradiol Levels as Determined by SALIMETRICS Salivary 
Immunoassay in the Late Follicular (LF) and Late Luteal (LL) Phases of the Menstrual Cycle in 
a Group of Women Reporting Symptoms of Premenstrual Syndrome (PMS) (N= 14) and a Group 
of Control Women (N= 18)  
 
 
       Estradiol Level (Ug/mL) 
 
    Late Follicular Phase   Late Luteal Phase Overall Mean 
Group              (M, SD)           (M, SD)       (M, SD) 
 
 
Women Reporting PMS         4.91 (1.64)        4.74 (1.77)    4.83 (0.35) 
Symptoms 
 
Control Women           5.43 (1.77)        4.31 (1.24)    4.87 (0.31) 
 
Grand Mean           5.20 (1.71)        4.50 (1.27)    4.85 (0.24) 
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control women, women with PMS symptoms did not show phasic cycling of estradiol across the 
menstrual cycle (see Figure 5). Overall, it appears that women are exhibiting the expected 
tendency to show higher estradiol levels in the LF phase and lower levels in the LL phase; 
thereby providing additional confirmation that women were tested at the appropriate times in 
their menstrual cycles. Further analysis of the same data, however, shows that the control group 
may be accounting for this phase effect as they, and not the group of women with PMS 
symptoms, show an overall effect for a change in estradiol between cycle phases. As noted 
earlier, this effect cannot be explained by differences in the testing days, as there were no 
significant differences in testing days between the groups.  
Chromatic Contrast Sensitivity (C CS)  
Initial effects for relative CCS were explored using a four-factor repeated measures 
ANOVA. In this analysis, the within subjects factors consisted of colour (2 levels), phase (2 
levels), frequency (3 levels), and orientation (3 levels). For colour, the two levels of analysis 
were R/G and B/Y contrast presentations; for phase the two levels of analysis were LL and LF; 
levels of analysis for spatial frequency were represented by 0.5, 1.5, and 4 cycles/degree (cpd); 
and finally the three levels of orientation were defined as 0q, 45q, and 90q, where 0° was 
representative of a horizontal orientation. Group (control and PMS) was entered as the between 
subjects factor. For both R/G and B/Y conditions, means and standard deviations for CS are 
reported for frequency, orientation, and phase in Tables 4, 5, and 6. This analysis confirmed an 
overall effect of colour, indicating higher overall relative CCS for RG stimuli (M = 2.07, SD = 
.032) compared to BY stimuli (M = 1.81, SD = .020), F(1, 32) = 105.99, p <.001, K2 = .77, power 
= 1.0, indicating higher overall sensitivity for these stimuli. There was also a significant effect of 
phase, indicating higher relative CCS in the LL (M = 1.96, SD = .029) compared to the LF phase 
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Table 4 
 
0HDQVDQG6WDQGDUG'HYLDWLRQVIRU³5HG-*UHHQ´Log Contrast Sensitivity Measurements for Three Spatial F requencies at 0q, 45q, 
and 90q Spatial Orientations in the Late Follicular (LF) and Late Luteal (LL) Phases of the Menstrual Cycle for Control (N=18) and 
PMS Groups (N=16)   
 
Control Group 
 
 Frequency  Late Follicular  Phase (M, SD)                             Late Luteal Phase (M, SD)          Grand Mean (SE) 
 
    0q           45q         90q          0q                45q             90q  
 
 0.5 Hz      2.36 (0.19)      2.33 (0.21)     2.34 (0.22)   2.32 (0.36)   2.37 (0.30)     2.39 (0.24) 2.35 (0.05)  
 
 1.5 Hz      2.21 (0.29)      1.97 (0.19)   2.11 (0.26)  2.31 (0.40)   2.11 (0.26)     2.24 (0.35)  2.16 (0.05)  
  
 4.0 Hz      1.80 (0.29)      1.72 (0.27)              1.74 (0.22)  1.88 (0.25)   1.70 (0.35)     1.89 (0.25) 1.79 (0.05) 
 
Marginal Mean (SE)     2.12 (0.05)      2.01 (0.05)   2.07 (0.05)  2.17 (0.06)   2.06 (0.06)     2.17 (0.06) 2.10 (0.04) 
 
 
PMS Group 
 
 Frequency  Late Follicular  Phase (M, SD)                          Late Luteal Phase (M, SD)       Grand Mean (SD) 
 
    0q           45q         90q        0q               45q            90q  
 
 0.5 Hz  2.19 (0.25)    2.12 (0.29)      2.26 (0.24)  2.26 (0.30)     2.26 (0.27)     2.18 (0.21) 2.21 (0.05) 
 
 1.5 Hz  2.13 (0.25)    2.06 (0.29)      2.07 (0.35)  2.14 (0.40)     2.07 (0.33)     2.14 (0.26) 2.10 (0.05) 
 
 4.0 Hz  1.76 (0.25)    1.68 (0.24)      1.80 (0.20)  1.86 (0.28)     1.62 (0.21)     1.91 (0.23) 1.77 (0.05)      
 
Marginal Mean (SE) 2.03 (0.05)   1.95 (0.05)      2.05 (.053)  2.09 (0.06)     1.98 (0.06)     2.08 (0.06) 2.03 (0.05) 
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Table 5 
 
Means and Standard Deviations for ³%OXH-<HOORZ´ Log Contrast Sensitivity Measurements for Three Spatial F requencies at 0q, 45q, 
and 90q Spatial Orientations in the Late Follicular (LF) and Late Luteal (LL) Phases of the Menstrual Cycle for Control (N=18) and 
PMS Groups (N=16)   
 
Control Group 
 
 Frequency  Late Follicular  Phase (M, SD)             Late Luteal Phase (M, SD)      Grand Mean (SE) 
 
    0q           45q         90q          0q                45q             90q  
 
 0.5 Hz      2.03 (0.15)      2.11 (0.15)     2.03 (0.20)   2.09 (0.19)    2.22 (0.23)     2.14 (0.18) 2.10 (0.03)  
 
 1.5 Hz      1.93 (0.16)      1.99 (0.12)   2.01 (0.23)  1.97 (0.23)    1.97 (0.17)     2.03 (0.24)  1.98 (0.03)  
  
 4.0 Hz      1.43 (0.18)      1.36 (0.11)              1.49 (0.16)  1.42 (0.18)    1.41 (0.11)     1.49 (0.21) 1.43 (0.03) 
 
Marginal Mean (SE)     1.79 (0.03)    1.82 (0.04)   1.84 (0.03)  1.83 (0.04)    1.86 (0.04)   1.89 (0.04) 1.84 (0.03) 
  
PMS Group 
 
 Frequency  Late Follicular  Phase (M, SD)             Late Luteal Phase (M, SD)      Grand Mean (SE) 
 
    0q           45q         90q        0q               45q            90q  
 
 0.5 Hz       1.96 (0.22)    2.04 (0.15)   2.06 (0.17)  2.02 (0.25)     2.06 (0.16)     2.03 (0.23) 2.02 (0.04) 
 
 1.5 Hz       1.94 (0.16)    1.92 (0.12)   1.93 (0.15)  1.96 (0.18)     1.91 (0.22)     1.96 (0.26) 1.94 (0.03) 
 
 4.0 Hz       1.40 (0.17)    1.30 (0.12)   1.40 (0.15)  1.48 (0.20)     1.36 (0.20)     1.43 (0.18) 1.40 (0.03)    
 
Marginal Mean (SE)      1.77 (0.03)    1.75 (0.02)   1.80 (0.03)  1.82 (0.04)     1.78 (0.04)    1.81 (0.04) 1.79 (0.03)
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Table 6 
 
Means and Standard Errors for ³5HG-*UHHQ´DQG³%OXH-<HOORZ´ Log Contrast Sensitivity 
Measurements Collapsed Across F requency and Orientation for Control Women (N=18) and 
Women with PMS Symptoms (N =16) in the Late Follicular (LF) and Late Luteal (LL) Phases of 
the Menstrual Cycle    
 
 
³5HG-*UHHQ´&KURPDWLF&RQWUDVW6HQVLWLYLW\ 
 
Group Late Follicular Phase (M, SE) Late Luteal Phase (M, SE) 
 
Control 
 
2.07 (.044) 
 
2.14 (.053) 
 
PMS 
 
2.01 (.046) 
 
2.05 (.056) 
 
Grand Mean 
 
2.04 (.032) 
 
2.09 (.039) 
 
  
³%OXH-<HOORZ´&KURPDWLF&RQWUDVW6HQVLWLYLW\ 
 
Group Late Follicular Phase (M, SE) Late Luteal Phase (M, SE) 
 
Control 
 
1.82 (.023) 
 
1.86 (.035) 
 
PMS 
 
1.77 (.025) 
 
1.80 (.037) 
 
Grand Mean 
 
1.80 (.017) 
 
1.83 (.026) 
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(M = 1.92, SD = .021) of the menstrual cycle, F(1, 32) = 5.83, p < .02, K2 = .15, power = .65. No 
main effect was indicated for group. Results of the ANOVA reflecting trends and main effects 
are reported in Table 7. The overall effect of colour served to confirm the operation of discrete 
system-specific operations with respect to the PC and KC visual streams.  
As such, two mixed ANOVAs were conducted for each of the relative R/G and B/Y 
chromatic contrast conditions. Consequently this enabled us to examine any effects unique to the 
associated visual streams. 
R/G chromatic contrast sensitivity. For both PMS and control groups, log sensitivity 
was plotted as a function of log spatial frequency for each of 0q, 45q, and 90q orientations (see 
Figure 6). For this condition, a three-level mixed ANOVA was conducted using menstrual cycle 
phase (LF and LL), frequency (0.5 cpd, 1.5 cpd, and 4.0 cpd) and orientation (0q, 45q, and 90q) 
as within subjects IVs and group (PMS or control) as the between subjects variable. A summary 
of effects is presented in Table 7.  
 )RUWKLVDQDO\VLV0DXFKOH\¶VWHVWRIVSKHULFLW\ZDVUHWXUQHGZLWKLQDFFHSWDEOHOLPLWVS!
.05). As such, no corrections were employed in the reporting of the following findings.  All 
efforts were made to counter-balance women according to menstrual cycle phase at time of 
session one and time of session two, however, to determine the potential influence of a phase x 
session effect, a confirmatory ANCOVA using cycle phase at time of training as a covariate was 
conducted to rule out possible practice effects. This analysis revealed no effect of session order 
on performance, F(1, 31) = 0.29, p =.59. 
 For the R/G stimulus condition, there was no evidence of a group effect, indicating that 
PMS and control groups did not show overall differences in R/G CCS. There was a significant 
main effect of orientation on CCS, p < .001, indicating that  relative sensitivity for the 45q gabor 
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Table 7 
 
ANOVA Table Showing Overall and System Specific Parvocellular and Koniocellular E ffects in a Contrast 
Sensitivity Experiment with Three F requency and Three Orientation Conditions 
 
Overall Effects 
 
Dependent Variable  F  df Error df    p   K2 
 
Group             1.64 1     32              .21 .05           
Color***        105.99 1     32         < .001       .77                                                   
Phase*             5.83 1     32              .02       .15          
Frequency***                    748.27         2     64         < .001       .96        
Orientation***                   14.92 2     64         < .001       .30        
Phase x Group            0.29 1     32  .59       .01           
Color x Frequency***          32.22 2     64         < .001       .41         
Color x Orientation***           10.19 2     64         < .001       .24           
Frequency x Orientation*** 8.12 4    128         < .001       .21         
 
³5HG-*UHHQ´3DUYRFHOOXODU(IIHFWV  
 
Dependent Variable  F  df Error df  p   K2   
 
Group               1.19 1     32  .28 .04           
Phaset               3.77 1     32            .061        .11           
Frequency***                       252.56      2     64         < .001        .89         
Orientation***                      16.48 2     64         < .001        .34        
G roup x F requency*  4.03 2     64            .022 .11           
Phase x Group   0.26 1     32            .610 .01            
Frequency x Orientation** 3.86 4   128            .005        .11           
Phase x F requency                    2.43 4   128            .051        .07            
     x O rientationt 
F requency x O rientation 2.22 4   128            .070       .065            
     x G roupt 
Phase x Frequency   1.26 2      64            .29  .04          
     x Group* 
³%OXH-<HOORZ´.RQLRcellular) Effects 
 
Dependent Variable  F  df Error df  p   K2  
 
Group                 1.73 1     32            .20   .05          
Phaset                 3.47 1     32            .07            .10           
Frequency***                        564.32     2     64         < .001          .95        
Orientation*    3.36 2     64         < .04            .10          
Group x Frequency  0.025 2     64            .70   .01          
Phase x Group   0.09 1     32            .76  .003                              
Frequency x Orientation*** 6.21 4    128         < .001          .16            
Phase x Frequency                    2.43 4   128            .59            .67           
     x Orientationt 
Frequency x Orientation             2.22 4   128            .80            .53            
     x Groupt 
Phase x F requency   3.46 2      64            .04  .10           
     x G roup* 
 
t p < .10, *p p p 
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presentations was lowest of the three orientation conditions, and significantly lower than that for 
the 90q gabor, p < .001, K2 = .45, observed power = 1.00. Sensitivity for 0q gabors did not differ 
from that of 90q gabors F(1, 32) = .43, p = .52, K2 = .013, observed power = .098. Finally, a trend 
was revealed for the effect of phase, p = .061, indicating increased CCS in the LL phase as 
compared to the LF phase of the menstrual cycle. No group x phase effect was observed. For F  
values, and effect sizes, for all reported R/G CCS analyses, refer to the middle panel of Table 7.  
 With respect to two-way interactions between variables, a significant group x frequency 
effect was noted, p = .022, indicating that CCS measures at different frequencies differed for the 
PMS and control groups. To further examine this effect, contrasts were performed comparing 
each level of frequency across PMS and control groups. These revealed a significant difference 
between group performance at 0.5 cpd and 4.0 cpd, F(1, 32) = 5.60, p = .024, K2 = .15, observed 
power = 0.63. Figure 7 illustrates the group x frequency interaction indicating that there are 
larger performance differences between control and PMS women at the lower 0.5 cpd frequency 
condition as opposed to the higher 4.0 cpd condition (which conforms to a typical, chromatic 
low-pass function as highlighted in the Data Analysis section of the Methods above). Follow-up 
analyses revealed that at the 0.5 cpd frequency condition, control women performed significantly 
better than women in the PMS group, F(1, 33) = 4.50, p = .042. Thus, the group difference was 
strongest at the lowest frequency condition. 
 Two three-way trends were reported for the chromatic R/G stimuli. Of particular note 
was a trend indicating a phase x frequency x orientation interaction, p = .051.  With respect to 
this trend, contrasts illustrated that at the 45q the orientation, women exhibited higher CCS in the 
LL phase at 0.5 cpd and higher CCS in the LF phase at 4.0 cpd. In contrast, at 90q presentations, 
women exhibited greater CCS in the LF phase at 0.5 cpd and higher CCS at 4.0 cpd in the LL 
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phase of the menstrual cycle. F(1, 32) = 12.24, p = .001, K2 = .28, observed power = 0.92. This 
effect is partially illustrated in the middle and right-hand panels of Figure 8. Thus, with respect 
to R/G stimuli, this interaction shows that CCS is differentially influenced by menstrual cycle 
phase when comparing oblique (45q) and vertical (90q) gabors at high frequency (4.0 cpd) 
presentations.  Specifically, it shows that higher CCS performance at 4.0 cpd is found in the LF 
phase when gabors are rotated obliquely and the LL phase when gabors are presented vertically.  
 Finally, a trend was noted for a frequency x orientation x group effect, p = .07. Again, 
contrasts were used to deconstruct the finding. These comparisons revealed that for the 45q 
orientation condition, women in the control group exhibited lower CCS than women with PMS 
symptoms at 1.5 cpd, and higher CCS than women with PMS symptoms at 4.0 cpd. The reverse 
was observed with respect to the 90q orientation condition, in which women in the control group 
exhibited greater R/G chromatic CS than women with PMS symptoms with stimuli presented at 
1.5 cpd, and lower CCS than women with PMS symptoms at 4 cpd presentations, F(1, 32) = 
4.84, p = .035, K2 = .13, observed power = 0.57 . Figure 9 shows that at both 45q and 90q 
orientations, however, CCS was noted to converge at 4 cpd presentations, revealing few 
differences between performances in groups at higher spatial frequencies.  
B/Y chromatic contrast sensitivity. For both PMS and control groups, log sensitivity as 
a function of log spatial frequency was plotted for each of 0q, 45q, and 90q orientations (see 
Figure 10). As with the R/G stimuli, a three level mixed ANOVA was conducted using 
menstrual cycle phase, frequency, and orientation as within subjects factors and group as the 
between subjects factor. Levels of analysis were as above for the R/G CCS analyses. All trends 
and main effects are summarized in the bottom panel of Table 7. 
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 $JDLQIRUDOOUHSRUWHGHIIHFWVDQGWUHQGV0DXFKOH\¶s test of sphericity was returned 
within acceptable limits (p > .05) and as such, no corrections were employed in the reporting of 
the following findings. 
 As with the R/G contrast condition, there was no evidence of a significant group effect (p 
=.20), indicating that PMS and control groups did not show overall differences in B/Y CCS. A 
significant main effect of orientation on CCS for B/Y gabors was observed, p = .041. Contrasts 
revealed that sensitivity for 45°  stimuli was significantly less than that for 90° stimuli, F(1, 32) = 
4.60, p = .04, K2 = .13, observed power = .55.  A strong trend was also indicated for greater 
sensitivity for 90° stimuli over 0° stimuli, F(1, 32) = 4.06, p = .052, K2 = .11, observed power = 
.50.  
In addition to the main effect of orientation, a trend was revealed for the effect of 
menstrual cycle phase, p = .072, indicating increased CCS in the LL phase as compared to the LF 
phase of the menstrual cycle. Examination of Table 7 shows the highest sensitivity for women in 
the LL phase of the menstrual cycle at all orientation conditions. This effect can be seen in 
Figure 8. 
 With respect to two-way interactions, a significant frequency x orientation effect was 
found for the B/Y gabors, p < .001. Contrasts revealed that for 45° and 90° stimuli, sensitivity 
was significantly greater for 0.5 cpd than in for 4.0 cpd presentations, F(1, 32) = 16.98, p < .001, 
K2 = .35, observed power = .98, and that for 0.5 cpd presentations, sensitivity was higher for 45° 
compared to 0q and 90° orientations. At 4.0 cpd, however, sensitivity for both orientations 
converges.  
 Finally, an effect of phase x frequency x group was observed, p = .037, in which 
differences in performance by phase and by group were most pronounced when comparing the 
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lower, 0.5 cpd presentations to the higher, 4.0 cpd frequency presentations, F(1, 32) = 1.01, p 
= .016, K2 = .17, observed power = .70, with women in both groups showing higher CCS 
performance at 0.5 cpd presentations compared to 4.0 cpd presentations.  Figure 11 best 
illustrates the three way interaction and shows that, CCS at all frequencies is highest for women 
in the LL phase of the menstrual cycle, and that this effect is most noticeable at the lower 0.5 and 
1.5 cpd frequency presentations. Statistical contrasts, revealed that for both groups CCS for the 
highest 4.0 cpd frequency presentations was significantly less than that of the 0.5 cpd 
presentations F(1, 32) = 703.95, p < .001, K2 = .69, observed power = 1.0, and 1.5 cpd  
presentations, F(1, 32) = 90.29, p < .001, K2 = .97, observed power = 1.0 (see Figure 11). Paired 
samples t-tests revealed that only women in the control group demonstrated a significant 
difference in performance at a frequency of 0.5 cpd between the LF (M = 6.16, SD = .40) and LL 
phases (M = 6.44, SD = .50), t(17) = 3.40, p = .003 . No additional significant differences were 
observed between phases for any group at any other frequency conditions.  
 Chromatic contrast sensitivity and estradiol. The influence of estradiol on R/G and 
B/Y CCS (collapsed across phases) at all three conditions of orientation for the pooled sample of 
participants, as well as for each of the control and PMS groups was explored using a hierarchical 
model of regression using concentrations of estradiol in each phase at step one and percent 
change in estradiol between phases {([LF]-[LL]/[LL]) *100} at step two. Results for the R/G 
analyses are reported in Table 8. These analyses revealed that for the R/G gabors, none of the 
overall models significantly predicted CCS. However, percent change in estradiol significantly 
added to prediction over and above estradiol levels in each phase for all three orientations. 
Furthermore, at all three orientations all three variables were significant unique predictors of 
CCS at step 2 (see Table 9; all p < .05).  The model for the 45q condition also showed an overall
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Table 8 
 
Table Showing statistics for a Hierarchical Model of Regression Using Concentrations of Estradiol in both the 
Late Follicular (LF) and Late Luteal (LL) Phases at Step One, and Percent Change Estradiol Between the LF 
and LL Phases at Step Two in the Prediction of R/G Chromatic Contrast Sensitivity Across Phases at Three 
Conditions of Orientation for a Pooled Sample of Women (N= 32), a Control Group of Women (N= 18) and a 
Group of Women Reporting PMS Symptoms (N= 14)   
Pooled Sample (N=32) 
Orientation Step df Error df R Adjusted R2 R Square 
Change 
F  F  change 
0q 1 2 29 .17 -.04 .03 0.45  
 2* 1 28 .40 .07 .13 1.79 4.36 
45q 1 2 29 .10 -.06 .01 0.16  
 2** 1 28 .49 .16 .23 2.93 8.39 
90q 1 2 29 .13 -.05 .02 0.26  
 2* 1 28 .42 .09 .16 1.97 5.32 
 
Control Group (N=18) 
Orientation Model df Error df R Adjusted R2 R Square 
Change 
F    F  change 
0q 1 2 15 .08 -.13 .01 0.053  
 2* 1 14 .52 .11 .26 1.72 5.01 
45q 1 2 15 .15 -.11 .02 0.18  
 2** 1 14 .68 .35 .44 4.04 11.50 
90q 1 2 15 .02 -.13 .00 0.002  
 2* 1 14 .58 .20 .34 2.38 7.13 
 
PMS Group (N=14) 
Orientation Model df Error df R Adjusted R2 R Square 
Change 
F  F  change 
0q 1 2 11 .30 -.08 .09 0.53  
 2 1 10 .31 -.18 .01 0.35 .07 
45q 1 2 11 .11 -.17 .01 0.06  
 2 1 10 .25 -.22 .05 0.22 .54 
90q 1 2 11 .21 -.13 .04 0.25  
 2 1 10 .25 -.22 .02 0.22 .18 
NOTE: Significance is indicated for steps within the model not the overall model  
t p < .10, *p p p  
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Table 9 
 
Coefficients for a Hierarchical Model of Regression Using Concentrations of Estradiol in both 
the LF and LL Phases at Step One and Percent Change Estradiol Between the Late Follicular 
(LF) and Late Luteal (LL) Phases at Step Two in the Prediction of R/G Chromatic Contrast 
Sensitivity Collapsed Across Phases at Three Conditions of Orientation. 
 
Pooled Sample (N= 32) 
0q B SE B E p 
[Estradiol LF] 1.29 0.57 1.66 .03 
[Estradiol LL] -1.60 0.71 -1.53 .03 
% change [E] -0.05 0.02 -1.45 .05 
45q     
[Estradiol LF] 1.27 0.48 1.87 .01 
[Estradiol LL] -1.65 0.59 -1.82 .009 
% change [E] -0.06 0.02 -1.91 .007 
90q     
[Estradiol LF] -1.18 0.51 1.70 .03 
[Estradiol LL] -1.52 0.63 -1.64 .02 
% change [E] -0.05 0.02 -1.59 .03 
Control Group (N= 18) 
0q     
[Estradiol LF] 1.55 0.74 2.13 .06 
[Estradiol LL] -1.83 0.92 -1.75 .07 
% change [E] -0.07 0.03 -1.81 .04 
45q     
[Estradiol LF] 1.57 0.52 2.65 .009 
[Estradiol LL] -2.00 0.64 -2.37 .007 
% change [E] -0.07 0.02 -2.35 .004 
90q     
[Estradiol LF] 1.57 0.62 2.45 .02 
[Estradiol LL] -1.92 0.77 -2.09 .03 
% change [E] -0.07 0.03 -2.06 .02 
PMS Group (N= 14) 
0q     
[Estradiol LF] 0.49 1.12 0.60 .64 
[Estradiol LL] -0.67 1.40 -0.65 .67 
% change [E] -0.01 0.05 -0.37 .80 
45q     
[Estradiol LF] 0.69 1.09 0.87 .54 
[Estradiol LL] -0.96 1.37 -0.97 .50 
% change [E] -0.03 .05 -1.06 .48 
90q     
[Estradiol LF] 0.49 1.05 0.64 .65 
[Estradiol LL] -0.77 1.33 -0.81 .57 
% change [E] -0.02 0.05 -0.62 .68 
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 strong trend at step 2 (p = .051) indicating that the three estradiol variables showed a trend to 
predict general CCS ability in women. The same pattern of results was observed for control 
women, except that the model for the 45q condition was significant at step 2 (p = .029), 
indicating that the three estradiol variables together predicted general CCS ability in women 
across the cycle. For the PMS women, none of the models showed any associations between the 
estradiol variables and CCS for R/G stimuli at any of the orientations. Thus, the strongest effects 
of estradiol on R/G CCS were found for control women with the 45qcondition.  
Examination of beta coefficients (see Table 9) reveals that the relationship between CCS 
performance and percent change in estradiol across all orientation conditions is negative. Thus, 
higher CCS is associated with smaller changes in estradiol across the cycle from the LL to LF 
phase.  
Unlike the R/G CCS where estradiol best predicted CCS in the 45q orientation condition 
for control women, estradiol best predicted B/Y CCS in the 0q orientation condition for all 
women. As indicated in Tables 10 and 11, when all women were examined together, the three 
estradiol variables significantly predicted CCS at step 2, and all three estradiol variables were 
unique predictors for 0q and 45q. When the control women were examined, similar weaker 
effects were found only for 0q. Regressions using the PMS women indicated the same strong 
effects were found only for 0q. Thus, the strongest effects of estradiol on B/Y CCS were found 
for the PMS and control women with the 0q condition. As with the R/G stimuli, coefficients for 
the B/Y regression analyses (see Table 11) indicated that higher CCS was associated with a 
smaller shift in estradiol across the cycle from the LL to the LF phase.
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Table 10 
 
Table Showing Statistics for a Hierarchical Model of Regression Using Concentrations of Estradiol in 
both the Late Follicular (LF) and Late Luteal (LL) Phases at Step One and Percent Change Estradiol 
Between the LF and LL Phases at Step Two in the Prediction of B/Y Chromatic Contrast Sensitivity 
Across Phases at Three Conditions of Orientation for a Pooled Sample of Women (N= 32), a Control 
Group of Women (N= 18) and a Group of Women Reporting PMS Symptoms (N= 14)   
 
Pooled Sample (N=32) 
Orientation Step df Error df R Adjusted R2 R Square 
Change 
F   F  Change 
0q 1 2 29 .37 .07 .13 2.24  
      2** 1 28 .61 .31 .24 5.53 10.61 
45q 1 2 29 .33 .05 .11 1.75  
   2* 1 28 .54 .22 .19 3.89 7.40 
90q 1 2 29 .12 -.06 .01 0.20  
   2* 1 28 .41 .08 .16 1.92 5.29 
 
Control Group (N=18) 
Orientation Step df Error df R Adjusted R2 R Square 
Change 
F   F  Change 
0q 1 2 15 .24 -.07 .06 0.48  
 2* 1 14 .55 .16 .25 2.07 5.01 
45q 1 2 15 .29 -.04 .09 0.70  
 2 1 14 .44 .02 .11 1.14 1.93 
90q 1 2 15 .29 -.04 .09 0.71  
 2 1 14 .43 .01 .10 1.06 1.70 
 
PMS Group (N=14) 
Orientation Step df Error df R Adjusted R2 R Square 
Change 
F   F  Change 
0q 1 2 11 .58 .21 .33 2.76  
 2* 1 10 .78 .48 .27 5.03 6.72 
45q 1 2 11 .29 -.08 .09 0.51  
 2 1 10 .56 .11 .23 1.52 3.31 
90q 1 2 11 .28 -.09 .08 0.47  
 2 1 10 .47 -.02 .14 0.92 1.75 
NOTE: Significance is indicated for steps within the model not the overall model  
t p < .10, *p p p  
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Table 11 
 
Coefficients for a Hierarchical Model of Regression Using Concentrations of Estradiol in both 
the Late Follicular (LF) and Late Luteal (LL) Phases at Step One and Percent Change Estradiol 
Between the LF and LL Phases at Step Two in the Prediction of B/Y Chromatic Contrast 
Sensitivity Collapsed Across Phases at Three Conditions of Orientation.  
 
Pooled Sample (N= 32) 
0q B SE B E p 
[Estradiol LF] 0.98 0.29 2.18 .002 
[Estradiol LL] -1.36 0.36 -2.26 .001 
% change [E] -0.40 0.01 -1.95 .003 
45q     
[Estradiol LF] 0.79 0.27 1.97 .007 
[Estradiol LL] -1.07 0.33 -2.00 .003 
% change [E] -0.03 0.01 -1.73 .01 
90q     
[Estradiol LF] 0.84 0.36 1.72 .03 
[Estradiol LL] -0.95 0.44 -1.46 .04 
% change [E] -0.04 0.02 -1.59 .03 
Control Group (N= 18) 
0q     
[Estradiol LF] 0.84 0.41 2.02 .06 
[Estradiol LL] -1.17 0.51 -1.98 .04 
% change [E] -0.04 0.02 -1.76 .04 
45q     
[Estradiol LF] 0.49 0.37 1.40 .21 
[Estradiol LL] -0.74 0.46 -1.49 .13 
% change [E] -0.02 0.02 -1.18 .19 
90q     
[Estradiol LF] 0.45 0.47 1.03 .36 
[Estradiol LL] -0.48 0.58 -0.78 .42 
% change [E] -0.03 0.02 -1.12 .21 
PMS Group (N= 14) 
0q     
[Estradiol LF] 1.37 0.45 2.69 .01 
[Estradiol LL] -1.84 0.58 -2.90 .01 
% change [E] -0.05 0.02 -2.44 .03 
45q     
[Estradiol LF] 0.97 0.49 2.34 .08 
[Estradiol LL] -1.24 0.62 -2.40 .07 
% change [E] -.04 0.02 -2.25 .10 
90q     
[Estradiol LF] 1.01 0.66 1.91 .16 
[Estradiol LL] -1.11 0.84 -1.68 .22 
% change [E] -0.04 0.03 -1.74 .22 
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S-cone Sensitivity: Short-Wavelength Automated Perimetry (SW AP) 
 Retinal location: Eccentricity. In order to determine the effect of group and menstrual 
cycle phase on S-cone sensitivity, two mixed ANOVAs were performed. In the first analysis, 
phase and retinal eccentricity were used as within-subjects IVs. As with the above CCS analyses, 
menstrual cycle phase was defined using two levels represented by both the LF and LL phases. 
Retinal eccentricity consisted of three levels corresponding to three different radial regions of the 
retina (central, paracentral, and peripheral zones). Again, group (PMS or control) was used as a 
between subjects factor. Means and standard deviations for S-cone sensitivity for all areas of 
retinal eccentricity for control and PMS groups in both LF and LL menstrual cycle phases are 
shown in Table 12. 
 )RUWKLVDQDO\VLV0DXFKOH\¶VWHVWRIVSKHULFLW\ZDVUHWXUQHGDVVLJQLILFDQWSDQG
as such, the Greenhouse Geisser correction is used for the reporting of the following findings. 
Not surprisingly, results revealed a significant effect of retinal zone, p < .001, indicating that S-
cone sensitivity varied as a function of retinal eccentricity. For this analysis, no significant 
effects of phase or group and or interactions with either phase or group were observed. All 
effects are summarized in Table 13. 
 Contrasts revealed significant differences in S-cone sensitivity between central and 
peripheral regions, F(1, 32) = 1159.39, p < .001, K2 = .97, observed power = 1.0, and paracentral 
and peripheral regions, F(1, 32) = 1104.47, p < .001, K2 = .97, observed power = 1.0, with 
women showing higher S-cone sensitivities in central and paracentral regions compared to 
peripheral regions. In addition to the main effect of retinal zone, a trend was noted for the effect 
of phase x retinal zone, p = .10. No other trends or significant main effects or interactions were 
noted for phase. 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      132 
Table 12 
 
Means and Standard Deviations (in	  decibel	  power	  ratios,	  dB)	  for S-cone Sensitivity as Assessed 
using Short-Wavelength Automated Perimetry (SWAP) for Three Zones of Retinal Eccentricity in 
the Late Follicular and Late Luteal Phases of the Menstrual Cycle for Control (N=18) and PMS 
Groups (N =16)   
 
Control Group 
 
Retinal Zone           Late Follicular  Late Luteal   Grand Mean 
         Phase (M, SD)  Phase (M, SD)      (M, SD) 
 
Central   28.41 (1.01)  29.04 (0.85)  28.73 (0.29) 
 
Paracentral   25.38 (1.85)   25.92 (1.50)  25.65 (0.47) 
  
Peripheral   17.38 (2.05)  17.36 (2.64)  17.37 (.64) 
 
 
Marginal Mean  23.72 (0.48)  24.11 (0.46)  23.92 (0.44) 
 
PMS Group 
 
Retinal Zone        Late Follicular  Late Luteal   Grand Mean 
      Phase (M, SD)  Phase (M, SD)      (M, SD) 
 
Central   29.32 (1.74)  29.70 (1.81)  29.51 (0.31) 
 
Paracentral   26.89 (2.54)  27.36 (2.67)  27.12 (0.49) 
  
Peripheral   18.28 (3.86)  17.97 (3.19)  18.12 (0.67) 
      
 
Marginal Mean  24.83 (0.51)  25.00 (0.49)  24.92 (0.46)
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Table 13 
 
ANOVA Table Showing E ffects of Retinal Location (Eccentric and Hemiretinal) on a 
Performance of SWAP
 
Eccentric Regions 
 
Dependent Variable  F  df Error df p   K2  
 
Group            2.05 1     32          .16 .06    
Phase             1.11 1     32          .30 .03    
Phase x Group           .148 1              32          .70 .01    
Retinal Zone***      967.51 2     64      < .001  .97             
Group x Zone           1.14 2     64          .33 .03    
Phase x Zonet            2.63 2     64          .10 .08    
Group x Phase x Zone         0.18 2     64          .86 .003    
 
Hemiretinal Sections  
 
Dependent Variable  F  df Error df p   K2  
 
Group            2.07 1     32          .16 .06    
Phase             2.47 1     32          .13 .072    
Phase x Group           .066 1              32          .80 .002   
Hemiretinal Section***   360.64 4     29      < .001  .98            
Group x Hemiretinal          0.49 4     29          .74 .063    
Section 
Phase x Hemiretinal          1.78 4     29          .16 .20   
Section 
Group x Hemiretinal          0.27 4     29          .90 .036             
Section x Phase            
 
t p < .10, *p p *p 
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In order to further investigate the trend for a phase x retinal zone effect, three paired 
samples t-tests were performed for each of the central, paracentral, and peripheral zones using 
SWAP measurements repeated in the LF and LL phases as the IV pairs. These analyses revealed 
that women exhibited significantly higher SWAP sensitivity in the LL phase (M = 29.35, SD = 
1.40) compared to the LF phase (M = 28.84, SD = 1.45) in the central zone, t(33) = 2.29, p = 
.029. A similar trend for higher overall sensitivity in the LL phase (M = 26.60, SD = 2.22) over 
the LF phase (M = 26.09, SD = 2.30) was additionally observed for the paracentral zone, t(33) = 
1.69,    p = .10. No differences were revealed between the LF (M = 17.80, SD = 3.02) and LL (M 
= 17.65, SD = 2.88) phases for peripheral regions t(33) = -.37, p = .72. A histogram showing S-
cone sensitivity in the three retinal zones for both menstrual cycle phases is shown in Figure 12. 
Retinal location: Hemiretinal Superior and Inferior Zones.  A second mixed ANOVA 
was conducted on S-cone sensitivity, with phase (LF and LL) entered as the first within-subjects 
factor, and hemiretinal zones as a second, five-level, within-subjects variable. The five levels for 
hemiretinal zones included: central, superior nasal, inferior nasal, superior temporal, and inferior 
temporal. Group was used as the between-subjects variable. Means and standard deviations of S-
cone sensitivity for all hemiretinal sections for PMS and control groups in both menstrual cycle 
phases are found in Table 14.  
For this analysis, no main effects for phase or group were observed indicating that 
women did not differ in S-cone sensitivity as a function of hormonal sensitivity or phase. A 
significant effect of hemiretinal section was observed, F(4, 128) = 425.53, p < .001, K2 = .93, 
observed power = 1.0, with the highest S-cone sensitivity observed in the central region (refer to 
Table 13 for the ANOVA results). Examination of means and standard deviations in Table 14 
revealed that S-cone sensitivity was highest, irrespective of menstrual cycle phase or group, in 
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Table 14 
 
Means and Standard Deviations for S-cone sensitivity (dB) as assessed using Short-Wavelength 
Automated Perimetry (SWAP) for Superior and Inferior Hemiretinal Sections in the Late 
Follicular (LF) and Late Luteal (LL) Phases of the Menstrual Cycle for Control (N=18) and 
PMS Groups (N=16).   
 
 
Control Group 
 
Retinal Zone  Late Follicular  Late Luteal   Grand Mean 
Phase (M, SD)  Phase (M, SD)      (M, SD)  
 
Central      28.41 (1.01)    29.04 (0.85)  28.73 (0.29) 
 
Superior Nasal     19.81 (2.17)    20.27 (2.05)   20.04 (0.56) 
 
Inferior Nasal      24.07 (2.31)    24.45 (2.21)  24.26 (0.52) 
 
Superior Temporal     18.60 (2.26)    19.46 (1.74)  19.03 (0.60) 
 
Inferior Temporal     21.64 (2.28)    21.94 (2.22)  21.79 (0.53) 
 
 
Marginal Mean     22.50 (0.49)    23.03 (0.51)  22.77 (0.46) 
 
 PMS Group 
 
Retinal Zone  Late Follicular  Late Luteal   Grand Mean 
Phase (M, SD)  Phase (M, SD)      (M, SD) 
 
Central      29.32 (1.74)    29.70 (1.81)  29.51 (0.31) 
 
Superior Nasal         21.00 (2.91)    21.25 (3.34)  21.13 (0.60) 
 
Inferior Nasal      25.60 (2.74)    25.54 (2.76)  25.55 (0.55) 
 
Superior Temporal     19.45 (3.33)    20.55 (3.66)  20.00 (0.64) 
 
Inferior Temporal     22.38 (2.40)    22.56 (3.08)  22.47 (0.56) 
      
 
 
Marginal Mean     23.54 (0.52)  23.92 (0.54)  23.73 (0.49)
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the central retinal location. Follow up t-tests indicated that S-cone sensitivity in the central 
region (M = 58.19, SD = 2.54) was significantly higher than in the superior nasal region (M = 
41.10, SD = 4.84), t(33) = 29.89, p < .001; the inferior nasal region (M = 49.73, SD = 4.57), t(33) 
= 15.99, p < .001; the superior temporal region (M = 38.97, SD = 5.10), t(33) = 32.07, p < .001; 
and the inferior temporal region (M = 44.22, SD = 4.48 ), t(33) = 27.80, p < .001. In addition, 
women showed higher S-cone sensitivities in both inferior nasal and inferior temporal retinal 
locations as compared to parallel areas in the superior portion of the retina. Combined scores for 
all women comparing the superior and inferior retinal regions revealed significantly higher 
sensitivity in inferior (M = 93.95, SD = 8.68) compared to superior retinal locations (M = 80.07, 
SD = 9.53), t(33) = -17.03, p < .001.  
S-Cone Sensitivity and Estradiol. In order to examine the effect of estradiol levels in 
the LF and LL phases on S-cone sensitivity, a series of multiple regressions was performed using 
the sensitivity of the retinal zones as DVs, and concentrations of estradiol in the LF and LL 
phases as predictors. Given that theoretical evidence links estrogen levels to S-cone sensitivity, 
but does not suggest a strong rationale for estradiol levels in either the LF or LL predicting 
differential outcomes, a forced entry method was employed in which both predictors were 
entered into the model simultaneously. As well, given the large number of conditions in this 
experiment, a decision was made to collapse retinal zones within each phase in order to prevent 
conducting a large number of analyses and inflating error rates.  Collapsing of retinal zones was 
accomplished by creating new variables in which S-cone sensitivities were combined according 
to phase. The new variables used as DVs in the six regression analyses were as follows: (1) 
retinal eccentricity LL, (2) retinal eccentricity LF, (3) inferior retina LL, (4) inferior retinal LF, 
(5) superior retina LL and (6) superior retina LF.  The first two regression variables (1 & 2) were 
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created by adding the S-cone sensitivity values in the central, paracentral and peripheral retinal 
regions together for each of the LL and LF phases, respectively, while the last four regression 
variables (3-6) were created by combining the superior nasal and superior temporal S-cone 
sensitivities together, and the inferior nasal and inferior temporal S-cones sensitivities together 
for each of the LL and LF phases.  
A summary of all regression analyses is found in Table 15. For the eccentric regions, 
levels of estradiol in both menstrual cycle phases predicted S-cone sensitivity in the LF phase, p 
= .02, adjusted R2= .18. A trend was found for the same combination of variables in the 
prediction of S-cone sensitivity in the LL phase, p = .09, adjusted R2 = .10. For the inferior and 
superior hemiretinal zones, estradiol levels at the LF and LL positions in the menstrual cycle 
predicted S-cone sensitivity in both regions when women were tested in the LF phase only. Thus, 
for testing sessions occurring in the LF phase, estradiol concentrations in the LF and LL phases 
significantly predicted S-cone sensitivity in the inferior hemiretinal section, p = .007, adjusted   
R2 = .24 , and the superior hemiretinal section, p = .05, adjusted R2 = .13.  
These analyses revealed that S-cone sensitivity is best predicted in the LF phase by a 
combination of estradiol levels in the LF and LL phases. Interestingly, the results also indicated 
that, for all analyses, the E weights for the predictors were in opposite directions, with those for 
estradiol levels in the LF phase having negative weights and those for estradiol levels in the LL 
phase having positive weights (see Table 16). This would suggest that higher levels of estradiol 
in the LL phase are related to higher S-cone sensitivity in the late follicular phase of a 
subsequent cycle, while high levels of estradiol in the late follicular phase predict poorer S-cone 
sensitivity at that time in the cycle. The same combination of predictors did not significantly 
predict S-cone sensitivity in the LL phase. Thus, higher estradiol in the LL phase and lower 
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Table 15 
 
Table Showing Statistics for a Forced Entry Model of Regression Using Mean Concentrations of Estradiol in Each of the Late 
Follicular (LF) and Late Luteal (LL) Phases of the Menstrual Cycle as Predictors of S-cone Sensitivity in Central, Paracentral, and 
Peripheral Locations in both the LF and LL Phases
 
 
Dependent Variable df Error df R Adjusted R2 R Square        F     p     
   
 
Eccentric LL  2     29  .40     .10     .16      2.69            .09t 
 
Inferior LL  2     29  .26     .001     .07      1.01            .38  
 
Superior LL  2     29  .34     .06     .12      1.94            .16 
 
Eccentric LF*  2     29  .48     .18     .23      4.35            .02 
 
Inferior LF**  2     29  .54     .24     .29      5.89           .007 
 
Superior LF*  2     29  .43    .13    .19      3.31             .05 
 
t p < .10, *p p p  
NOTE: Dependent Variables represent S-cone sensitivity for the respective retinal location
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Table 16 
 
Coefficients (from Analyses in Table 15) for Mean Concentrations of Estradiol in Each of the 
Late-Luteal (LL) and Late-Follicular (LF) Phases for a Forced Entry Model of Regression in the 
Prediction of S-Cone Sensitivity in Eccentric, Inferior, and Superior Regions for Each Menstrual 
Cycle Phase in an Overall Sample of Participants (N=32)  
 
 
Retinal Location and       B       SEB    E      p 
Menstrual Cycle Phase 
 
Eccentric Regions LL 
Mean [Estradiol] LF*   -1.58      0.72  -.44    .035   
Mean [Estradiol] LL    1.67      0.96   .35    .092 
 
Inferior Regions LL 
Mean [Estradiol] LF   -.89      0.62   -.30     .17 
Mean [Estradiol] LL    .57      0.83    .14     .50 
 
Superior Regions LL 
Mean [Estradiol] LFt   -1.12       0.64    -.36    .09   
Mean [Estradiol] LL    1.43       0.86     .34    .11 
 
Eccentric Regions LF 
Mean [Estradiol] LF*   -1.91      0.71    -.51    .012 
Mean [Estradiol] LL*    2.31      0.95     .46    .022 
 
Inferior Regions LF 
Mean [Estradiol] LF**  -1.55      0.50    -.56    .005   
Mean [Estradiol] LL**  1.94      0.67     .53    .007  
 
Superior Regions LF 
Mean [Estradiol] LF*   -1.37       0.58    -.46   .026 
Mean [Estradiol] LL*    1.66       0.78     .41   .043 
 
 
t p < .10, *p p p 
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estradiol in the LF phase were associated with higher S-cone sensitivity in the LF phase, with 
similar directional, though non-significant trends observed for S-cone sensitivity in the LL phase. 
These results seem to suggest that women with the least cyclicity in estradiol levels may perform 
best on the SWAP (i.e., those with a lower estradiol periovulatory surge and a higher late luteal 
phase estradiol level). This was explored further (see below) by examining change in estradiol 
between the two phases.  
 Correlations between changes in estradiol concentrations between the LF and LL 
menstrual cycle phases (LF-LL) and S-cone sensitivity measurements in the eccentric and 
hemiretinal sections from each testing session were examined (see Table 17). These correlations 
were performed for the pooled sample of women, as well as for women in each of the control 
and PMS groups. The results of these correlations indicated an inverse relationship between 
amount of change in estradiol between menstrual cycle phases and SWAP sensitivity in several 
eccentric and hemiretinal zones. Specifically, a greater amount of change in estradiol levels 
between the LF and LL phases (e.g. across the cycle) was significantly associated with either 
higher or lower S-cone sensitivities in most retinal locations in both phases. Results indicate that 
women who experience a higher level of the expected decrease in estradiol levels between the 
LF and LL phases demonstrate poorer SWAP performance (e.g. lower S-cone sensitivity) in both 
phases. Conversely women who show increases in estradiol from the LF to the LL phase 
demonstrate better SWAP performance (e.g. higher S-cone sensitivity). Thus, decreases in 
estradiol across the cycle were associated with low S-cone sensitivity, while increases in 
estradiol were associated with heightened S-cone sensitivity. These relationships were present 
for both PMS and control women, but the results were most pronounced for the pooled sample of 
women (N = 32).   Examination of the scatterplot of the relationship between the change in 
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Table 17 
 
Correlations Examining the Relationship Between Change in Estradiol Concentrations between 
the Late-Follicular (LF) and Late-Luteal (LL) Phases (LF-LL) and S-Cone Sensitivity 
Measurements in Eccentric and Hemiretinal Sections in Each Cycle Phase for Women with PMS 
Symptoms (Column A), Control Women (Column B), and the Combined Sample of all Women 
(Column C) 
 
 
Correlations Between Change in Estradiol ([LF]-[LL]) and Change in SWAP Scores 
 
Retinal Location Women with PMS   Control Group      Total Sample 
                          symptoms (N=14)       (N=18)            (N=32) 
 
 
Central LL    -.55*        -.41    -.52**   
 
Paracentral LL  - .48        - .06   -.39* 
 
Peripheral LL   -.31        - .20   -.27   
 
Central LF   -.32         -.52   -.44* 
 
Paracentral LF   -.30        - .39   -.40* 
 
Peripheral LF   .49        - .45   -.48* 
 
Superior Nasal LL  -.33        - .04   -.25 
 
Inferior Nasal LL  -.33                     .31   -.10 
 
Superior Temporal LL -.39         -.32   -.38* 
 
Inferior Temporal LL   -.42         -.25   -.37 
 
Superior Nasal LF  -.45       - .22    -.40* 
 
Inferior Nasal LF  -.44         -.33   -.44* 
 
Superior Temporal LF -.35       - .47*   -.41* 
 
Inferior Temporal LF   -.55**       - .55*   -.56** 
 
t p < .10, *p p p 
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estradiol concentrations between the LF and LL phases and S-cone sensitivity in the central 
location for a testing session occurring in the LL phase in Figure 13 indicates that that is indeed 
the case. That is, women with lower estradiol during the LL than the LF phase (the expected 
pattern) did more poorly on the SWAP while those with higher estradiol during the LL than the 
LF phase performed relatively better.  
 Texture Discrimination Task (T D T) 
 Means and standard deviations of trials responded to correctly in training and testing for 
the overall sample of women, women in the control group, and women with PMS symptoms are 
found in Table 18. Figure 14 shows the percentage of trials responded to correctly (i.e., %C) as a 
function of SOA for all women.  Figure 15 shows the percentage of trials responded to correctly 
(i.e., %C) as a function of SOA for control women and women with PMS symptoms. The figures 
LOOXVWUDWHWKDWZRPHQ¶V scores improved between day of training and day of testing as indicated 
by the leftwards shift in the psychometric function (i.e., %C improves with decreasing levels of 
SOA). This finding conforms to expected patterns of learning for TDT experiments (Karni & 
Sagi, 1991; 2006).  
Given that scores of 50% correct at any level of SOA parallels chance performance in 
this 2AFC design, the requisite threshold for assuming learning is assumed to be 75% correct or 
higher. The mean %C scores of women at training and testing in this study, however, seldom met 
the criterion necessary to achieve threshold (see Table 18). These truncated data did not allow us 
to make adequate Weibull-function curve fits needed to interpolate fitting parameters such as 
sensitivity (i.e., 1/threshold) or slope (i.e., performance efficiency). Despite the failure of our 
data to meet sufficient lapse rates of 95% or greater correct, overall gain changes characteristic 
of psychometric shifts along the SOA axis indicating improvement (learning) from training to 
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Table 18 
 
Mean Percent of Trials Identified Correctly for Six Levels of Stimulus Onset Asynchrony (SOA) 
in the Training and Testing Sessions of a Texture Discrimination Task (TDT) for: (1) a Pooled 
Sample of Women from Control and PMS Groups (Top Panel), (2) a Group of Control Women 
(Middle Panel) and (3) a group of Women with PMS Symptoms (Bottom Panel). 
 
Total Sample (N= 27) 
 
Training 
SOA 
Percent of Trials Correct at 
Training (M, SD) Testing SOA 
Percent of Trials Correct 
at Testing (M, SD) 
360 70.88 (16.21) 300 78.59 (21.03) 
160 69.17 (19.02) 200 77.25 (20.29) 
100 54.76 (11.90) 140 75.69 (19.16) 
80 52.93 (13.61)) 100 68.21 (16.35) 
60 51.71 (6.22) 60 54.95 (9.67) 
40 50.03 (5.41) 40 52.14 (5.14) 
 
Control Women (N= 14) 
 
Training 
SOA 
Percent of Trials Correct at 
Training (M, SD) Testing SOA 
Percent of Trials Correct 
at Testing (M, SD) 
360 72.84 (16.29) 300 76.37 (22.35) 
160 73.02 (17.13) 200 77.64 (21.37) 
100 53.50 (11.53) 140 74.79 (20.12) 
80 53.61 (17.33) 100 69.03 (15.43) 
60 50.77 (6.52) 60 53.34 (6.40) 
40 50.80 (4.60) 40 52.89 (4.82) 
 
 
Women with PMS Symptoms (N= 14) 
 
Training 
SOA 
Percent of Trials Correct at 
Training (M, SD) Testing SOA 
Percent of Trials Correct 
at Testing (M, SD) 
360 68.76 (16.50) 300 80.98 (20.13) 
160 65.02 (20.74) 200 76.83 (19.93) 
100 56.12 (12.62) 140 76.67 (18.84) 
80 52.19 (8.66) 100 67.32 (17.86) 
60 52.65 (6.01) 60 56.68 (12.32) 
40 49.26 (6.21) 40 51.33 (5.53) 
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testing were nonetheless observed. Thus, in order to control for individual idiosyncratic 
performance differences with the task, as well as to make comparisons, relative change scores 
were calculated for each SOA. These scores were calculated using the differential proportion of 
correct responses obtained by women for each SOA level: 330, 150, 100, 60, and 40 msec with 
the following formula: 
eq.1  (%C during Test Session - %C during Train Session) / 
  (%C during Test + %C during Train)  
Prior to performing any analyses examining group and phase effects, an independent 
samples t-test was conducted to determine any between group differences in the number of days 
between the TDT training and testing sessions. This test revealed no differences (p = .19) 
between the control (M= 13.07, SD= 4.68) and PMS groups (M= 18.62, SD= 13.89) in terms of 
days between TDT sessions. Given the absence of differences between groups in terms of days 
between training and testing, the influence of 1) group and 2) order of training and testing on 
performance at each level of SOA was examined using a two level repeated measures ANOVA 
using group (control or PMS) and training order (LL-LF or LF-LL) as between subjects IVs and 
relative change scores for the five levels of SOA as DVs (see Table 19). This analysis did not 
reveal a significant effect of group, p = .27, however, a trend was noted for the effect of 
menstrual cycle phase at the time of testing and training (phase order), p = .06. This trend 
indicated a higher proportion of correct responses for women who trained in the LL phase and 
tested in the LF phase, as opposed to those who performed the experiment in the reverse order. A 
second trend was also noted for an SOA x group effect, p = .07. A summary of the main effects 
and interaction results can be found in Table 20. 
The relative proportion of improvement between SOAs at training and testing days are 
shown according to menstrual cycle phase for the pooled sample of women in Table 21. To 
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Table 19 
 
Means and Standard Deviations for the Relative Proportion of Improvement Between Training 
and Testing Sessions for F ive Levels of Stimulus Onset Asynchrony (SOA) for a Group of 
Control Women (N = 14) and a Group of Women with PMS symptoms (N = 13) Participating in a 
Texture Discrimination Task (TDT) 
 
SOA Level 
Proportion Improvement 
 
Control (M, SD) PMS (M, SD) Total 
330 .012 (.09) .076 (.13) .043 (.11) 
150 .007 (.08) .088 (.12) .046 (.11) 
100 .122 (.12) .082 (.14) .103 (.13) 
60 .029 (.08) .029 (.10) .029 (.09) 
40 .017 (.07) .021 (.06) .019 (.06) 
 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      146 
Table 20 
 
ANOVA Table Showing the E ffects of Group and Cycle Phase at Time of Training and Testing on 
Proportion Improvement at F ive levels of SOA in a Task of Texture Discrimination  
 
 
Effect       F    df   Error df   p   K2  
 
 
Group     1.27   1       22  .27 .06          
Phase Ordert   3.86   1       22  .06 .15          
Group x Phase Order   2.23   1       22  .15 .09          
SOA**   4.26   4       88  .003     .16           
SOA x Groupt   2.29   4       88  .07 .09          
SOA x Phase Order  0.70   4       88  .59 .03          
SOA x Group x  1.73   4       88  .15 .07            
  Phase Order   
 
t p < .10, *p p p 
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Table 21 
 
Descriptive Data (Mean Proportion Improvement from Training to Testing) and ANOVA Results 
for the Texture Discrimination Task (TDT): Performance as a Function of Menstrual Cycle 
Phase at Training and Testing for Proportion of Correct Responses at F ive Levels of Stimulus 
Onset Asynchrony (SOA) for a Pooled Sample of Women (N= 26)  
 
Dependent 
Variable Session Order M (SD) F df Error df p K
2 
SOA 330* LF-LL .02 (.09) 4.86 1 23 .038 .17 
 LL-LF .11 (.12)      
SOA 150t LF-LL .03 (.10) 3.47 1 23 .075 .13 
 LL-LF .11 (.09)      
SOA 100 LF-LL .10 (.15) 0.42 1 23 .53 .02 
 LL-LF .13 (.88)      
SOA 60 LF-LL .02 (.09) 0.74 1 23 .40 .03 
 LL-LF .05 (.08)      
SOA 40 LF-LL .01 (.06) 1.61 1 23 .22 .07 
 LL-LF .04 (.07)      
 
 
Note: Women Trained in the Late-Follicular Phase and Tested in the Late-Luteal Phase (N=18) 
are Indicated by LF-LL while Women Trained in Late-Luteal Phase and Tested in Late-
Follicular Phase (N=9) are Indicated by LL-LF. 
t p < .10, *p p p  
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further examine the trend for order of menstrual cycle phase at time of training and testing, a 
follow-up univariate ANOVA was conducted in which relative proportion change in 
performance for the five levels of SOA were used as DVs, and phase order at time of training 
and testing was used as the between subjects IV. See Table 21 for a summary of all trends and 
main effects. For this test, homogeneity of variance calculations were returned within acceptable 
limits (p > .05), and as such, no corrections were employed in the interpretation of results. These 
post-hoc analyses indicated a significant difference in proportion change scores for SOA 330, p 
= .038, and a trend for those at SOA 150, p = .075. In both cases, women who trained in the LL 
phase and tested in the LF phase showed a higher proportion of correct answers between sessions 
than woman who trained and tested in the reverse order (see Figure 16). 
 In order to investigate the second trend of an SOA x group effect, a follow up ANOVA 
was conducted using the five levels of proportion change scores for each SOA as DVs and group 
as the between subjects factor. Means and standard deviations for proportion improvement for 
women in the control group, women with PMS symptoms, and across groups are found in Table 
19. The ANOVA revealed a significant between group effect at SOA 150, F(1, 26) = 4.20, p = 
.05, indicating that women with PMS symptoms had a higher proportion of improvement at the 
150 ms SOA than control women. Although no other trends or significant findings were revealed 
for the other SOAs, examination of Figure 17 shows the group x SOA interaction and indicates 
that the PMS women also demonstrated a higher, though non-significant proportion 
improvement at SOA 330.  
As with the SWAP analyses, five multiple regressions were performed using the 
proportion improvement scores for each of the five SOAs as the DV in each analysis with 
measured estradiol concentrations in the LF and LL phases and session order as the three 
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predictors. Session order was coded as 1 for women training in the LF phase and testing in the 
LL phase and 2 for the reverse. The five regressions were performed for the pooled sample of 
women, and then repeated for each of the PMS and control groups (see the overall regression 
findings in Table 22). For the pooled sample of women, the regression analyses revealed that the 
combination of IVs successfully predicted the proportion of correct responses for SOA 330, p = 
.049, adjusted R2 = .21, and SOA 150, p = .013, adjusted R2 = .31. While the same series of 
regressions performed on the control group yielded no significant effects, the combination of IVs 
predicted the proportion of performance improvement at three SOAs for women with symptoms 
of PMS: (a) SOA 330, p = .008, adjusted R2 = .71, (b) SOA 150, p = .032, adjusted R2 = .56, and 
(c) SOA 40, p = .002, adjusted R2 = .82. These results suggest that the performance on the TDT 
task in women with PMS symptoms may be influenced by session order and estradiol 
concentrations in each session to a much greater degree than control women. Furthermore, for 
the noted SOAs, estradiol levels and session order explained 56% to 82% of the variance in 
performance improvement between sessions for the PMS group. Examination of beta weights 
and the significance of the individual predictors in each regression analysis (see Tables 23 to 25) 
revealed that for all SOAs with a significant main effect, among the three predictors, order of 
testing session was usually the only unique predictor (although the exception was with SOA 40 
in the PMS group), and there was a positive relationship between session order and performance. 
Specifically, improvement in texture discrimination performance was predicted best by a session 
order characterized by training in the LL phase and testing in the LF phase. This finding that the 
menstrual cycle phase of testing and training affected improvement in texture discrimination 
performance was strongest for the PMS group at the extreme SOAs (40, 150, and 330). This 
finding indicates a possible link between menstrual cycle phase and texture learning in women 
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Table 22 
 
Summary Table Denoting E ffects for a Forced Entry Model of Regression using Concentrations 
of Estradiol at Training and Testing, and Session Order as Predictors of Improvement in a 
Texture Discrimination Task (TDT) with F ive Levels of Stimulus to Onset Asynchrony  
 
 
Pooled Sample (N= 24)  
 
SOA  df Error df  R Adjusted R2 R Square       F      p 
        Change 
 
330*  3     21  .55      .21    .31     3.10  .049 
150*  3     21  .63      .31    .39     4.53  .013 
100  3     21  .31     -.03    .10     0.76  .53 
60  3     20  .63     -.04    .10     0.70  .56 
40  3     20  .37      .01    .14     1.08  .38  
 
Control Group (N= 13) 
 
330  3     10  .24    -.23    .06     0.20   .11 
150  3     10  .66     .27    .44     2.62   .89 
100  3     10  .34    -.15    .12     0.44   .73 
60  3       9  .44    -.07    .20     0.74   .55 
40  3       9  .37    -.15    .13     0.47   .71 
 
Women with PMS Symptoms (N= 11) 
 
330**  3       7  .89     .71   .80    9.32   .008  
150*  3       7  .83     .56   .70    5.32   .032 
100  3       7  .58     .04   .33    1.16   .39 
60  3       7  .34    -.26   .12    0.31   .82 
40**  3       7  .93     .82   .87   15.79   .002 
 
 
t p < .10, *p  **p p  
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Table 23 
 
Coefficients for a Forced Entry Model of Regression for Prediction of Improvement in a TDT 
Paradigm with F ive SOAs using Concentrations of Estradiol at Training and Testing, and 
Session Order as Predictors in a Pooled Sample of Women (N = 24)  
 
 
SOA          B       SEB  E      p 
 
SOA 330 
[Estradiol] at Training .020        .014 .33    .16     
[Estradiol] at Testing  -.021        .019         -.27    .26   
Session Order**  .16        .052 .65  .007  
 
SOA 150 
[Estradiol] at Training -.005        .011 .093    .67     
[Estradiol] at Testing  -.017        .014         -.26    .25   
Session Order**  .12        .041 .61  .007  
 
SOA 100 
[Estradiol] at Training -.003        .018 -.047    .86     
[Estradiol] at Testing  -.016        .024          -.18    .52   
Session Order    .08        .069  .29    .26  
 
SOA 60 
[Estradiol] at Training -.003        .012 -.069    .80     
[Estradiol] at Testing  -.002        .016          -.030    .91   
Session Order    .052        .045  .29    .26   
 
SOA 40 
[Estradiol] at Training  .006        .010   .15    .56     
[Estradiol] at Testing  -.016        .012          -.36    .20   
Session Order    .057        .035  .40    .12 
 
t p < .10, *p p p  
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Table 24 
 
Coefficients for a Forced Entry Model of Regression for Prediction of Improvement in a TDT 
Paradigm with F ive SOAs using Concentrations of Estradiol at Training and Testing, and 
Session Order as Predictors in a Sample of Control Women (N = 13)  
 
 
SOA        B       SEB    E      p 
 
SOA 330 
[Estradiol] at Training  .011        .020  .23    .60     
[Estradiol] at Testing  -.017        .027          -.28    .55   
Session Order    .060        .079  .33    .47 
 
SOA 150 
[Estradiol] at Training -.008        .014 -.18    .60     
[Estradiol] at Testing  -.027        .019          -.49    .19   
Session Order    .087        .056  .52    .15 
 
SOA 100 
[Estradiol] at Training -.025        .026 -.38    .37     
[Estradiol] at Testing   .004        .035           .05    .91   
Session Order   -.047        .10  .19    .66 
 
SOA 60 
[Estradiol] at Training -.010        .017 -.24    .57     
[Estradiol] at Testing   .016        .022           .31    .50   
Session Order    .029        .066  .18    .67 
 
SOA 40 
[Estradiol] at Training  -.012        .017 -.29    .51     
[Estradiol] at Testing  -.004        .022          -.08    .86   
Session Order   -.030        .063 -.20    .65 
 
 
t p < .10, *p p p  
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Table 25 
 
Coefficients for a Forced Entry Model of Regression for Prediction of Improvement in a TDT 
Paradigm with F ive SOAs using Concentrations of Estradiol at Training and Testing, and 
Session Order as Predictors in a Sample of Women with PMS symptoms (N = 13)  
 
 
SOA        B       SEB    E      p 
 
SOA 330 
[Estradiol] at Trainingt .030        .015 .42    .09     
[Estradiol] at Testing            -.022        .020         -.23    .31   
Session Order***  .27        .053 .95  .001  
 
SOA 150 
[Estradiol] at Training .004        .014 .07    .80     
[Estradiol] at Testing            -.011        .019         -.15    .58   
Session Order**  .19        .048 .86  .006  
 
SOA 100 
[Estradiol] at Training -.001        .028        -.016    .97     
[Estradiol] at Testing  -.005        .038        -.047    .91   
Session Order    .17        .099 .58    .13  
 
SOA 60 
[Estradiol] at Training  .003        .022         .07    .88     
[Estradiol] at Testing  -.021        .030        -.31    .50   
Session Order    .06        .076         .27    .50  
 
SOA 40 
[Estradiol] at Training*  .017        .006          .51    .02     
[Estradiol] at Testing* -.018        .008        -.40    .05   
Session Order***  .134        .020        1.00  <.001  
 
 
t p < .10, *p p p  
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with PMS symptoms, but not women without such symptoms, and that the effect is present at 
particular SOAs (i.e., 40, 150, and 330).  Examination of the results from SOA 40 suggests that 
PMS women with higher estradiol at testing and lower estradiol at training, and those in the LL-
LF group, showed the greatest improvement in texture discrimination.  
 To further examine the effect of cycle phase on learning in this paradigm an additional 
series of hierarchical regressions was performed in which percent change in estradiol was 
entered at step one and session order was entered at step two, These analyses were performed for 
the pooled sample of women as well as for each group, A summary of all regression analyses is 
reported in Table 26. Coefficients are reported in Table 27. For the pooled sample of women, 
this series of analyses revealed that percent change in estradiol did not significantly predict 
improvement, but session order was a significant predictor of improvement on the TDT beyond 
that of percent change in estradiol at both SOA 330, p = .005, and SOA 150, p = .012. For the 
control group neither percent change in estradiol or session order was found to predict 
improvement on the TDT at any level of SOA. For the PMS group, however, session order was 
found to significantly predict performance above and beyond percent change in estradiol for 
SOA 330, p < .001, SOA 150, p = .004, and SOA 40, p < .001. Thus, the effect of session order 
seems to hold only for the PMS group and not the control group. In addition, percent change in 
estradiol was also a significant unique predictor of TDT improvement at SOA 330 and SOA 40; 
and both session order and change in estradiol explained 80 and 85 percent of the variance in 
TDT improvement, respectively. As with the first set of regressions, beta coefficients for 
significant models revealed that the relationship between proportion improvement and session 
order was positive, indicating that training in the LL phase and testing in the LF phase was 
associated with a higher proportion of improvement on the TDT.  
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Table 26 
 
Summary Table Denoting E ffects for a Hierarchical Regression using Percent Change Estradiol 
Between Training and Testing at Step 1, and Session Order at Step 2 as Predictors of 
Improvement in a Texture Discrimination Task (TDT) with F ive Levels of Stimulus to Onset 
Asynchrony  
 
Pooled Sample (N= 25)  
SOA    Step   df Error df  R Adjusted R2 R Square      F            F change 
        Change 
 
330   1    1     23  .04     -.04      .002    0.041   
   2**    1     22  .56      .25    .31     4.94  9.82 
150   1    1     23  .24      .02    .06     1.42   
   2*    1     22  .55      .24    .24     4.68  7.55  
100   1    1     23  .01     -.04    .00     0.05   
   2    1     22  .26     -.02    .07     0.82             1.64  
60   1    1     22  .10     -.04    .10     0.21   
   2    1     21  .30      .001   .08     1.02  1.81  
40   1    1     22  .12     -.03    .02     0.34   
   2    1     21  .36      .04    .11     1.51   2.66 
 
Control Group (N= 14) 
 
330   1    1     12  .02     -.08      .00     0.004  
   2    1     11  .19     -.14    .04     0.21  0.42 
150   1    1     12  .23     -.03    .05     0.67   
   2    1     11  .36     -.03    .07     0.80  0.94  
100   1    1     12  .18     -.05    .03     0.39   
   2    1     11  .28     -.09    .05     0.48  0.58  
60   1    1     11  .47      .15    .22     3.07   
   2    1     10  .48      .08    .01     1.51  0.18  
40   1    1     11  .03     -.09    .001     0.07   
   2    1     10  .19     -.16    .04     0.19   0.36 
 
Women with PMS Symptoms (N= 11) 
 
330   1    1      9  .15     -.09      .02     0.20   
   2***    1      8  .90      .77    .80    17.95          34.97 
150   1    1      9  .15     -.09    .02     0.21   
   2**    1      8  .83      .60    .66     8.58          16.59  
100   1    1      9  .03     -.11    .001     0.08   
   2t    1      8  .60      .20    .36     2.24           4.46  
60   1    1      9  .17     -.08    .03     0.27   
   2     1      8  .31     -.13    .06     0.41           0.56  
40   1    1      9  .25     -.04    .06     0.59   
   2***    1      8  .95      .89    .85    40.74          76.00  
 
t p < .10, *p p p 01 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      156 
Table 27 
 
Coefficients for a Hierarchical Model of Regression using Percent Change Estradiol Between 
Training and Testing at Step 1, and Session Order at Step 2 as Predictors of Improvement in a 
Texture Discrimination Task (TDT) with F ive Levels of Stimulus to Onset Asynchrony  
 
Pooled Sample (N= 25) 
SOA B SE B E p 
330     
% change [E] -0.001 .001 -0.31 .13 
Session Order 0.15 0.05 0.62 .01 
150     
% change [E] < 0.01 < 0.01 0.01 .97 
Session Order 0.11 0.04 0.54 .01 
100     
% change [E] < 0.01 0.001 -0.11 .63 
Session Order 0.08 0.06 0.29 .21 
60     
% change [E] < 0.01 < 0.01 -0.03 .90 
Session Order 0.06 0.04 0.31 .19 
40     
% change [E] > 0.01 > 0.01 -0.28 .23 
Session Order 0.05 0.03 0.37 .12 
Control Group (N= 14) 
330     
% change [E] < 0.01 0.01 -0.18 .65 
Session Order 0.05 0.07 0.25 .53 
150     
% change [E] < 0.01 0.001 -0.003 1.00 
Session Order 0.06 0.06 0.36 .35 
100     
% change [E] 0.001 0.001 0.37 .36 
Session Order -0.07 0.09 -0.29 .46 
60     
% change [E] 0.001 0.001 0.37 .33 
Session Order 0.02 0.06 0.15 .68 
40     
% change [E] < 0.01 0.001 0.13 .76 
Session Order -0.04 0.06 -0.24 .56 
 
Women with PMS Symptoms (N= 11) 
330     
% change [E] -0.001 < 0.01 -.037 .05 
Session Order 0.26 0.05 0.92 < 0.01 
150     
% change [E] < 0.01 < 0.01 -0.05 .81 
Session Order 0.18 0.04 0.84 .004 
100     
% change [E] -0.001 0.001 -0.18 .55 
Session Order 0.18 0.09 0.62 .07 
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60     
% change [E] < 0.01 0.001 -0.23 .52 
Session Order 0.05 0.07 0.26 .47 
40     
% change [E] -0.001 < 0.01 -0.48 .002 
Session Order 0.13 0.02 0.95 < 0.01 
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Eyetracking  
The final averaged and fitted eye movement plots for all temporal frequencies (0.25 to 
2.0 Hz) can be seen in Figure 18.  The first column shows traces made during the LL menstrual 
cycle phase and the second column shows traces made during the LF phase. Data are the result of 
signal averaging as outlined in the Data Analysis section of the Procedure. This averaging 
procedure resulted in six women being omitted from the control group and three women being 
omitted from the PMS group due to extensive eye blinks or missed tracking positions. 
Continuous lines are sinusoidal functions fitted to the data. Characteristic lag shifts are evident in 
the higher frequency target movements (details in Figure 18 caption). The means and standard 
deviations for the latency between eye-gaze and stimulus position as a function of frequency and 
menstrual cycle phase are reported in Tables 28 (control group) and 29 (PMS group). Means and 
standard deviations for latency between eye-gaze and stimulus position collapsed across 
sinusoidal wave position for the five frequencies for both groups in both menstrual cycle phases 
are found in Table 30. 
As with the CCS and SWAP procedures, the effect of group and menstrual cycle phase 
on smooth pursuit eye-movement was tested using a three factor mixed ANOVA. Again, 
menstrual cycle phase consisted of two levels (LF and LL phases) and constituted the first within 
subjects IV. The second within subjects factor and was defined by the five oscillating target 
frequencies: 0.25 Hz, 0.5 Hz. 1.0 Hz, 1.25 Hz, and 2.0 Hz., while the final factor entered in the 
analysis was sinusoidal phase position, which was defined by five levels corresponding to 0q, 
90q, 180q, 270q and 360q  along the function. These positions represent tracking a target position 
start (center), extreme left-of-center, through the center, extreme right-of-center, and return-to-
end at center, respectively.  As with all other analyses, group was used as a between subjects 
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Table 28 
 
Means and Standard Deviations for Latencies Between Eye-gaze and Stimulus Position (q) at F ive Positions along an Averaged Sinusoidal 
Function in an Eye-Tracking Procedure. Late Follicular (LF) and Late Luteal (LL) Phase Latencies for a Control Group of Women (N=12) are 
shown Across the F ive Oscillating Target F requencies. 
 
Control Group 
 
Frequency (Hz)   Late Follicular Phase (M, SD)                        Late Luteal Phase (M, SD) 
 
   0q       90q  180q           270q       360q   0q           90q        180q   270q            360q 
 
 
0.25               -0.48 (2.91)   -12.79 (1.34)  1.47 (2.52)  13.07 (.69)    -0.50 (2.94)       -.59 (2.08)  -12.79 (0.83)    0.43 (2.10) 12.82  (0.81)  -0.53 (2.20) 
 
0.50     0.26 (2.71)   -12.42 (1.38)  1.17 (3.68)  13.04 (.82)    0.12 (3.23)        .30 (2.81)    -12.36 (1.23)  -.52 (3.25)    12.56 (0.89)  .017 (3.15) 
 
1.0     4.44 (5.00)  -8.17 (1.69) -2.01 (5.48)   9.46 (1.71)   4.68 (5.49)        4.58 (3.02)   -8.88 (1.60)   - 1.68 (5.30) 10.00 (2.15)  5.17 (3.15) 
 
1.25     5.42 (3.41)    -7.05 (2.26)  -5.23 (3.62)  8.32 (2.03)   5.99 (3.78)         5.34 (3.52)   -7.33 (1.30)    -6.03 (3.03)   7.63 (1.86)   6.03 (3.50) 
 
2.0      5.07 (3.06)  1.20 (4.62)   -3.38 (3.17)  0.96 (2.64)   5.06 (3.02)        5.08 (2.08)     -.43 (3.66)   -4.10 (2.42)    1.46 (4.09)  5.44 (2.10)
  
 
Marginal Mean   2.94 (0.63)   -7.85 (0.38)   -1.60 (0.57)   8.97 (0.35)   3.07 (0.67)        2.89 (0.58)   -8.36 (0.52)   -2.29 (0.60)    8.89 (0.46)  3.23 (0.62) 
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Table 29 
 
Means and Standard Deviations for Latencies Between Eye-gaze and Stimulus Position (q) at F ive Positions along an Averaged Sinusoidal 
Function in an Eye-Tracking Procedure. Late Follicular (LF) and Late Luteal (LL) Phase Latencies for a Group of Women Reporting PMS 
Symptoms (N=13) are shown Across the F ive Osci llating Target F requencies 
 
PMS Group 
 
Frequency (Hz)   Late Follicular Phase (M, SD)                        Late Luteal Phase (M, SD) 
 
   0q     90q            180q       270q    360q              0q       90q      180q                270q           360q 
 
 
0.25  -0.78 (2.48)   -13.21 (1.17) 0.34 (1.84)  12.97 (.72)    -0.62 (2.85)      0.24 (2.41)  -12.94 (.98)     0.54 (2.02)    13.79 (1.32)   .38 (2.37) 
 
0.50  0.27 (3.39)   -10.74 (5.66)  0.65 (3.19)  12.35 (1.01)    0.37 (3.62)      2.09 (4.29)  -10.25 (4.49)  -0.98 (3.92)   11.99 (3.55)  2.14 (4.89) 
 
1.0  4.88 (1.98)    -8.41 (1.54)  -2.30 (3.97)   9.48 (1.86)   5.23 (1.89)       4.22 (4.67)   -7.17 (2.16)    -.84 (3.42)   10.65 (2.20)  4.65 (4.98)  
 
1.25  5.23 (3.64)   -6.43 (1.79)   -5.41 (2.75)   7.49 (2.22)   5.96 (3.95)      5.38 (4.49)  - 6.25 (2.75)  -3.93 (4.44)    8.10 (3.16)   5.80 (4.56) 
 
2.0  5.12 (2.32)    0.89 (2.86)    -3.64 (3.34)   .012 (2.95)   5.09 (2.24)      5.10 (2.84)     0.21 (3.71)  -2.64 (3.75)   1.74 (3.43)    5.47 (2.77) 
   
 
Marginal Mean 2.95 (0.61)   -7.58 (0.36)  -2.07 (0.54)   8.46 (0.34)   3.21 (0.64)      3.41 (0.56)     -7.28 (0.50)  -1.57 (0.57)  9.26 (0.44)  3.69 (0.59) 
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Table 30 
 
Means and Standard Deviations for Latencies Between Eye-gaze and Stimulus Position Collapsed Across Sinusoidal Position (q) for the F ive 
Oscillating Target F requencies in the Late Follicular (LF) and Late Luteal (LL) Phases of the Menstrual Cycle for Both Women with PMS 
symptoms (N= 13) and Control (N= 12) Groups. 
 
 
 Control PMS  
Frequency Late Follicular Late Luteal Late Follicular Late Luteal Marginal Mean 
0.25 0.16 (.30) -0.13 (.25) -0.26 (.29) 0.40 (.24) 0.04 (.16) 
0.50 0.43 (.51) 0.04 (.35) 0.58 (.49) 1.00 (.34) .51 (.22) 
1.0 1.68 (.56) 1.84 (.53) 1.78 (.54) 2.30 (.51) 1.90 (.33) 
1.25 1.49 (.45) 1.13 (.45) 1.37 (.43) 1.82 (.43) 1.45 (.25) 
2.0 1.78 (.65) 1.49 (.50) 1.50 (.62) 1.97 (.48) 1.69 (.36) 
Grand Mean 1.11 (.36) 0.87 (.29) 0.99 (.35) 1.50 (.28)  
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variable. For this analysis no significant main effects or interactions were observed for either 
menstrual cycle phase or group (see Table 31). As expected, significant main effects were 
observed for frequency, p < .001, and position, p < 7KHVHHIIHFWVLQGLFDWHGWKDWZRPHQ¶V
eye position differed as a function of stimulus position as well as the speed at which the stimulus 
was traveling at each of the five frequencies. This was not surprising given that target velocity 
increased with each presentation of a trial. 
In addition to the anticipated effects described above, a trend was noted for a menstrual 
cycle phase x group interaction, p = .057. This trend reflected the fact that in the LL phase of the 
menstrual cycle, women with PMS symptoms demonstrated a greater excursion distance with a 
bias toward eye movements from the left to right. In order to further elucidate this trend, 
ZRPHQ¶VVFRUHVZHUHFRQVROLGDWHGDFURVVDOOILYHDYHUDJHGJD]HSRVLWLRQVIRUHDFKIUHTXHQF\IRU
both menstrual cycle phases. A series of independent samples t-tests revealed group differences 
in excursion distance (i.e., amplitude) in the LL phase of PMS women compared to controls with 
the slower oscillating target frequencies of 0.25 Hz, t(31) = -2.43, p = .021 (control mean = -
1.66, SD = 4.29, PMS mean = 2.22, SD = 4.87) and 0.50 Hz, t(34) = -2.63, p = .013, (control 
mean = -0.75, SD = 5.38, PMS mean = 4.39, SD= 6.37). No group differences in frequency were 
noted in the LF phase of the menstrual cycle. In addition, no significant within group differences 
were noted between menstrual cycle phases. Thus, the eye-tracking experiment revealed a trend 
for differences between groups in the LL phase of the menstrual cycle, in which women with 
PMS symptoms demonstrated higher left-to-right excursions at lower-end frequencies (see 
Figure 19).
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Table 31 
 
ANOVA Table Showing the E ffects Between Smooth Pursuit Stimulus F requency (0.25 Hz, 0.5 
Hz, 1.0 Hz. 1.25 Hz, and 2.0 Hz), Sinusoidal Target Position (0q, 90q, 180q, 270q and 360q), 
Menstrual Cycle Phase, and Group in an Eye tracking Experiment 
 
Eccentric Regions 
 
Dependent Variable  F    df Error df p   K2  
 
Group    .38   1     23          .54 .02     
 
Phase      .54   1     23          .47 .02     
 
Phase x Group t  4.06   1     23          .06 .15   
 
Frequency***   .72   4     20      < .001 .72   
 
Frequency x Group  .70   4     20          .60 .12   
 
Position***         431.76   4     20       < .001 .99  
 
Position x Group  .30   4     20          .88 .06  
 
Phase x Frequency  .19   4     20          .94 .04   
 
Phase x Frequency x Group .11   4     20          .98 .02   
   
Phase x Position  .74   4     20          .57 .13   
 
Phase x Position x Group .39   4     20          .81 .07   
 
Frequency x Position***     97.20  16      8       < .001 1.00   
 
Frequency x Position x 
Group    1.42  16     8          .32 .74   
 
Phase x Frequency x    
Position   .51 16     8         .88 .51   
 
Phase x Frequency x 
Position x Group  .72 16     8         .73 .59   
 
t p < .10, *p p p  
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Discussion 
Summary of F indings 
Psychophysical techniques have proven to be an informative and noninvasive method of 
H[SORULQJYLVXDOIXQFWLRQLQJLQQHXURGHJHQHUDWLYHGLVRUGHUVVXFKDV3DUNLQVRQ¶VGLVHDVH
(Archibald, Clarke, Mosimann, & Burn, 2009), Multiple Sclerosis (Caruana, Davies, Weatherby, 
Williams, Haq, Foster et al., 2000) and psychiatric disorders such as depression (Wesner & Tan, 
2006; Zomet, Amiaz, Grunhaus, & Polat, 2008). Initial psychophysical investigation of the 
influence of reproductive hormones on visual stream functionality has additionally suggested 
anomalies in KC pathways related to hormone exposure (e.g., Eisner & Incognito, 2006). Given 
the perceptual differences noted in such clinical presentations, the substantial overlap between 
the physiological and emotional symptoms of PMS and seasonal depression, and the absence of 
literature examining the effects of reproductive hormones on neurological mechanisms 
responsible for learning and memory, further investigation of cognitive, cortico-perceptual, and 
brainstem operations was warranted. The purpose of the present study therefore was to 
investigate the effect of menstrual cycle phase and hormonal sensitivity on a series of 
psychophysical tasks designed to best isolate visual pathway hierarchical functioning  in women 
with and without PMS symptoms.  
Given the natural fluctuation of hormones across the menstrual cycle, it was expected that 
estradiol levels would be higher during the LF than during the LL phase of the menstrual cycle. 
Results confirmed this effect and also indicated a trend for a phase x group interaction. 
Exploration of this trend revealed that women in the control group demonstrated expected 
fluctuations in estradiol levels between laboratory sessions, showing significantly higher 
concentrations of the hormone during the LF phase of the menstrual cycle. Women in the PMS 
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group, however, did not show the expected change in estradiol levels across the menstrual cycle 
despite being scheduled using the same procedures as women in the control group. Thus, the 
typical shift in estradiol levels between the LF and LL phases was attenuated in women with 
PMS symptoms.  
 With respect to CCS, there was evidence of an overall phase effect (p = .02) whereby 
analyses revealed higher overall CCS in the luteal versus the follicular phase across both colour 
V\VWHPV,QDGGLWLRQGLVFUHWHV\VWHPVSHFLILFHIIHFWVIRU³UHG-JUHHQ´DQG³EOXH-\HOORZ´VWLPXOXV
conditions were found (p = .001). For the R/G condition, a trend for phase indicated higher 
overall sensitivity for stimuli presented in the LL as opposed to the LF phase of the menstrual 
cycle (p = .06). A group x frequency effect (p = .02) revealed that differences in performance 
between groups were most notable in the lower frequency (e.g. 0.5 cpd) conditions and that in 
these conditions, women in the control group demonstrated greater CCS than women with PMS 
symptoms. A phase x frequency x orientation interaction (p = .05) also revealed that, at the 45 
degree orientation LL phase CCS was greater than LF CCS at low frequencies but not high 
frequencies, while at the 90 degree orientation, LL CCS was better than LF at high frequencies 
but not low frequencies. A group x orientation x frequency trend (p = .07) indicated that, at 45 
degrees, PMS women outperformed control women at 1.5 cpd but not 4.0 cpd, while at 90 
degrees, PMS women outperformed control women at 4.0 cpd but not 1.5 cpd. Furthermore, 
regressions revealed that estradiol levels were the best predictors of R/G CCS for the control 
women in the 45q orientation condition. 
As with R/G stimuli, results for B/Y stimuli showed a trend for the effect of phase (p = 
.07), with higher sensitivity values observed in the LL as opposed to the LF phase of the 
menstrual cycle. A group x phase x frequency interaction (p = .04) revealed that the control 
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group showed a phase effect (LL > LF) at 0.5 cpd (p = .016), but the PMS group did not. Lowest 
CCS values were observed across all groups and all orientation conditions at 4.0 cpd with the 
convergence of values especially notable in the 45q and 90q orientation conditions.  In addition, 
between session changes in estradiol predicted CCS at all orientations for all women (pooled 
sample), and estradiol levels and changes in estradiol best predicted B/Y CCS in the 0q 
orientation condition for all women. 
Although no group differences were observed with respect to S-cone sensitivity in either 
eccentric or hemi-retinal sections, a trend for a phase x zone effect (p = .10) was observed for the 
eccentric regions. This trend showed heightened S-cone sensitivity in the LL phase of the 
menstrual cycle in the central region of the retina. Regression analyses using total S-cone 
sensitivity in six retinal locations as dependent variables and estradiol levels in the LL and LF 
phases of the menstrual cycle as independent variables revealed that SWAP performance is 
predicted in the LF phase by a combination of estradiol concentrations in the LL and LF phases, 
and that each of these variables serves as a unique predictor. Surprisingly, this analysis indicated 
that the weights of the predictors were in opposition to one another suggesting that high levels of 
estradiol in the LL phase and low levels of estradiol in the LF phase best predict S-cone 
sensitivity in the LF phase of the menstrual cycle. No combination of variables was found to 
predict S-cone sensitivity in the LL phase of the menstrual cycle. Correlational analyses and 
examination of scatterplots indicated that women whose estradiol levels increased from the LF to 
the LL phase generally had the highest SWAP performance at both phases.   
)RUWKH7'7H[SHULPHQWZRPHQ¶VVFRUHVGHPRQVWUDWHGDQH[SHFWHGOHIWZDUGVKLIWIURP
training to testing, indicating consolidation of the task, however, no significant between group 
differences were observed with respect to the percentage of trials responded to correctly for any 
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level of SOA in training or testing. A trend for a group x SOA interaction (p = .07) revealed 
better TDT performance in PMS than control women at a SOA of 150 with a similar trend at 
DQRWKHUORZ62$7RHYDOXDWHZRPHQ¶VSHUIRUPDQFHEHWZHHQWUDLQLQJDQGWHVWLQJPRUH
thoroughly, the proportion of improvement between sessions was also examined. As well, the 
influence of menstrual cycle phase and level of estradiol at training and testing was taken into 
consideration. Results indicated that the order of menstrual cycle phase at the points of training 
and testing exerted a significant effect on performance such that women training in the LL phase 
and testing in the LF phase exhibited a higher proportion of correct responses than women who 
trained and tested in the reverse order. The effect of session order exerted a more pronounced 
influence on texture learning than concentrations of estradiol in either phase and than percent 
change in estradiol. This effect was found for the PMS group only. Session order was found to 
be a unique predictor of improvement at SOAs of 330, 150, and 40 in PMS women. At the SOA 
of 40, estradiol levels at both training and testing were also unique predictors. Finally, 
percentage change in estradiol between training and testing was a unique predictor of 
improvement for PMS women at SOAs of 330 and 40. 
The final eye-tracking experiment examined whether women differed in their ability to 
track stimuli moving at five different frequencies as a function of menstrual cycle phase or 
group. Notwithstanding a main effect of frequency, no significant effects were observed for 
differences in SPEM between women in the control and PMS group or between menstrual cycle 
phases. However, a group x phase trend (p = .06) revealed differences in eye movement 
excursion (amplitude) with women with PMS symptoms showing a bias for higher excursion 
distances from left to right during the LL phase.  
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F indings for Salivary Estradiol Analyses 
 The finding that estradiol levels fluctuated differentially between women in the control 
and PMS groups was unexpected given that differences of this kind in women with PMS or 
PMDD have not been previously reported. The hypothesis that luteal phase-specific differences 
in gonadal steroids accompany mood and behavioral symptoms has been inconsistently reported 
in previous studies. Rubinow and Schmidt (2006) did not observe any group differences in the 
levels or patterns of secretion of several different reproductive hormones, including: 
progesterone, estradiol, follicle-stimulating hormone, luteinizing hormone, testosterone-
estradiol-binding globulin, dehydroepiandrosterone sulfate, dihydrotestosterone, prolactin, and 
cortisol. Other researchers such as Seippel and Backström (1998) have found associations 
between high LL phase concentrations of estradiol and the severity of PMS symptoms.  Thus, 
our findings, while compelling, require replication and should be interpreted with caution.  
 In the present study, control women and women with PMS symptoms did not differ 
significantly in their levels of estradiol within phases. That is, in both the LL and LF phases, the 
JURXSV¶HVWUDGLROOHYHOVZHUHFRPSDUDEOHp > .05), and despite an overall effect for the full 
sample of women to exhibit a shift in the expected direction between menstrual cycle phases 
(higher estradiol levels in the LF phase than in the LL phase), only control women demonstrated 
a phase shift change that was significant. Thus, the data obtained from women in the present 
study indicates that those reporting a history of few, if any, premenstrual symptoms have a 
tendency to exhibit a greater drop in estradiol levels between the late follicular and late luteal 
phases when compared with women reporting a high level of PMS symptoms. Certainly, the 
relative stability of estradiol levels between the LF and LL phases in our PMS group could be of 
importance in understanding any evidence of dysregulated visual-based perceptual and non-
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perceptual mechanisms of the systems in PMS women that often appear to be responsive to the 
dynamic changes of estradiol levels in non-PMS women. More research is necessary, however, 
as it will be important to replicate the estradiol assay results in another sample before the 
findings can be tied to the experimental findings with confidence.  
 As described above, findings in this area are inconsistent. Previous studies have shown 
no evidence of differences in estradiol levels between women with and without PMS symptoms 
(Schmidt et al., 1998) while others have found differences between amounts of free and bound 
estradiol and overall levels of estradiol in the LL phase.  In a sample of 129 women who 
provided eight serum and urine samples across the cycle, Thys-Jacobs, McMahon, and 
Bilezikian (2007) found significantly lower free (e.g. unbound) estradiol, percent free estradiol, 
and significantly higher serum hormone binding globulin in the LL phase of PMDD women 
compared to asymptomatic controls. No differences were found between groups in overall levels 
of estradiol within phases. This is in contrast to the findings of Wang, Seippel, Purdy, and 
Backström, (1996) who reported higher serum estradiol and lower serum progesterone during the 
luteal phase in women with PMS symptoms. Although neither of these studies commented 
specifically on the shift in hormone levels between phases, Wang et al. (1996) provided raw data 
which was similar to the present study in that control women, and not women with PMS 
symptoms, exhibited a characteristic and expected shift in levels of estradiol between the LF and 
LL phases. This supports a hypothesis of dysregulated cyclicity in women with PMS women and 
validates our findings in the study herein. The interpretation and generalization of findings in 
studies comparing steroid concentrations in women with and without PMS symptoms is difficult 
as often different methods are used to operationalize PMS symptoms, and at times, the meanings 
of subjective ratings are unclear (Smith, Schmidt, & Rubinow, 2003). This is complicated further 
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by the absence of an agreed upon method of classification for women with symptoms of PMS or 
PMDD and difficulty tracking the parameters of the menstrual cycle. For example, it is not clear 
whether PMS definitions should require an increase in symptoms between the rest of the cycle 
and the luteal phase, how much of a shift is required, the extent to which high symptoms in the 
luteal phase is important to the overall definition of pms, and whether having a high level of 
luteal phase symptoms is more or less important than the having a large increase in symptoms 
during the luteal phase.   
When considering the degree of change between phases, these data are unique in that 
they suggest that women with PMS symptoms demonstrate smaller fluctuations in their estradiol 
levels between the LF and LL phases than women without PMS symptoms. This suggests that 
larger shifts in estradiol levels may act as a protective factor against the aversive constellation of 
physiological and affective symptoms that occur in some women with regularity across the 
menstrual cycle and which characterize PMS and PMDD.  
Evidence suggests that PMS symptoms are likely the result of several complex factors 
whose interactions and interplay, may culminate in its phenotypic expression. Among these 
include the other neuroendocine systems, neurotransmitter systems, genetics (e.g. epistasis), and 
environmental characteristics. Recent evidence has implicated four single nucleotide 
polymorphisms in intron four of the ESR1 gene as conferring genotypic differences between 
women with and without PMDD (Miller, Vo, Huo, Roca, Schmidt, & Rubinow, 2010). This 
finding alone does not guarantee the presence of mood dysfunction, but it does implicate such 
factors as heredity, and potentially epigenetics (as symptoms were associated with SNPs and not 
more substantial alterations of DNA) in the expression of dysphoric symptoms associated with 
the menstrual cycle. Although overly simplistic on its own, the contribution of shifts in estradiol 
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(or lack of a shift) between menstrual cycle phases as a potential etiological factor of PMS in 
concert with the additional factors described above warrants further investigation. 
  Although extremely intriguing, these results should be interpreted with caution as 
salivary sampling occurred on only one occasion for each phase for each woman participating in 
the study. Thus, these data suggest a pattern of hormonal fluctuation characteristic of one 
menstrual cycle only, and may not hold up if pooled with data collected across several 
consecutive menstrual cycles. However, it is also worth noting that our method of saliva 
sampling was superior to the majority of methods published so far. That is, each salivary sample 
we collected contained saliva that was provided on three occasions over a period of 
approximately three hours. This differs from the protocols of some previous studies that have 
permitted participants to collect their own salivary estradiol samples at home (e.g. Chatterton, 
Mateo, Hou, Rademakeer, Acharya, Jordan, et al., 2005), sampled at only one interval (Rosen 
and Lopez, 2009) or employed the use of aids such as cotton salivettes to assist with the 
production of saliva (Budde, Voelcker-Rehage, Pietrassyk-Kendziorra, Machado, Ribeiro, & 
Arafat, 2009), which is not typically recommended (Shirtcliff, Granger, Schwartz, & Curran, 
2001). The fact that our samples were collected in a laboratory under controlled conditions and 
across a three hour interval to control for pulsatile steroid release may mean that our salivary 
sampling method better captured actual estradiol levels at each cycle phase, and may constitute a 
strength of this study. 
F indings for Chromatic Contrast Sensitivity (C CS) 
 Cortical PC and KC functionality was assessed in the CCS experiment.  Hypothesis 1 
held that higher CCS would be observed in the LF as opposed to the LL phase, while hypothesis 
2 examined whether PMS symptoms would be associated with potential enhancements in CCS 
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owing to the supposition that these symptoms may be the result of a heightened sensitivity to 
normally fluctuating levels of ovarian steroids. The constellation of symptoms that define PMS 
and PMDD are primarily captured by two clusters represented by disturbances in somatic and 
affective functioning, and the broad spectrum of these symptoms suggests several potential 
avenues of investigation into the effects of estradiol on central nervous system functioning. 
Given the substantial overlap between symptoms of PMS and those of other affective disorders 
such as seasonal depression, and the recently identified deficits associated with visual system 
functionality in those with seasonal depression (Wesner & Tan, 2006), menopausal women 
(Eisner & Incognito, 2006), and patients using the anti-cancer agent tamoxifin (Eisner et al., 
2004b), an examination of the influence of estradiol on these systems was warranted.  
The finding of a significant overall phase effect and trends for a phase effect indicating 
higher CCS in the LL phase of the menstrual cycle in both R/G and B/Y CCS conditions 
supports a putative effect of reproductive steroids on V1 and associated ventral streams, 
however, this finding was not in keeping with the expected hypothesis (hypothesis 1) of 
enhanced performance in women with PMS symptoms or women in the LF phase of the 
menstrual cycle when levels of estradiol are highest. The present findings suggest that lower 
estradiol levels (LL phase) and low hormone sensitivity (control group) are associated with high 
cortical-based CCS. Interestingly, although not significant, with respect to the R/G stimuli, 
women in the PMS group demonstrated poorer performance than women in the control group at 
corresponding menstrual cycle phases for all orientation conditions and for the 0.5 cpd frequency 
condition. A similar, though non-significant observation of superior performance in CCS for 
control women in the LL phase was also noted with B/Y stimuli. These observations suggest that 
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further investigation may be warranted to better elucidate the effect of hormonal sensitivity on 
CCS.   
 As well, results demonstrated that the differentiation of groups and, in many cases, 
menstrual cycle phase is possible using only one of the three frequency conditions. Separation of 
performance on measures of CCS was evident using 0.5 cpd gabor presentations. Convergence 
of CCS measurements between groups and phases, however was noted with the higher frequency 
4.0 cpd gabors. This may simply be due to the fact that the discernment of chromatic contrast 
changes are significantly reduced at higher frequencies (i.e., the low pass nature of chromatic 
channels), and because of this overall reduction in sensitivity, less salient CCS separations across 
experimentally manipulated variables are to be expected. The convergence of group and phase 
CCS data at the higher frequency was most pronounced with respect to the R/G gabors and less 
so with the B/Y condition. This suggests that somehow, factors such as receptive field 
orientation and reproductive hormones may play a larger role in PC operations than in KC 
operations. We base this conclusion on two assumptions: (1) R/G and B/Y gabors typically elicit 
early cortical operations (e.g., Elliott, Roth, Highsmith, Werner, & Webster, 2010; Wachtler, 
Sejnowski, & Albright, 2003), and 2) our near-isoluminant gabors were specifically modulated 
along deutan and tritan confusion lines which we infer optimally elicit PC and KC responses, 
respectively. 
The higher overall CCS and greater performance separation between menstrual cycle 
phases with R/G stimuli suggests a stronger influence of the effects of estradiol on PC systems, 
and that this occurs perhaps further downstream in primary visual cortex (V1). Color information 
from L and M cones is supplied to layer 4CE of V1 (Chatterjee & Callaway, 2003) via the outer 
layers of the LGN forming the PC pathway which has also been shown to provide detailed form 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      174 
information via small centre-surround receptive fields (Sumner, Anderson, Sylvester, Haynes, & 
Rees, 2008). Researchers believe that the PC pathway was shared by ancestral primates 
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primates. This supposition has led investigators to hypothesize that colour information 
communicated along the PC pathway could be exploiting a pre-existing older mechanism used to 
convey form perception (Mollon, 1989). It is thus possible that information destined for form 
perception and L and M chromatic information share a common population of cells in V1 
(Sumner et al., 1998). In contrast, chromatic information from S cones is supplied to V1 via 
layers 3B and 4A (Chatterjee & Callaway, 2003) through afferent projections of the KC system 
and is therefore segregated from parvocellular input at layer 4CE. However, recent evidence 
from fMRI investigations has demonstrated effects in V1 for S-cone defined orientation 
selectivity as well (Sumner et al., 2008). This suggests that a proportion of S-cone cell 
projections throughout primary visual cortex have joint responsiveness to both color and early 
form features such as orientation that are not anatomically distinguishable . Thus, the KC stream 
may be unique in that chromatic and orientation selective information share common processing 
areas in V1. Such a convergent pathway could therefore explain the less prominent estradiol 
modulation effects we noted in the B/Y conditions. 
The trend for the effect of phase was strongest for the R/G as opposed to the B/Y 
chromatic condition indicating a more robust change in performance between phases for the R/G 
stimuli. The fact that chromatic information (R/G and B/Y) is processed through distinct streams 
could account for the apparent lack of change in CCS with changes in phase and/or orientation 
when the B/Y gabors were chromatically modulated along the tritan line (e.g. the KC pathway). 
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These results also indicate that parvocellular as opposed to koniocelluar pathways may be more 
responsive to changes in reproductive steroids such as estradiol. 
 That overall sensitivity values were highest for R/G stimuli was not surprising given the 
inherent properties of the parvocellular system and the apparatus used to perform these 
measurements (e.g., CRT characteristics). Noteworthy, however, were the trends for the effect of 
menstrual cycle phase for both chromatic conditions. In this experiment, we observed trends for 
phase effects in both chromatic conditions indicating heightened CCS in the LL phase of the 
menstrual cycle and better performance when estradiol levels are low. In addition, and although 
not significant, control women nearly always outperformed women with PMS symptoms in 
corresponding phases of the menstrual cycle suggesting better performance in women who are 
not hormonally sensitive. These results suggest downstream effects of estradiol on cells of V1 
layers 3B and 4A. Although phase differences were also noted with the implied KC systems, the 
inter-phase relative differences in CCS were less apparent than those observed for the 
parvocellular system and may indicate a greater resistance to the influence of estradiol in layers 
unique to these projections (i.e. layer 4CE). 
A hypothesis of a potentially differential response of cortical cells to menstrual cycle 
phase position in the present study indicates that low levels of estradiol in the LL phase are 
associated with a higher performance, while higher levels of estradiol in the LF phase are 
associated with a reduced ability to discriminate chromatic stimuli and thereby lower 
performance. This effect is especially pronounced in women without premenstrual symptoms 
and in PC-inferred systems. With respect to inferred KC operations, a similar but somewhat 
attenuated result was observed in both groups, with the highest CCS observed in control women 
during the LL phase of their cycle. However, this finding was accompanied by less separation 
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between phases in controls and near complete overlap between phases for women with PMS 
symptoms. This suggests that KC feeds to areas of V1 and associated extrastriate regions may be 
less influenced by the phasic shift of estrogens over the course of the menstrual cycle, especially 
for women that experience premenstrual symptoms. This was somewhat of a surprising finding 
given that previous investigations of SWAP have shown differential S-cone response as a result 
of variations in estradiol concentrations (e.g. across the menstrual cycle) or modifications in 
estradiol binding (e.g. with tamoxifen). It is possible that estradiol-enhanced S-cone responses 
may in fact be compensating for an attenuated post-receptoral differencing signal characteristic 
of B/Y opponency. Or alternatively, the KC pathway may be tempering the estradiol-enhanced 
S-cone responses to avoid bias in the opponency channels.  Either way, it is the cortical 
opponency channels that are called upon to enable individuals to discern contrasts and 
compensatory mechanisms are often used to avoid higher-end signal saturation (e.g., neural gain 
systems). Distinctions in steroidal influences on retinal versus cortical functions therefore, 
should not be that surprising. 
At a very general level, the findings that distinguish inferred PC from KC processing 
abilities supports a hypothesis of disrupted or potentially altered functioning in women with 
PMS symptoms in not only the receptor-based periphery, but in regions of the central nervous 
system that have not been previously examined. This phenomenon is exemplified by the finding 
that women with PMS symptoms exhibited the same relative pattern of results as control women, 
but to a lesser degree (non-significant difference). Given the collapsed CCS performance 
between LF and LL phases in these women, disrupted receptor functionality may be especially 
notable with respect to areas of V1 specific to KC streams. For both R/G and B/Y gabor 
presentations, a greater separation in CCS between menstrual phases was observed in control 
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women. These women also demonstrated a significant shift in estradiol levels between phases as 
compared to women with PMS symptoms who did not. The corresponding changes in CCS and 
estradiol levels between menstrual cycle phases in control women provides some initial evidence 
for the influence of estradiol levels on V1 cortical mechanisms, however, more research is 
required to fully establish this link.  
 Estradiol has been shown to modulate GABAergic systems in several brain regions.  It 
has also been shown to reduce GABA levels in brain sections of female rats (Blurton-Jones & 
Tuszynski, 2006) and neuronal orientation selectivity has been shown in animal models to 
require corticocortical network cooperation that is dependent on GABAergic inhibition. For 
example, orientation specific cells have been shown to be reversibly influenced by the 
application of GABA antagonists such as bicuculline which reduce orientation selectivity (Wolf, 
Hicks, & Albus, 1986), or the direct application of GABA which promotes the sharper tuning of 
orientation selectivity (Li, Yang, Liang, Xia, Yang, & Zhou, 2008). Given the previous findings 
with respect to the influence of estradiol on GABAergic neurons, and the known effect of GABA 
on orientation selectivity, it is plausible that lower levels of estradiol characteristic of the LL 
phase of the menstrual cycle may promote a higher degree of GABAergic expression, which may 
account for the higher CCS performance observed in this phase. Conversely, higher levels of 
estradiol characteristic of the LF phase of the menstrual cycle may promote a greater degree of 
GABAergic inhibition, thus lowering the firing rate of orientation-specific cells, consequently 
reducing overall CCS levels. This could also account for some of the lower CCS levels found 
with the 45° orientated gabors (see Tables 5 and 7) in which detection is contingent on active 
oblique receptive fields ± receptive fields that require greater GABAergic inhibitory activity to 
achieve selectivity than a 0 or 90° oriented receptive field (Edden, Muthukumaraswamy, 
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Freeman, & Singh, 2009). In other words, oblique receptive fields may actually be less 
susceptible to potential estradiol modulation thereby reducing behaviourally-defined sensitivity 
for all groups and phases, particularly at lower chromatically-relevant spatial frequencies. Once 
again, this finding was most evident for the inferred-PC stimuli.  We argue that for the inferred-
KC stimuli, it is more difficult to disentangle these subtle phase and orientation effects because 
of the overall CCS diminution with B/Y gabors.  
 The non-significant observation (as seen through visual inspection of Figures 6, 7, 9, 10 
and 11) of a group effect indicating that women with PMS symptoms exhibited lower CCS in 
menstrual cycle phases parallel to those of controls, with less variable performance between 
menstrual cycle phases lends preliminary support to our hypothesis that estradiol may alter 
cortical PC and KC functions. Again, these effects may also have implications for GABAergic 
systems responsible for orientation discrimination. As described above, however, women with 
PMS symptoms also showed more stable salivary concentrations of estradiol during their LF and 
LL phases which could account for the restrained performance variation in that their levels of 
estradiol did not change enough to alter their performance comparably to controls. 
 For the R/G stimuli, supplementary regression analyses indicated that percent change in 
estradiol predicted CCS at all three orientation conditions across phases better than 
concentrations of estradiol in either phase alone. This finding was observed for the pooled 
sample of women as well as for women in the control group. Percent change in estradiol was best 
able to predict CCS in control women at the 45qorientation, explaining 35% of the variance in 
performance. For the B/Y stimuli, estradiol was best able to predict CCS in both PMS and 
control women at the 0q orientation, explaining 16% and 48% of the variance in CCS 
performance respectively. Given that the R/G stimuli make use of the PC pathway, which is 
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sensitive to orientation, it is plausible that oblique orientations may be maximally affected by 
changes estradiol and that this effect is not as robust in women with PMS symptoms. The 
differential CCS performance of women with PMS symptoms and control women suggests that 
the parvocellular system of those with PMS symptoms is less responsive to changes in estradiol 
possibly due to decreased receptoral sensitivity or a down-regulation in receptor number.  
F indings for SW AP 
 The influence of S-cone sensitivity on upstream (retinal) KC functionality was assessed 
with SWAP. Hypothesis 3 held that both control women and women with PMS symptoms would 
demonstrate higher S-cone sensitivity in the LF as opposed to the LL phase, while Hypothesis 4 
held that women with PMS symptoms might exhibit higher sensitivity relative to controls in both 
phases. The results of the SWAP experiment suggested no significant overall changes in S-cone 
sensitivity as a function of menstrual cycle phase or group. Thus, little support was found for 
Hypotheses 3 and 4. A trend for a menstrual cycle phase x zone effect, however, indicated 
significantly higher S-cone sensitivity in the central zone in the LL phase, and a similar but non-
significant trend for higher S-cone sensitivity in the paracentral region in the LL phase, a time of 
lower estradiol. These findings are, however, in the opposite direction from the hypothesized 
effects. 
Not, surprisingly, S-cone sensitivity was also found to differ as a function of retinal 
location. Specifically, results showed significantly higher sensitivities for women in the central 
and paracentral retinal regions compared to the periphery. Regression analyses indicated that 
high S-cone sensitivity in the LF phase is predicted by a combination of high levels of estradiol 
in the LL phase and low levels of estradiol in the LF phase. This finding is interesting as it, along 
with scatterplots, suggests that women whose estradiol levels increase from the LF to the LL 
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phase demonstrate higher S-cone sensitivity, as compared to those women whose estradiol levels 
show the expected decrease from the LF to the LL phase. In the present study, women with PMS 
symptoms demonstrated more stable levels of estrogen across the cycle (i.e., less of a decrease), 
and although a significant group effect was not observed, there were weak trends (p = .16). An 
examination of means and standard deviations (Table 12) shows that the PMS group exhibited 
higher S-cone sensitivity in nearly all conditions. Given the lack of significance of a group 
effect, however, this observation could be spurious and thus requires replication.     
 Previous research has implicated estrogen-altering pharmaceuticals such the ER 
antagonist tamoxifen, hormonal contraceptives, and reproductive events such as menopause in 
the modulation of S-cone pathways (Eisner et al., 2004b), suggesting the role of estradiol in its 
effect at the retinal level. However, very little research has previously examined the effect of 
PMS on S-cone sensitivity using SWAP. 
To our knowledge, this is the first known study to examine the effects of changing levels 
of endogenous estrogen in a sample of healthy university aged women using SWAP. Although 
Eisner et al. (2004a) found higher S-cone sensitivity near ovulation and lower S-cone sensitivity 
premenstrually, S-cone sensitivity in that study was assessed using a 2-channel Maxwellian 
View visual testing apparatus and not SWAP. Moreover, their effect was observed in only one 
woman classified as having PMS symptoms and who began taking oral contraceptives at a point 
mid-way through the study. Thus, their results are difficult to generalize to a larger population of 
women and could be spurious or confounded by the use of hormonally-acting medications. 
Although the remaining six women in their study did not demonstrate S-cone mediated change 
across the cycle, three of the remaining six participants were taking oral contraceptives. Thus, 
comparisons with our participants are difficult. With respect to the findings of Eisner et al. 
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(2004b) in which SWAP was used to assess the S-cone sensitivity of women taking tamoxifen, 
the authors report that lower mean deviations in sensitivity were found in eccentric regions 
among those taking tamoxifen for a comparatively long period, however, the average duration 
for which participants in that study were using the drug was not reported. As well, those results 
are difficult to contrast with those of our study as the average age of women in that study was 
55.2 years (range 42 to 69 years) and therefore several participants had likely transitioned from 
the fertile to the menopausal period. Despite inconsistencies between these studies, the findings 
of variable S-cone sensitivity in different populations of women (e.g., those with PMS 
symptoms, those taking tamoxifen, those taking oral contraceptives, and those in the menopausal 
period) suggests that estrogens likely play a role in S-cone mediated sensitivity, and more 
research is required to further elucidate these mechanisms, their effects across the cycle, their 
potential influence on post-receptoral circuits, and implications for these systemic changes over 
the lifespan.   
The findings of the present experiment lend some support to the potential influence of 
estrogens at the level of the retina, and the concomitant alteration of S-cone functionality with 
naturally fluctuating levels of estradiol. In contrast to Eisner et al. (2004a), who found that a 
single participant with PMS symptoms showed higher S-cone sensitivity in the mid-follicular 
phase of her menstrual cycle, in this study, both groups of women demonstrated higher S-cone 
sensitivity in the LL phase of the menstrual cycle. To investigate this effect further, three paired 
samples t-tests were conducted using data from the entire sample of women to compare mean S-
cone sensitivities between menstrual cycle phases in the three eccentric regions of the retina. 
These analyses revealed that S-cone sensitivity was significantly higher in the central region in 
the LL phase compared to the LF phase of the menstrual cycle. A similar directional trend was 
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also revealed for higher S-cone sensitivity in paracentral regions in the LL phase compared to the 
LF phase of the menstrual cycle. This may be due to the spatial heterogeneity of S-cone 
populations, although our paracentral region (10 ° to 22°) far exceeds the ±0.5° characteristic of 
prevailing S-cone numerosity (e.g., Williams, MacLeod, & Hayhoe, 1981). Certainly, it is 
plausible that S-cone spatial heterogeneity (i.e., receptor density highest foveally) can account 
for the few, if any sensitivity differences found in the peripheral zones.  
 The finding that in general (across groups) women demonstrated higher S-cone 
sensitivity in the LL phase of the menstrual cycle suggests that S-cone functionality may be 
contingent upon changing levels of estradiol, however, in a direction opposite of what was 
originally hypothesized. In addition, higher levels of estradiol in the LL phase of the menstrual 
cycle were predictive of higher S-cone sensitivity in the LF phase of the menstrual cycle, 
indicating that a priming effect may be occurring in which higher levels of estradiol in a phase of 
the menstrual cycle where estradiol levels are generally at their lowest (e.g. in the LL phase), 
may predispose, or sensitize women to better performance at points later in the menstrual cycle 
when estradiol is rising. Such hypotheses, however, require further investigation and replication 
of the current results. 
Retinal Enhancements, Contrast Sensitivity, and PMS symptoms 
The current study hypothesized that the experience of PMS symptoms (a putative 
indicator of higher hormonal sensitivity) would be associated with increased visual sensitivity 
manifested in measures of visual functioning owing to the actions of estrogens in the retina and 
further downstream in V1, and that the KC stream may be most affected by these enhancements. 
Previous findings have indicated that short-wavelength light is most effective in influencing 
neurometric and psychometric dysphoric symptoms (Glickman et al., 2005; Harrison & Wesner, 
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2010). Although no significant effects or trends were noted for women in either group to 
demonstrate higher S-cone sensitivity, examination of means show that sensitivity in central and 
paracentral regions was higher in women with PMS symptoms. Although our findings did not   
support an effect of group, the observation of higher, though non-significant, S-cone sensitivity 
for women with PMS symptoms across both cycle phases is interesting as it suggests the 
possibility of potential enhancements at the retinal level for women with menstrual cycle-related 
somatic and mood disturbances. Furthermore, these enhancements may occur in women with 
PMS in order to compensate for a lower sensitivity to estradiol in the parvocellular system. This 
would also explain why short-wavelength light might be more effective in influencing dysphoric 
symptoms in women with PMS.   
There are several possibilities that may account for the discrepant performance of women 
with and without PMS symptoms across the two previous experiments. The higher performance 
of PMS women on measures of SWAP did not translate into enhanced B/Y CCS. Rather, in this 
experiment, the experience of PMS was associated with reduced B/Y CCS in parallel phases of 
the menstrual cycle and across most experimental conditions, suggesting the possibility of 
compensatory activity in post-retinal mechanisms. Alternatively, the neurological mechanisms 
underlying PMS may differentially impact the distinct S-on and S-off cell pathways of the KC 
stream, both of which are involved in the processing of B/Y CCS, whereas SWAP assessment 
relies more prominently on receptor functionality prior to post-receptoral increment/decrement 
processing and opponency (e.g., Racheva, & Vassilev, 2008; Vassilev, Zlatkova, Manahilov, 
Krumov, & Schaumberger, 2000). Finally, the relatively lower CCS observed in women with 
PMS symptoms across most spatial and chromatic conditions suggests that in hormonally 
sensitive women, the parvocelluar system may be less affected by changes in estradiol than in 
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controls. It may also suggest a stronger suppressive role for the actions of estradiol in layers of 
V1 for women with PMS symptoms as compared to control women; an action which may be 
contingent upon the interaction of estrogens with the GABAergic system, or reflective of 
compensation for a phase-dependent dysregulated receptor system.  
F indings for Texture Discrimination 
 The potential influences of cycle phase and reproductive steroids on V1-specific 
plasticity were assessed via the use of the TDT. With respect to this experiment, it was 
hypothesized that a group effect would be observed whereby control women would demonstrate 
better performance (e.g. a higher proportion improvement between training and testing) than 
women with PMS symptoms (hypothesis 5). The results of the TDT experiment showed that 
group membership did not generally confer an advantage to performance at testing, however, 
training in the LL phase of the menstrual cycle and testing at the LF phase was associated with 
better performance than the opposite train-test order. Regression analyses confirmed that the 
effect of session order was significant for women with PMS symptoms and that for this group, 
session order and estradiol levels predicted improvement on the TDT for some SOAs while these 
variables were not significant predictors for control women. Given that women with PMS 
symptoms exhibited a non-significant change in estradiol levels between sessions, this finding 
suggests that more stable levels of estradiol across the cycle may be associated with 
enhancements in V1-specific task performance and/or plasticity. Improved performance on this 
task is indicated by an increasing efficiency with which observers are able to identify a target 
texton orientation from an array of horizontal line elements. Given that these textons are 
repeatedly presented to the same area of the retina, Karni and Sagi (1991) hypothesized that 
learning on this task involves areas of V1 in which involve both: 1) a high degree of 
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monocularity, and 2) orientation gradient sensitive specificity that likely occurs prior to 
processing at or before area 17 of V1. Thus, consistent levels of estradiol across the cycle from 
the LL to the LF phase may enhance mechanisms related to texture learning in or associated with 
areas of V1.  
A combination of variables including concentrations of estradiol at training and testing 
and session order predicted TDT performance at SOA 330 and SOA 150 for the pooled sample 
of women and women with PMS symptoms. Given that the coefficients for session order were 
significant, task consolidation in PMS women may also be contingent upon changes in other 
reproductive hormones such as progesterone that were not examined in this study. Findings with 
respect to the effect of progesterone on learning and memory are mixed and based primarily 
upon laboratory and animal models. Frye and Walf (2010) report that progesterone 
administration improved performance on a number of memory dependent tasks including object 
placement, water maze, and cued and contextual fear conditioning in both wild-type mice and 
mice with an absence of functional progesterone receptors. Although such findings indicate 
progesterone-induced learning enhancement, a 2008 review of the effects of progesterone in the 
brain reported: no effect of progesterone on long-term potentiation in rat hippocampal CA1 
slices; interference of progesterone with the estradiol mediated enhancement of synaptic 
transmission; progesterone induced impairment of performance on the Morris water maze; and a 
progesterone induced reduction of hippocampal pyramidal cell spine density which can be 
blocked by the progesterone antagonist RU-38486 (Diaz-Brinton, Thompson, Foy, Baudry, 
Wang, Finch et al. 2008). The evidence presented within this review suggests that progesterone 
is unlikely to account for increases in performance on tasks such as the TDT from the LL to the 
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LF phase, as training (e.g. consolidation) would occur when progesterone levels are high and 
more likely to affect learning negatively.  
 In contrast, several studies have demonstrated the effect of estradiol improving 
performance on tasks of learning and memory.  For example, chronic estrogen treatment has 
been shown to enhance performance in radial arm maze navigation in ovariectomized rats 
(Luine, Richards, Wu, and Beck, 1998). In humans, transient levels of endogenous estrogens 
have been associated with changes in specific measures of spatial ability across the menstrual 
cycle (see review by Hampson, 1995) while exogenous estrogen administration has improved 
cognitive decline in post-menopausal women (Henderson, 2010). The observation of differential 
performance on tasks of spatial and/or cognitive ability in both animals and humans is complex, 
however, and it is widely held that these effects are both age and dose dependent. (Barha & 
Galea, 2010). Thus, different concentrations of estrogens are thought to exert variable effects 
depending upon such factors as the age of the subject (human or animal), their reproductive 
period (e.g. juvenile, pre, peri, or post-menopausal), cycle phase, and dose of hormone 
administered.  
 Improvements in task performance may be attributable to anatomical changes in 
hippocampal post-synaptic dendritic spines, which have been shown to increase proportionally 
with estradiol treatment and over the estrous cycle (Woolley, 1998). Both estrogen receptor 
subtypes D and ß (ERD and ERE) have been mapped at diffuse locations throughout the 
mammalian brain, including within the hippocampus, and although both share similar homology, 
the two receptor subtypes have been associated with differential functionality as demonstrated by 
studies in which ERD knockout mice exhibit disrupted fertility but ERE mice do not (Krege, 
Hodgin, Couse, Enmark, Warner, Mahler et al., 1998), suggesting that the ERD may play a 
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greater role in reproductive functioning. Recent evidence has substantiated this hypothesis and 
suggests the action of the ERE in the regulation of hippocampal synaptic plasticity and memory 
improvement. Liu, Day, Muniz, Bitran, Arias, Revilla-Sanchez et al. (2008) demonstrated that 
ERE activation promoted long-term potentiation (LTP) in rat hippocampal slices. In addition, Liu 
et al. (2008) found elevated levels of phosphorylated CREB (pCREB) indicating the genomic 
influence of ERE binding, Liu et al. (2008) also found elevated levels of a range of synaptic 
proteins including PSD-95, synaptophysin, and GluR1 in response to in vivo dosing with the ERE 
agonist WAY-200070. All of these observed proteins have been implicated in mechanisms 
underlying synaptic plasticity. Thus, the present findings fit with previous evidence suggesting 
that estradiol plays a role in visuospatial learning and memory.  With respect to the observed 
effect of women with PMS symptoms exhibiting a higher proportion improvement between 
sessions for the TDT, this renders a hypothesis of a non-significant shift in estradiol between 
phases as more plausible, and suggests future avenues for investigation that regard hormonal 
shifts and not individual cycle phases as predictors of task performance and expression of 
symptom severity. 
Task consolidation was also observed to be robust between training in the LL phase and 
testing in the LF phase for the pooled sample of women, who as a group showed an overall 
increase in levels of estradiol between phases, suggesting that the dynamic changes (increases) in 
estrogen levels across the cycle may improve consolidation of the TDT task over time. Such 
effects may be produced through the actions of estrogen on neurotransmitter systems, which 
facilitate communication between brain areas outside of V1, thereby strengthening the 
consolidation process between training and testing, or perhaps through the actions of estrogens 
directly in retinotopic regions of V1. A possible hypothesis is that estradiol may aid in the 
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UHFUXLWPHQWRI³WUDLQHG´QHXURQVLQ9LPSURYLQJFRQVROLGDWLRQDQG\LHlding a higher total 
neuronal response during testing, which translates into an overall improvement in performance.  
In a more recent TDT study, Schwartz, Maquet, and Frith (2002) showed that repeated 
exposure to texture gradients provided direct evidence linking learning to enhanced neural 
activation in early retinotopically-specific regions of the human visual cortex. In this study, 
Schwartz et al. (2002) trained participants monocularly using a total of 1760 trails across 22 
blocks. Following 24 hours, participants were tested in an fMRI session in which stimuli were 
presented binocularly with trials administered alternatively to trained and untrained eyes. Results 
showed an increased response in calcarine cortex to target texture stimuli presented to previously 
trained eyes, suggesting that plasticity in the adult brain can be induced during initial stages of 
visual cortical processing, where monocular inputs are still segregated. As the recruitment of 
additional brain areas outside of early visual cortex was not observed in task consolidation for 
trained eyes, their results support the effect of local neuronal plasticity in low-level V1 pathways. 
Interestingly, however, performance for the untrained eye was associated with a greater 
functional coupling between early visual cortex and distant areas in the parietal and frontal 
cortex, as well as the amygdala. The recruitment of these additional structures in the untrained 
eyes could be reflective of the invocation of brain areas involved in exposure to novel stimuli 
and/or tasks. With respect to TDTs these structures are likely involved in attentive processing, 
motivation, and the processing of visual cues necessary for task consolidation prior to testing 
(Schwartz et al. 2002).  That additional brain areas outside of V1 were not activated in the 
untrained eye condition, provides further evidence for a localized effect of estrogens on texture 
learning and suggests early visual cortex as the primary area of plastic effects unique to TDT.    
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With respect to the TDT experiment, our findings suggest that naturally fluctuating levels 
of endogenous estrogens observed across the menstrual cycle may influence memory 
consolidation and subsequent performance in retinotopically-constrained tasks of spatial learning 
such that training in the LL phase confers an advantage to testing in the LF phase.  That this 
effect was observed more prominently in the PMS group, suggests that this group is potentially 
more sensitive to phase order and changes in E; it also fits with the finding that for PMS women, 
both change in estradiol and session order significantly predicted TDT performance at SOA 
levels 330, 150, and SOA 40. 
F indings for Eye tracking 
 Finally, potential differences in cortico-collicularpontine circuitry responsible for eye 
movement were assessed using the eye tracking procedure. For this experiment, a group x phase 
effect was hypothesized in which compared to controls, women with PMS symptoms would 
exhibit a deficit in eye-tracking performance that was more pronounced in the LL phase 
(hypothesis 6). Previous studies have not examined the relationship between PMS symptoms and 
SPEM, however, given the previous research in which women with PMS symptoms were found 
to exhibit disrupted circadian functioning, REM sleep disturbances, and greater PPI, it was 
hypothesized that these disturbances may also involve eye movement pathways and manifest as 
anomalous SPEM eye tracking responses.  
No significant findings indicating the influence of either menstrual cycle phase or group 
were observed for the eye-tracking experiment, however a phase x group trend was observed. 
This trend indicated that women in the PMS group exhibited higher excursion values than 
women in the control group in the LL phase of the menstrual cycle at lower tracking frequencies. 
Such group differences indicate more eccentric gaze patterns in tracking stimuli presented at 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS      190 
these speeds for the PMS women in the LL phase of their menstrual cycle. Thus, the findings of 
this experiment lend partial support to hypothesis 6. Our findings of increased eccentric gaze in 
the LL phase for women with PMS symptoms suggest that procedures that assess collicular and 
collicular-cerebellar networks may be worthy of examination in women who are hormonally 
sensitive or more concentration invariant, and may provide a non-invasive method of identifying 
additional clinical populations affected by atypical endocrine responses. 
 This finding is somewhat consistent with the literature suggesting anomalous sleep 
architecture in women with premenstrual symptoms, and implies a potential disruption in the 
neural circuits underlying eye movements. Knowledge of occulomotor circuitry during sleep is 
sparse, however, eye-movement characteristic of REM sleep are thought to be the result of 
desynchronized cortical activity and muscle atonia (Escudero & Marquez-Ruiz, 2008). As 
described in the Introduction, previous research has also found decreased PPI in the LL phase of 
the menstrual cycle in women with PMDD (Kask et al., 2008). The authors of that study 
suggested the progestin-induced alteration of the GABAergic system and/or disrupted responses 
of estrogen binding in brain areas such as the nucleus accumbens and amygdala as potential 
mechanisms underlying the observation of decreased PPI. Taken together, the results of CCS and 
eye-tracking experiments provide some evidence suggestive of potentially disrupted GABAergic 
functioning in women with PMS systems (e.g. lower CCS than controls, lack of responsiveness 
to estradiol in the parvocellular system, and higher excursion distance in the LL phase than 
controls). As with performance in the CCS experiment in which women with PMS symptoms 
demonstrated significantly lower sensitivities for stimuli across most conditions, the observation 
of higher values for gaze position at lower frequencies in the eye-tracking experiment could be 
attributable to a dysregulation in GABAergic systems attributable to a lack of response to 
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estradiol or progesterone binding thereby supporting a hypothesis of differential hormonal 
sensitivity in this population of women.  
L imitations of the Present Study and Directions for Future Research 
 Limitations of the present study are associated with time constraints, sampling 
restrictions, and the use of relatively strict inclusion criteria. First, the research community lacks 
a universally accepted and reliable system with which the construct of PMS or PMDD can be 
validated.  Given this difficulty, women were screened using a variety of measures and classified 
as experiencing or not experiencing PMS symptoms based upon a number of measures of PMS 
from a group of women largely in undergraduate university classes. Given these diagnostic 
issues and limited access to a population expressing full diagnostic criteria for PMDD, we 
elected to look at groups of women reporting high and low levels of PMS symptoms.  In 
establishing the existence of PMS symptoms, other researchers have employed the use of diaries 
across two or more menstrual cycles. Given the already substantive commitment required of 
women in this study and the time constraints associated with the collection of data, the use of 
menstrual cycle journals was impractical.  This logistical limitation, however, should not 
preclude the use of such journals when possible in future research investigating performance 
measures across the menstrual cycle. As well, there is little research regarding the epidemiology 
of PMS and PMDD across the lifespan, and sampling conducted using a cohort of women with 
greater variability in age may have yielded different results with respect to selecting participants 
into groups. This is because fertile women in their late twenties and thirties may exhibit 
inherently different effects associated with: (1) the physiology of the menstrual cycle, (2) the 
experience of PMS symptoms, and/or (3) the influence of reproductive steroid binding in the 
brain; and that such differences may have differentially affected the outcome of the four 
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laboratory experiments.  Reproductive maturity is typically reached in tKHPLG¶VIURPZKLFK
point forward greater cycle-related hormone change is observed until perimenopausal and 
menopausal periods (Hampson & Young, 2008). While the use of women with low and high 
PMS symptoms, as opposed to women with and without PMDD, may represent a limitation of 
this study, it is expected that our findings would be even stronger if we had used a clinical group. 
Nevertheless, our use of five measures of PMS, including two prospective measures and one 
measure of functional impact, appears to be one of the most comprehensive methods of 
evaluating the presence of such symptoms in research on PMS to date.  
Exhaustive efforts were made to ensure women participating in laboratory sessions were 
scheduled at appropriate intervals corresponding to points in both the LF or LL phases, and that 
those participating in the laboratory portion of the study experienced regular menstrual cycles. It 
is nonetheless possible, however, that a few women were not tested at the appropriate time. 
Sixty-seven percent of participants in the study reported positive test results using the luteinizing 
hormone detection test strips provided, and although this an acceptable rate of response, it 
implies that thirty-three percent of women did not present to laboratory sessions in the LF phase 
with the corroborating information afforded by a positive test, and their session was scheduled 
using self reported estimates of menstrual cycle parameters alone. However, it is important to 
note that we did get some collaborative evidence of proper phase scheduling with the control 
group using the estradiol bioassay. It is reasonable to assume, therefore that if significant 
erroneous scheduling were present, then larger standard errors in our estradiol concentration 
levels would have been obtained. Furthermore, if a few women were not truly in the LF phase at 
the time of testing this does not invalidate our findings. If anything, it suggests that our phase 
effects or phase interactions may be an underestimate of the true effect sizes.  
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 With respect to the four experiments conducted in the laboratory, menstrual cycle phase 
during the LF and LL phase was especially relevant for the training and testing sessions of the 
TDT. Optimally, time would have permitted all women to be tested and trained in 
complementary menstrual cycle phases. In such a design, women, irrespective of group, would 
have been trained in both the LL and LF (with the stimulus presented in different quadrants to 
prevent further learning) phases and tested later in the opposite phase, for a total of four 
laboratory sessions. Such a schedule would have allowed for a more comprehensive examination 
of the influence of menstrual cycle phase and estradiol on learning and plasticity as it relates to 
this paradigm, however, as described previously, task-specific confounds such as retinotopic 
inconsistencies or practice effects prohibited this. As well the collection and analysis of 
progesterone may have been beneficial as a way to both confirm cycle phase as well as to 
examine putative effects of this hormone on task performance in terms of main effects or 
interactions with estradiol. 
Given the nature of the TDT in which participants typically exhibit higher performance 
(e.g. approaching 100% correct) at higher levels of SOA, we sampled those SOA levels that 
better represent the shifting psychometric operating range of the testing session. This was done 
in accordance to previous TDT studies (Karni & Sagi, 1991; 1993).  For statistical purposes, 
averaging was required for two SOA levels at the high end between 360 ms and 300 ms and 160 
ms and 140 ms. These two averaged SOA levels produced the best performance (e.g. highest 
percent correct). The remaining SOA levels between training and testing sessions were matched, 
however, producing subliminal responses.  Given the lower overall performance of our 
participants, the 20 ms SOA used during testing was omitted from analysis. 
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As well, the fact that a number of data sets had to be excluded from main analyses for the 
TDT would suggest a certain level of difficulty with acquisition of the task. Although the exact 
reason for this difficulty is unclear, future experiments may benefit from the presentation of all 
participants with a modified session of initial trial learning using slower SOAs to acquaint them 
with the task over a longer interval of time. Although all women were provided with an 
opportunity to practice trials prior to the initiation of the experiment, more trials at higher SOAs 
may have been necessary for some women to fully comprehend the task. As well, several of the 
TDT studies reported in the literature have employed graduate students or trained research 
assistants as participants in their experiments, and such participants may exhibit characteristics 
different from a sample of mostly undergraduate students. Such differences may not be limited to 
their more advanced level of training including a higher degree of familiarity with the nature of 
visuo-perceptual stimuli and more experience as participants in research studies in general, but 
also personal traits that accompany a high level of performance at the university level; such as a 
higher level of perseverance at difficult tasks or a lesser concern of asking questions if material is 
not fully understood. 
 Despite these limitations, however, this is the first known study examining the influence 
of PMS and menstrual cycle phase on retinal, cortical and brainstem pathways using more than 
single case study data, and provides relevant data on the underlying neurological mechanisms of 
PMS and the influence of normal, phasic, reproductive steroids on neurological functioning. 
Future research should be directed toward the continued evaluation of circadian parameters 
related to the menstrual cycle including conceptualizing the magnitude of the shift in hormones 
over time and not necessarily as unique indicators at circumscribed points within a cycle. 
Evidence suggests that reproductive steroids such as estradiol manifest themselves in 
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neurological functions beyond those of reproduction and that this may have implications for 
women who are predisposed to atypical concentrations of, or sensitivities to such hormones. It is 
plausible that hormonal effects on visual perception may contribute to the experience of somatic 
and emotional symptoms experienced by women with PMS. Replication of findings from the 
four visual tasks employed herein or the use of additional control groups such as women using 
hormonal contraceptives, peri or post menopausal women, and men would be of benefit in 
further clarifying the effects observed in this study and how they may relate or contribute to the 
experience of PMS symptoms and hormonal sensitivity.  
Conclusions 
This study provides evidence suggesting that hormones play a role in response patterns 
on psychophysical tasks assessing visuo-perceptual systems in women. First, we provide 
evidence of altered hormonal functioning and visuoperceptual response patterns in women with 
PMS symptoms. In addition to exhibiting non-significant phase shifts in estradiol between 
menstrual cycle phases, differential performance in women with PMS symptoms was evident 
based on tasks suggesting a lower orientation-based CCS at the post-retinal level and higher, 
though non-significant short-wavelength sensitivity at the retinal level. These observations 
suggest a potential compensatory mechanism occurring at the LGN or further downstream in 
cortical areas and implicate the role of reproductive steroids in moderating these responses. Also, 
with respect to eye-tracking, women with PMS symptoms demonstrated higher excursion values 
at lower frequencies; a finding which is in line with previous studies suggesting disrupted 
GABAergic functioning manifesting in decreased inhibition and, in this case, motoric control of 
SPEM.  
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Second, we provide evidence of changes in response patterns on psychophysical tasks 
assessing visuo-perceptual systems across the menstrual cycle and with changing estradiol levels. 
With respect to the TDT task, a higher proportion improvement in scores was observed for 
women who trained in the LL phase of the menstrual cycle and tested in the LF phase of the 
menstrual cycle. This increase in performance between sessions also corresponded to substantial 
increases in estradiol between sessions, and suggests the role of this hormone in the 
consolidation of memory for tasks requiring retinotopically consistent operations, not unlike the 
improved consolidation effects observed with hippocampus.  
Although the exact mechanisms underlying these observations are unclear, the nature of 
these experiments suggest potential brain regions, behavioral outcomes, and phenotypes which 
can be targeted for the examination of the influence of reproductive steroids in the future.  
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F igure 1. Overview of the adult female menstrual cycle. The habitual cycling of pituitary and 
ovarian hormones is shown in conjunction with corresponding menstrual cycle phases and 
approximate cycle days. Hormonal concentrations are in relative scales. Relative basal body 
temperature is also shown. Late Follicular (LF) and Late Luteal (LL) phases in this study 
coincided with -10 to -20 days and -1 to -8 days respectively (forward count equivalent to days 
10 to 20 and days 22 to 28 respectively). Figure obtained from: 
http://embryology.med.unsw.edu.au/Science/ANAT2341lecture03.htm
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F igure 2&,(&RORXU6SDFHLGHQWLI\LQJWKH³%OXH-<HOORZ´%<DQG³5HG-*UHHQ´5*
³SHDN-to-WURXJK´FKURPDWLFJDERUPRGXODWLRQVDQGHQGSRLQWV%<HQGSRLQWVZHUH>.2263), 
(.4280, .4976) and R/G endpoints were [(.3828, .2846), (.2639, .3722)]. Background chromaticities 
were halfway between the two endpoints. Modulations from the endpoints through the background 
conformed to tritan and deutan confusion lines (Devalois & Devalois, 1990).  Details in text. 
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F igure 3. Representations of chromatic gabor stimuli. Top and bottom rows depict chromatic near 
LVROXPLQDQW³UHG-JUHHQ´DQG³EOXH-\HOORZ´ gabors, respectively. Anchor points for relative peak and 
trough contrasts are detailed in the Methods section.  Panels A, B, and C illustrate the appearance of 
gabors viewed at a distance of 75 cm with center spatial frequencies of 0.5, 1.5 and 4.0 cpd, 
respectively. 
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F igure 4. Illustration of the Texture Discrimination Task (TDT). Participants were presented with the above 
textures, consisting of a foreground target of three 566-QP³JUHHQ´ arc-min long elements (textons) differing 
only in orientation from a background of horizontal, identical textons. The grouping of the three-element textons 
was presented randomly as either three vertically stacked textons or three horizontally positioned, side-by-side 
textons. The target textons were always presented to a participant in the same one of four quadrants for all 
training and testing trials (the example above shows the target in Quadrant I).  To ensure central fixation Dµ7¶RU
µ/¶ZDVSUHVHQWHd in the middle of the monitor concurrently with the textons. All participants were asked to first 
identify the fixation letter followed by the orientation of the target textons (i.e., horizontal or vertical) that was 
presented in the target presentation (top panel). Following the target display and a brief inter-stimulus blank, a 
patterned mask was presented (bottom panel). The inter-stimulus blank, known as stimulus onset asynchrony 
(SOA), decreased in duration from 360 to 20 ms depending on the lab session and trial block.
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F igure 5. Salivary estradiol concentrations as a function menstrual cycle phase in a group of control 
women and a group of women with PMS symptoms. The figure illustrates an overall effect of phase p 
= .019, as well as a trend for a group x phase effect, p = .078. For the control group a paired samples t-
test revealed significantly higher estradiol concentrations in the LF than the LL phase of the menstrual 
cycle, t(17) = 3.48, p = .003. For the PMS group, however, a paired samples t-test revealed no 
differences between estradiol concentrations in the LF and the LL phase, t(14) = 1.00, p = .33.  Thus, 
with respect to the present study, these analyses revealed that, unlike control women, women with 
PMS symptoms did not undergo phasic cycling of estradiol across the menstrual cycle. Error bars 
equal r 1SEM.   
* 
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F igure 7. R/G CCS measurements for the three center spatial frequencies used in this 
study. The bar graph shows CCS for control women (N=18) and women with PMS 
symptoms (N = 16). For both groups, performance (sensitivity) at 4 cpd is lower that 
performance at 1.5 cpd. In addition, control women showed a tendency to perform better 
than women in the PMS group and significantly so at the lowest frequency, 0.5 cpd, F(1, 
33 )= 4.50, p = .042. Error bars equal r 1SEM. 
* 
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F igure 8. Chromatic Contrast Sensitivity (CCS) at three orientation conditions as a function of spatial frequency and menstrual cycle phaVHIRU³UHG-
JUHHQ´5*DQG³EOXH-\HOORZ´%<JDERUV7KHGDWDLVFROODSVHGDFURVVJURXSV5HGOLQHVGHSLFWGDWDILWVIRU5*SUesentations in the late 
follicular (LF) (open symbol; dashed line) and late luteal (LL) (solid symbol; continuous line) phases respectively. Blue lines data fits for B/Y 
presentations in the LF (open symbol; dashed line) and LL (solid symbol; continuous line) phases respectively. For R/G data, the figure illustrates a 
trend for the effect of phase, p = .061, indicating increased CCS in the LL phase as compared to the LF phase. A second trend was revealed for a 
phase x frequency x orientation interaction, p= .051. With respect to this trend, contrasts illustrated that at the 45q orientation, women exhibited 
higher CCS in the LL phase at 0.5 cpd and higher CCS in the LF phase at 4.0 cpd. In contrast, at 90q presentations, women exhibited greater CCS in 
the LF phase at 0.5 cpd and higher CCS at 4.0 cpd in the LL phase of the menstrual cycle. F(1, 32) = 12.24, p = .001, K2 = .28, observed power = 
0.92. This effect is notable in the middle and right-hand panels. For the B-Y data, a trend was revealed for the effect of menstrual phase, p = .072, 
indicating increased CCS in the LL phase as compared to the LF phase of the menstrual cycle. Error bars equal r 1SEM. 
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F igure 9. Chromatic Contrast Sensitivity (CCS) at three orientation conditions as a function of VSDWLDOIUHTXHQF\DQGJURXSIRU³UHG-JUHHQ´5/G) and 
³EOXH-\HOORZ´%/Y) gabors. Red lines depict data fits for R/G presentations for the control group (solid symbol; continuous line) and PMS group 
respectively (open symbol; dashed line). Blue lines data fits for B/Y presentations for the control group (solid symbol; continuous line) and PMS 
group respectively (open symbol; dashed line). For R/G data, the figure illustrates a trend for a frequency x orientation x group effect, p = .07 in 
which, for the 45q condition, women in the control group exhibited lower CCS than women with PMS symptoms at 1.5 cpd, and higher CCS than 
women with PMS symptoms at 4.0 cpd. The reverse was observed with respect to the 90q orientation condition, in which women in the control group 
exhibited greater R/G chromatic CS than women with PMS symptoms with for stimuli presented at 1.5 cpd and lower CCS than women with PMS 
symptoms at 4 cpd presentations. Error bars equal r 1SEM. 
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F igure 11.  Figure illustrating a group by spatial frequency by phase effect (p = .037) for 
³EOXH-\HOORZ´FRQWUDVWVHQVLWLYLW\DWWKHODWH-luteal (solid line) and the late-follicular 
(dashed line) phases of the menstrual cycle for women in control (light blue) and PMS  
(dark blue) groups. For this figure, means for phase and spatial frequency are collapsed 
across orientations. Higher performance for control women is noted across all three 
spatial frequencies in both phases, and especially in the LL phase. Only women in the 
control group demonstrated a significant difference in performance t(17) = 3.40, p = .003 
between the LF (M = 6.16, SD = .40) and LL phases (M = 6.44, SD = .50), at a frequency 
of 0.5 cpd. Error bars equal r 1SEM. 
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F igure 12. Figure illustrating a trend (p = .10) for a phase x retinal zone effect. Mean S-cone 
sensitivity as a function of menstrual cycle phase and retinal eccentricity (central, paracentral, and 
peripheral ) for all women (N = 34; n = 18 control women and n = 16 women with PMS symptoms ) as 
measured by Short-Wavelength Automated Perimetry (SWAP). Paired samples t-tests performed for 
each zone revealed that women exhibited significantly higher SWAP sensitivity in the LL phase 
compared to the LF phase in the central zone, t(33) = 2.29, p = .029. A similar trend for higher overall 
sensitivity in the LL phase over the LF phase was additionally observed for the paracentral zone, t(33) 
= 1.69, p = .10. No differences were revealed between phases for peripheral regions t(33) = -.37, p = 
.72. Error bars equal r 1SEM.
* 
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F igure 13. Scatterplot illustrating the relationship between the change in estradiol concentrations 
between the Late-Luteal (LL) and Late Follicular (LF) phases and S-cone sensitivity in the 
central retinal location for a testing session occurring in the LL phase. The scatterplot indicates 
that women showing the expected decreases in estradiol from the LF to the LL phase have the 
lowest S-cone sensitivity while those whose estradiol levels increase from the LF to the LL 
phase have the highest S-cone sensitivity.  
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F igure 14. Mean percent of trials responded to correctly (%C) as a function of stimulus to onset 
asynchrony (SOA) in a texture discrimination task (TDT):RPHQ¶V (N= 27) scores improved 
between day of training and day of testing as indicated by the leftwards shift in the psychometric 
function (i.e., %C improves with shorter SOA). Error bars equal r 1SEM.
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F igure 15. Mean percent of trials responded to correctly (%C) as a function of stimulus to onset 
asynchrony (SOA) in a texture discrimination task (TDT) for a control group (N =14) of women 
(top panel) and a group of women with PMS symptoms (N = 13) (bottom panel). With the data 
collapsed across menstrual cycle phase in these plots, both groups show the expected leftward 
shift of the curve on testing day indicating discrimination performance improvement. Error bars 
equal r 1SEM.
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F igure 16. Mean proportion of improvement between training and testing sessions for a group of 
women training in the late follicular phase and testing in the late luteal phase of the menstrual 
cycle (LF-LL; N = 18) and a group of women training in the late luteal phase and testing in the 
late follicular phase of the menstrual cycle (LL-LF; N = 9) at five levels of averaged stimulus to 
onset asynchrony (SOA) in a texture discrimination task. The figure shows a trend (p = .06) 
indicating a higher proportion of correct responses for women who trained in the LL phase and 
tested in the LF phase, as opposed to those who performed the experiment in the reverse order. 
Post-hoc analyses indicated a significant difference in proportion change scores at SOA 330, p = 
.038, and a trend for those at SOA 150, p = .075. Error bars equal r 1SEM.
* 
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F igure 17. Mean proportion of improvement between training and testing sessions for a group of 
control women (N = 14) and a group of women with PMS symptoms (N = 13) at five levels of 
averaged stimulus to onset asynchrony (SOA) in a texture discrimination task. The trend for a 
group x SOA level effect is shown above (p = .07). Post-hoc analyses revealed a significant 
between group effect at SOA 150, F(1, 26) = 4.20, p = .05, indicating that women with PMS 
symptoms indicated a higher proportion of improvement at this SOA than control women. Error 
bars equal r 1SEM.
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F igure 18. Spatial position of circular target and smooth pursuit eye position (in degrees visual angle) as a 
function of time.  Final averaged smooth-pursuit positions (across 10 repeating cycles) are shown (from top to 
bottom) for all oscillating target frequencies: 0.25 Hz, 0.5 Hz. 1.0 Hz, 1.25 Hz, and 2.0 Hz.  Data obtained during 
the LL and LF phases of the menstrual cycle are shown in the left and right columns, respectively. Control 
women responses are denoted with red symbols (N= 12) and women with PMS symptoms are denoted with blue 
symbols (N= 13). The continuous curves are fitted sinusoids to the data.  For comparison purposes, the target 
position is indicated with a continuous black sinusoid.  The quality of sinusoidal fits to the data confirm the 
validity of our averaging methods and saccadic/eyeblink filtering procedures.  Note the phase lag and diminished 
eye movement amplitude with increased oscillatory target frequency. No significant main effects were found for 
group, however there was a significant increase in SPEM left-to-right amplitude for the PMS symptoms during 
LL phase and with the lower 0.25 and 0.5 Hz frequency oscillations. 
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Appendix A 
 
 
 
SC R E E NIN G Q U EST I O NN A IR E 
 
 
1. Age: _______ 
2. Sex (Circle your answer):  male  female 
3. Please check the box that best describes the highest level of education that you have completed:   
[   ] some elementary [   ] completed high school [   ] some university 
[   ] completed grade 8 [   ] some college  [   ] completed a university degree 
[   ] some high school [   ] completed college [   ] some graduate studies 
        [   ] completed a graduate degree 
 
4. 7RGD\¶VGDWHBBBBBBBBBBBBBBBBBBBB 
d/m/y  
5. Height: _______ (feet & inches) or  _______ (cm) 
6. Weight: _______ (pounds) or _______ (kg) 
7. Are you currently taking any medication? (circle one) YES   NO  
If YES, what medications are you taking? (please list) 
___________________________________________________________________ 
___________________________________________________________________ 
8. Please list any medical or psychological conditions that you have been diagnosed with (e.g. 
hypothyroidism, depression, asthma, cancer, diabetes, etc.)  
__________________________________________________________ 
__________________________________________________________ 
 
9. Have you ever been diagnosed with or treated for depression? (circle your answer) 
YES  NO  MAYBE 
10. Have you ever been diagnosed with or treated for bipolar disorder or manic depression? (circle your  
answer) 
YES  NO  MAYBE 
      11. Have you ever been diagnosed or treated for an anxiety disorder? (circle your answer).   
   YES  NO  MAYBE 
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12.  Do you think any of your relatives (i.e. parents, siblings, children, grandparents) have had any mental 
health problems (i.e. depression, anxiety, schizophrenia, alcoholism, eating disorders)? (circle your 
answer) YES  NO  MAYBE 
 
13. For each of the following, please check the box if you think that one of your biological relatives has 
been diagnosed with or treated for this psychological problem. Also, on the line beside each mental 
health problem, please indicate the relationship of the family member(s) to you (e.g., mother, father, 
sister, grandmother, uncle). 
 
[   ]  Depression ______________    [   ]  Eating Disorder ______________ 
[   ]  Personality Disorder ______________   [   ]  Alcoholism ______________ 
[   ]  Schizophrenia ______________    [   ]  Drug Abuse ______________ 
[   ]  Anxiety Disorder ______________   [   ]  Other: ______________ 
[   ]  Bipolar Disorder/Manic Depression ______________ 
 
Section I I : Menstrual Cycle Related Questions 
 
1. The following list shows common symptoms and feelings associated with menstruation. For each item, 
choose the descriptive category from the box below that best describes your experience during each of three 
WLPHSHULRGVLQGLFDWHG7KDWLVIRUHDFKLWHPGHFLGHZKHWKHU\RXKDYH³QRH[SHULQFHRIWKHV\PSWRP´RU
ZKHWKHU\RXUH[SHULHQFHLV³SUHVHQWPLOG´³SUHVHQWPRGHUDWH´³SUHVHQWVWURQJ´RUSUHVHQWVHYHUH´7KHQ
indicate the number in the space provided. If none of the categories exactly describes your experience, 
choose the one that most closely matches what you feel. Be sure to rate every item. 
 
0=no experience of symptom 
1=present mild 
2=present moderate 
3=present strong 
4=present severe  
 
 Most recent menstrual 
period 
Four days before Remainder of cycle 
1. Muscle Stiffness    
2. Weight Gain    
3. Dizziness, faintness    
4. Loneliness    
5. Headache    
6. Skin Blemish or Disorder    
7. Cold Sweats    
8. Anxiety    
9. Mood Swings    
10. Cramps    
11. Painful or tender breasts    
12. Nausea, vomiting    
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13. Crying    
14. Backache    
15. Swelling (breasts/abdomen)    
16. Hot flashes    
17. Irritability    
18. Tension    
19. Fatigue    
20. Feeling guilty, sad, or blue    
21. General aches or pains    
22. Restlessness    
23. Insomnia    
24. Poor school or work performance    
25. Affectionate    
26. Feelings of suffocation    
27. Forgetfulness    
28. Take naps, stay in bed    
29. Orderliness    
30. Chest pains    
31. Confusion    
32. Poor judgment    
33. Stay at home    
34. Excitement    
35. Ringing in the ears    
36. Difficulty concentrating    
37. Avoid social activities    
38. Feelings of well-being    
39. Heart pounding    
40. Distractible    
41. Decreased efficiency    
42. Bursts of energy, activity    
43. Numbness, tingling    
44. Minor accidents    
45. Blind spots, fuzzy vision    
46. Poor motor coordination    
47. Increased appetite    
 
48. Was your last menstrual cycle in any way unusual?   Yes          No 
 If yes, please indicate the reason 
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________ 
 
2. As best as you can, please indicate the frequency, severity, and level of impairment encountered for the 
following 11 symptoms during your menstrual cycle. 
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1a.  In a12-month period, over how many cycles do you experience markedly depressed mood, feelings of 
hopelessness, or self-deprecating thoughts? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
2a.  In a12-month period, over how many cycles do you experience marked anxiety, tension, tension, or 
IHHOLQJVRIEHLQJ³NH\HGXS´RU³RQHGJH"´ 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
3a.  In a12-month period, over how many cycles do you experience marked affective lability (e.g. feeling 
suddenly sad or tearful, or increased sensitivity to rejection)? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
4a.  In a12-month period, over how many cycles do you experience persistent and marked anger or 
irritability, or increased interpersonal conflicts? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
5a.  In a12-month period, over how many cycles do you experience decreased interest in usual activities (e.g. 
work, school, friends, hobbies)? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
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b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
6.a.  In a12-month period, over how many cycles do you experience a subjective sense of difficulty 
concentrating? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
7a.  In a12-month period, over how many cycles do you experience lethargy, easy fatigability, or marked lack 
of energy? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
 
8a.  In a12-month period, over how many cycles do you experience marked change in appetite, overeating, or 
specific food cravings? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
9a.  In a12-month period, over how many cycles do you experie`nce sleeping too much or too little? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
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10a.  In a12-month period, over how many cycles do you experience a subjective sense of being 
overwhelmed or out of control? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
11a.  In a12-month period, over how many cycles do you experience other physical symptoms, such as breast 
WHQGHUQHVVRUVZHOOLQJKHDGDFKHVMRLQWRUPXVFOHSDLQRUVHQVDWLRQVRI³EORDWLQJ´RUZHLJKWJain? 
1- none 2- one to three  3. Four to six  4. Seven to Nine 5. Ten to Twelve 
 
b. To what extent do these symptoms cause impairment in work, school, or occupational functioning: 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
3 a. Are you currently taking oral contraceptives? YES NO 
 
b. What is the average length of your menstrual cycle right now (i.e., How many days are there from      
      the first day of one period to the first day of your next period ± most people range between 25 and  
      35)? ____________ days    
 
c.  Which statement best describes your menstrual cycle (Check the bo[ZLWKDQ³;´EHVLGHWKHDSSURSULDWH
response.) 
      [   ]  I never have my period. 
          >@6RPHPRQWKV,JHWP\SHULRGDQGVRPHPRQWKV,GRQ¶W 
          [   ]  I usually get my period every month, but it is irregular and I cannot predict when it will start. 
      [   ]  I usually get my period within two or three days of when I expect it. 
[   ]  My period is like clockwork and the same number of days elapse between periods each 
  month.  
 
d. How old were you when you first started menstruating (started your period)?                  years old 
e. As a teenager and young adult, how did/does you acne/pimples compare to your same-age peers? I 
had __________ acne compared to most girls/women my age (circle the best response).  
 
  Significantly Less          Slightly Less           About the same          Slightly More    Significantly More 
    0                   1                                  2                               3                            4  
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4a. Using the calendars below, please circle the first day of your last menstrual period. If you are not 
completely sure, please estimate the day that you believe you last menstrual period began. Also, please 
indicate with an X  the day that you believe your next menstrual period will start. 
 
January 
Su  Mo  Tu  We  Th  Fr  Sa    
                          1    2    3    
  4    5    6    7    8    9  10    
11  12  13  14  15  16  17    
18  19  20  21  22  23  24    
25  26  27  28  29  30  31    
 
February  
Su  Mo  Tu  We  Th  Fr  Sa    
  1    2    3    4    5    6    7    
  8    9  10  11  12  13  14    
15  16  17  18  19  20  21    
22  23  24  25  26  27  28  
 
March 
Su  Mo  Tu  We  Th  Fr  Sa    
  1    2    3    4    5    6    7    
  8    9  10  11  12  13  14    
15  16  17  18  19  20  21    
22  23  24  25  26  27  28    
29  30  31  
  
April 
Su  Mo  Tu  We  Th  Fr  Sa    
                    1    2    3    4    
  5    6    7    8    9  10  11    
12  13  14  15  16  17  18    
19  20  21  22  23  24  25    
26  27  28  29  30  
 
b. How confident are you that the above circled day was the first day of your last period? (circle the best 
response). 
 
  0%  25%  50%  75%  100% 
  0 1 2 3 4 5 6 7 8 
 
c. How confident are you that the above day with the X will be the first day of your next menstrual period 
(Circle the best response) 
 
  0%  25%  50%  75%  100% 
  0 1 2 3 4 5 6 7 8  
 
d. Do you think that you have started to go through menopause:  YES NO MAYBE 
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e. Are you currently pregnant? YES NO MAYBE 
 
Section I I I : Emotions and Personality 
 
1. Please read each of the following statements carefully and circle the one answer that best corresponds to 
your agreement or disagreement. &LUFOH³VG´LIWKHVWDWHPHQWLVGHILQLWHO\IDOVHRULI\RXstrongly disagree. 
&LUFOH³G´LIWKHVWDWHPHQWLVPRVWO\IDOVHRULI\RXdisagree&LUFOH³D´LIWKHVWDWHPHQWLVPRVWO\WUXHRULI
you agree&LUFOH³VD´LIWKHVWDWHPHQWLVGHILQLWHO\WUXHRULIyou strongly agree.   There are no right or 
ZURQJDQVZHUVDQG\RXQHHGQRWEHDQ³H[SHUW´WRFRPSOHWHWKLVTXHVWLRQQDLUH'HVFULEH\RXUVHOIKRQHVWO\
and state your opinions as accurately as possible.  
 
SD = strongly disagree,   D = disagree,   N = neutral,   A  = agree,   SA  = strongly agree 
 
1. I am known for my prudence and common sense.                                                                  sd d n      a        sa 
,GRQ¶WWDNHFLYLFGXWLHVOLNHYRWLQJYHU\VHULRXVO\ sd         d          n         a        sa 
3. I keep myself informed and usually make intelligent decisions. sd         d          n         a        sa 
4. I often come into situations without being fully prepared. sd         d          n         a        sa 
5. I pride myself on my sound judgment. sd         d          n         a        sa 
,GRQ¶WVHHPWREHFRPSOHWHO\VXFFHVVIXODWDQ\WKLQJ sd         d          n         a        sa 
,¶PDYHU\FRPSHWHQWSHUVRQ sd         d          n         a        sa 
8. I am efficient and effective at my work. sd         d          n         a        sa 
9.  I would rather keep my options open than plan everything in 
advance. 
sd         d          n         a        sa 
10. I keep my belongings neat and clean. sd         d          n         a        sa 
11. I am not a very methodical person. sd         d          n         a        sa 
12. I like to keep everything it its place so I know just where it is. sd         d          n         a        sa 
13. I never seem to be able to get organized. sd         d          n         a        sa 
14. I tend to be somewhat fastidious or exacting. sd         d          n         a        sa 
,¶PQRWFRPSXOVLYHDERXWFOHDQLQJ sd         d          n         a        sa 
,VSHQGDORWRIWLPHORRNLQJIRUWKLQJV,¶YHPLVSODFHG sd         d          n         a        sa 
17. I try to perform all of the tasks that have been assigned to me 
conscientiously.  
sd         d          n         a        sa 
18. Sometimes I am not as dependable or reliable as I should be. sd         d          n         a        sa 
19. I pay my debts promptly and in full. sd         d          n         a        sa 
20. Sometimes I cheat when I play solitaire. sd         d          n         a        sa 
21. When I make a commitment, I can always be counted on to 
follow through. 
sd         d          n         a        sa 
22. I adhere strictly to my ethical principles. sd         d          n         a        sa 
23. I try to do jobs FDUHIXOO\VRWKH\ZRQ¶WKDYHWREHGRQHDJDLQ sd         d          n         a        sa 
,¶GUHDOO\KDYHWREHVLFNEHIRUH,¶GPLVVDGD\RIZRUN sd         d          n         a        sa 
25. I am easy going and lackadaisical. sd         d          n         a        sa 
26. I have a clear set of goals and work toward them in an orderly 
fashion. 
sd         d          n         a        sa 
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27. When I start a self improvement project, I usually let it slide 
after a sew days. 
sd         d          n         a        sa 
28. I work hard to accomplish my goals. sd         d          n         a        sa 
,GRQ¶WIHHOOLNH,¶PGULYHQWRJHWDKHDG sd         d          n         a        sa 
30. I strive to achieve all I can. sd         d          n         a        sa 
31. I strive for excellence in everything I do. sd         d          n         a        sa 
,¶PVRPHWKLQJRID³ZRUNDKROLF´ sd         d          n         a        sa 
,¶PSUHWW\JRRGDERXWSDFLQJP\VHOIVRDVWRJHWthings done 
on time. 
sd         d          n         a        sa 
34. I waste a lot of time before settling down to work. sd         d          n         a        sa 
35. I am a productive person who always gets the job done. sd         d          n         a        sa 
36. I have trouble making myself do what I should. sd         d          n         a        sa 
37. Once I start a project, I almost always finish it. sd         d          n         a        sa 
38. When a project gets too difficult, I am inclined to start a new 
one. 
sd         d          n         a        sa 
39. There are so many little jobs that need to be done that I 
sometimes just ignore them all. 
sd         d          n         a        sa 
40. I have a lot of self-discipline. sd         d          n         a        sa 
41. Over the years I have done some pretty stupid things. sd         d          n         a        sa 
42. I think things through before coming to a decision. sd         d          n         a        sa 
43. Occasionally I act first and then think later. sd         d          n         a        sa 
44. I always consider the consequences before I take action. sd         d          n         a        sa 
45. I often do things on the spur of the moment. sd         d          n         a        sa 
46. I rarely make hasty decisions. sd         d          n         a        sa 
47. I plan ahead carefully when I go on a trip. sd         d          n         a        sa 
48. I think twice before I answer a question. sd         d          n         a        sa 
 
 
2. Below is a list of common symptoms of anxiety.  Please carefully read each item in the list.  Indicate how 
much you have been bothered by each symptom DURING THE PAST 7 DAYS INCLUDING 
TODAY, by placing an X in the corresponding space in the column next to each symptom. 
 
 
Not at all 
Mildly 
(I am not bothered 
much) 
Moderately 
(I feel very unpleasant, 
but I can handle it) 
Severely 
(I can barely 
stand it) 
1.  Numbness or tingling.     
2.  Feeling hot.     
3.  Wobbliness in legs.     
4.  Unable to relax.     
5.  Fear of the worst happening.     
6.  Dizzy or lightheaded.     
7.  Heart pounding or racing.     
8.  Unsteady.     
9.  Terrified.     
ESTRADIOL, VISUAL FUNCTIONING, AND PMS             254
    
  
 
10. Nervous.     
11. Feelings of choking.     
12. Hands trembling.     
13. Shaky.     
14. Fear of losing control.     
15. Difficulty breathing.     
16. Fear of dying.     
17. Scared.     
18. Indigestion or discomfort in abdomen.     
19. Faint.     
20. Face Flushed.     
21. Sweating (due to heat).     
 
 
3. Compared to how you feel when you are in an even or normal mood state, how would you rate yourself on 
the following items during the past 2 weeks? 
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    Not at all Just a little More than Quite a bit Marked or 
       just a little moderately severely 
I have been feeling    0  1  2  3  4 
 
1. down and depressed  0  1  2  3  4 
2. less interested in doing things 0  1  2  3  4 
3. less interested in sex  0  1  2  3  4 
4. less interested in eating  0  1  2  3  4 
5. that I have lost some weight 0  1  2  3  4 
WKDW,FDQ¶WIDOODVOHHSDWQLJKW 0  1  2  3  4 
7. That my sleep is restless  0  1  2  3  4 
8. that I wake up too early  0  1  2  3  4 
9. heavy in my limbs or aches 0  1  2  3  4 
in back, muscles, or head, more 0  1  2  3  4  
tired than usual 
10. guilty or like a failure  0  1  2  3  4 
11. wishing for death or suicidal 0  1  2  3  4 
12. tense, irritable, or worried 0  1  2  3  4 
VXUH,¶PLOORUKDYHDGLVHDVH 0  1  2  3  4 
14. that my speech and thoughts  0  1  2  3  4 
are slow 
15. fidgety, restless or antsy  0  1  2  3  4 
16. that morning is worse than  0  1  2  3  4 
evening. 
17. that evening is worse than 0  1  2  3  4 
morning 
18. unreal or in a dream state  0  1  2  3  4 
19. suspicious of people/paranoid 0  1  2  3  4  
20. preoccupied/obsessed that I  0  1  2  3  4 
must check things a lot 
21. physical symptoms when   0  1  2  3  4 
worried 
22. like socializing less  0  1  2  3  4 
23. that I have ganed weight  0  1  2  3  4 
24. that I want to eat more than  
usual 
25. that I HAVE eaten more than  0  1  2  3  4 
usual 
26. that I crave sweets and starches 0  1  2  3  4 
27. that I sleep more than usual 0  1  2  3  4 
28. that my mood slumps in the 0  1  2  3  4 
afternoons/evening 
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Section I V : Reproductive Questions: 
 
1a. Are you currently taking oral contraceptives? (Circle your answer)  YES  NO 
b.  If you are N O T  currently taking oral contraceptives, how many years and months has it been since you 
stopped taking your most recent oral contraceptive?          years and               months 
 
c.  Are you currently using any form of contraception?     YES  NO 
d. If yes, please identify ___________________ 
e. If you have previously taken oral contraceptives, did you experience any negative side effects?  
 YES  NO 
 
 If YES, please respond to question 1f. 
 
f. If you are N O T  currently taking oral contraceptives, but have in the past, please look at the following list 
of side effects that some people experience while taking oral contraceptives. Put a check beside any and all of 
the following PH YSI C A L  side effects that you have experienced while taking oral contraceptives. After 
indicating any side effects, please indicate what brand of oral contraceptive you were taking when you 
experienced the side effect and the severity of the symptom using the key below. Check all that apply.  
 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
Effect Brand Severity Effect Brand Severity 
Nausea/vomiting   Headaches   
Breast size increase   Breast size decrease   
Decreased ability to orgasm   Increased ability to orgasm   
Weight gain   Weight loss   
Increased sex drive   Decreased sex drive/arousal   
Fewer menstrual cramps   More menstrual cramps   
Positive mood change   Negative mood change   
Tiredness/Fatigue   Dizziness/faintness   
High blood pressure   Painful or tender breasts   
Irregular heartbeat   Swelling of breasts or 
abdomen 
  
Clearer complexion   Complexion problems   
Complete loss of periods   Heavier periods   
Lighter periods    Concerned about hormones   
Breakthrough Bleeding   Fibrocystic breasts   
      
 
g. If you are N O T  currently taking oral contraceptives, but have in the past, please look at the following list 
of side effects that some people experience while taking oral contraceptives. Put a check beside any and all of 
the following M O O D side effects that you have experienced while taking oral contraceptives. After 
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indicating any side effects, please indicate what brand of oral contraceptive you were taking when you 
experienced the side effect and the severity of the symptom using the key below. Check all that apply.  
 
Effect Brand Severity Effect Brand Severity 
Slept more than usual   Less moody   
Slept less than usual   Lower self-esteem   
Depression   Cried more than usual   
More Pessimistic   More self critical   
More irritable   More moody   
Feelings of Inferiority   Less trust in partner   
Disrupted sleep   More sensitive to criticism   
More aggessive   Sadness   
More jealous   Less jealous   
 
 
f)  Do you have a biological mother or sister who has experienced negative mood effects while taking  
  oral contraceptives? (Circle answer):  YES  NO  UNSURE 
 
 
Section V : Caffeine Consumption 
 
1a. Do you engage in the habitual consumption of caffeine?  YES NO 
 
b. How many servings of cafeine do you typically consume over the course of one day?  
Coffee SOHDVHQRWH7LP+RUWRQ¶V/DUJHDQG6WDUEXFNVJUDQGHYHQWLVL]HV VHUYLQJVBBBBBBB 
Tea _______ Canned Soda (355 ml)_________ Bottled Soda (710 ml)__________ 
Energy Drinks (Rock Star, Red Bull etc..)__________  
 
c. Please indicate if you experience any of the following effects either during, or following the consumption 
of caffeine. Please also indicate the severity of the effect using the following scale: 
1=not at all  2= a little  3= moderately  4= quite a bit   5= extremely 
 
Affects mood positively ____ Increased productivity _____  Increased urination _____ 
Affects mood negatively____  Increased Self Confidence ____ Increased creativity _____  
Irritability _____   Increased Focus ______  Increased social interaction ____ 
Anger _______   Panic Attacks _______  Difficulty Concentrating _____ 
Increase in alertness ______  Digestive problems_____  Migraines/Headaches ______ 
Increase in Heart rate ______  Heart burn _____   Fibrocystic Breasts ________ 
Racing thoughts _______  Ulcers _______ 
 
 
Section V I : Morningness-Eveningness 
 
1. Considering your own feelings, at what time would you get up if you were entirely free to 
plan your day 
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7LPH«««««««««««« 
 
2. Considering only your own feelings, at what time would you go to bed if you were entirely free to plan 
your day? 
7LPH««««««««««« 
 
3. If there is a specific time you have to wake up in the morning, to what extend do you depend on using an 
alarm clock? 
 
a. Not at all dependent [ ] 
b. Slightly dependent [ ] 
c. Fairly dependent [ ] 
d. Very dependent [ ] 
 
4. Assuming adequate environmental conditions, how easy do you find getting up in the morning? 
 
a. Not at all easy [ ] 
b. Slightly easy [ ] 
c. Fairly easy [ ] 
d. Very easy [ ] 
 
 
5. How alert do you feel during the first half hour after having woken in the morning? 
 
a. Not at all alert [ ] 
b. Slightly alert [ ] 
c. Fairly alert [ ] 
d. Very alert [ ] 
 
6. How is your appetite during the first half hour after having woken in the morning? 
 
a. Not at all good [ ] 
b. Slightly good [ ] 
c. Fairly good [ ] 
d. Very good [ ] 
 
7. During the first half hour after having woken in the morning, how tired do you feel? 
 
a. Very tired [ ] 
b. Slightly tired [ ] 
c. Fairly refreshed [ ] 
d. Very refreshed [ ] 
 
8. When you have no commitments the next day, at what time do you go to bed compared to your 
usual bedtime? 
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a. Seldom or never later [ ] 
b. Less than one hour later [ ] 
c. 1-2 hours later [ ] 
d. More than 2 hours later [ ] 
 
9. You have decided to engage in some physical exercise. A friend suggests that you do this one hour 
twice a week and the best time for him is between 0700 and 0800h. Bearing in mind nothing else 
but your own inclinations, how do you think you would perform? 
 
a. Would be on good form [ ] 
b. Would be on reasonable form [ ] 
c. Would find it difficult [ ] 
d. Would find it very difficult [ ] 
 
10. At what time in the evening do you feel tired and in need of sleep? 
7LPH««««««««««« 
 
11. You wish to be at your peak for a test which you know is going to be mentally exhausting and lasting 
for two hours. You are entirely free to plan your day, when would you do this task? 
 
a. 0800 ± 1000 [ ] 
b. 1100 ± 1300 [ ] 
c. 1500 ± 1700 [ ] 
d. 1900 ± 2100 [ ] 
 
 
12. If you went to bed at 11:00 p.m at what level of tiredness would you beat that time? 
 
a. Not at all tired [ ] 
b. A little tired [ ] 
c. Fairly tired [ ] 
d. Very tired [ ] 
 
13. For some reason you have gone to bed several hours later than usual, but there is no need to get up 
at any particular time the next morning. Will you: 
 
a. Wake up at the usual time and not go back to sleep [ ] 
b. Wake up at the usual time and doze [ ] 
c. Wake up at the usual time and go back to sleep [ ] 
d. Wake up later than usual [ ] 
 
14. One night you have to remain awake between 0400 and 0600h. You have no commitments the next 
day. Which suits you best: 
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a. Not to go to bed until 0600h [ ] 
b. Nap before 0400h and sleep after 0600h [ ] 
c. Sleep before 0400h and nap after 0600h [ ] 
d. Sleep before 0400h and remain awake after 0600h [ ] 
 
15. You have to do 2 hours physical work. Which hours would you prefer to do it between: 
 
a. 0800 ± 1000 [ ] 
b. 1100 ± 1300 [ ] 
c. 1500 ± 1700 [ ] 
d. 1900 ± 2100 [ ] 
 
16. You have decided to engage in some physical exercise. A friend suggests that you do this between 
10:00p.m and 11:00p.m twice a week. How do you think you would perform: 
 
a. Would be on good form [ ] 
b. Would be on reasonable form [ ] 
c. Would find it difficult [ ] 
d. Would find it very difficult [ ] 
 
17. Suppose that you can choose your own work hours, but had to work five hours in the day. Which 
five consecutive hours would you choose: 
 
+RXUV««««««««««««««««« 
 
18. At what time of day do you feel your best? 
7LPH«««««««««««««««« 
 
2QHKHDUVRI³PRUQLQJ´DQG³HYHQLQJ´W\SHV:KLFKGR\RXFRQVLGHU\RXUVHOIWREH" 
 
a. Morning type [ ] 
b. More morning than evening [ ] 
c. More evening than morning [ ] 
d. Evening type [ ] 
 
Section V I I : Seasonality 
 
1. In the following questions, fill in boxes for all applicable months. This may be a 
single month, a cluster of months, or any other grouping. 
 
At what time of year do you÷.. 
 
 jan feb mar apr may jun jul aug sept oct nov dec 
a. Feel Best             
b. Tend to gain most weight             
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c. Socialize Most             
d. Sleep least             
e. eat most             
f. lose most weight             
g. socialize least             
h. feel worst             
i. eat least             
j. sleep most             
 
2. To what degree do the following change with the seasons? 
 
 
 No Change 
(1) 
Slight Change 
(2) 
Moderate Change 
(3) 
Marked Change 
(4) 
Extremely Marked 
Change (5) 
a. Sleep length      
b. Social 
activity 
     
c. Mood (overall 
feeling of well 
being) 
     
d. Weight      
e. Appetite      
f. Energy level      
 
     
3a.  If you experience changes with the seasons, do you feel that these are a problem for you? No Yes 
 
b. If yes, is this problem:  MILD  MODERATE  MARKED  SEVERE  DISABLING 
 
4. By how much does your weight fluctuate during the course of the year? 
 
0-3 lbs.  4-7 lbs.  8-11 lbs.  12-15 lbs.  16-20 lbs.  Over 20 lbs 
 
5. Approximately how many hours of each 24-hour day do you sleep each season? (includes naps) 
 
Hours slept per day 
 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Over 
18 hrs 
Winter 
(Dec 21 -Mar 
20) 
                    
Spring 
(Mar 21 -June 
20) 
                    
Summer 
(June 21 - 
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Sept 20) 
Fall 
(Sept 21- Dec 
20) 
                    
 
6. Do you notice a change in food preference during the different seasons?  No     Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESTRADIOL, VISUAL FUNCTIONING, AND PMS             263
    
  
 
Appendix B 
 
Laboratory Questionnaire 
 
Date_____________ 
Time_____________ 
Participant number__________ 
 
Are you currently using oral contraceptives: Y ES N O 
 
Phase:  L L L F  
 
1) Please indicate how you feel at this moment by ci rcling the appropriate response; (1) very slightly or 
not at all, (2) a little, (3) moderately, (4) quite a bit, (5) extremely. 
    
 
  Very Slightly       A little Moderately    Quite a bit     Extremely  
  or not at all (1)          (2)        (3)           (4)  (5) 
 
 
   1  2  3  4  5 
Interested  1  2  3  4  5 
Distressed  1  2  3  4  5 
Excited  1  2  3  4  5 
Upset   1  2  3  4  5 
Strong   1  2  3  4  5 
Guilty    1  2  3  4  5 
Scared   1  2  3  4  5 
Hostile   1  2  3  4  5 
Enthusiastic  1  2  3  4  5 
Proud   1  2  3  4  5 
Irritable  1  2  3  4  5 
Alert   1  2  3  4  5 
Ashamed  1  2  3  4  5 
Inspired  1  2  3  4  5 
Nervous  1  2  3  4  5 
Determined  1  2  3  4  5 
Attentive  1  2  3  4  5 
Jittery   1  2  3  4  5   
Active   1  2  3  4  5 
Afraid   1  2  3  4  5 
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2) The following list shows common symptoms and feelings associated with menstruation. For each item, 
choose the descriptive category from the box below that best describes what you have been feeling for the 
past 24 hours. That is, for each item, decide whethHU\RXKDYH³QRH[SHULHQFHRIWKHV\PSWRP´RUZKHWKHU
\RXUH[SHULHQFHLV³SUHVHQWPLOG´³SUHVHQWPRGHUDWH´³SUHVHQWVWURQJ´RUSUHVHQWVHYHUH´7KHQLQGLFDWH
your response by circling the corresponding number. 
 
No experience         Present    Present      Present     Present  
   of symptom             Mild        Moderate     Strong      Severe       
                    (0)           (1)        (2)        (3)         (4) 
 
Muscle stiffness           0   1         2                3                      4   
Headaches          0   1         2                3                      4  
Cramps             0   1         2                3                      4  
Backache              0   1         2                3                      4  
Fatigue          0   1         2                3                      4  
General aches              0   1         2                3                      4  
   and Pains  
Weight gain           0   1         2                3                      4  
Skin Blemish          0   1         2                3                      4   
   or disorder  
Painful or tender             0   1         2                3                      4  
   breasts  
Swelling              0   1         2                3                      4  
Loneliness 
Anxiety          0   1         2                3                      4  
Mood Swings          0   1         2                3                      4  
Crying           0   1         2                3                      4  
Irritability           0   1         2                3                      4  
Tension           0   1         2                3                      4   
Feeling sad or          0   1         2                3                      4   
  Blue 
Restlessness               0   1         2                3                      4  
 
3) Please rate your cur rent level of pain by ci rcling the best answer . 
 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
 
4) Please rate your cur rent level of discomfort by ci rcling the best answer . 
 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
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5) Please rate your level of fatigue by ci rcling the best answer 
 
1- not at all severe 2- mild 3- moderate 4-severe 5-extremely severe/debilitating 
 
6a) Have you consumed ay alcohol in the past 24 hours?  YES NO 
 
  b) If yes, please indicate the number of drinks _____ 
 
7a) Have you consumed ay caffeine prior to coming to the lab this morning?  YES NO 
 
  b) If yes, please indicate the number of servings ______ 
 
8. Have you taken any medication to alleviate symptoms of pain in the past 24 hours (Tylenol, Advil, Midol, 
HWF«  YES  NO 
 
9. How many hours of sleep did you receive last night? ______  
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Appendix D 
 
INTRODUCTION 
For a Printable Version of Ovulation Test Instructions, please click here.  
Luteinizing hormone (or LH) in elevated quantities causes ovulation (the release of the egg - or ovum - from the ovarian 
follicle). During the menstrual cycle only a small amount of LH is made, but in the middle of the cycle LH briefly and 
dramatically increases. This increase is called the "LH surge" and precedes ovulation. Conception is most likely to 
occur within thirty-six hours following the LH surge. The LH Ovulation Test is specifically designed to detect your LH 
surge - the time when you are likely to ovulate. If you receive a positive on an lh test, you are in your most fertile phase 
of your menstrual cycle.  
SPECIMEN COLLECTION AND PREPARATION 
COLLECTION 
Collect urine once per day, at about the same time between 10:00 A.M. and 8:00 P.M. Do not use first morning urine 
as a sample. Collect urine in a clean, dry cup or container. 
The sample may be stored at room temperature (15º-28ºC) for up to eight hours, or in the refrigerator for up to twenty-
four hours. Do not freeze the urine sample. Let refrigerated samples reach room temperature before starting the test 
(this will take about 30 minutes). For best results, test the urine on the same day it is collected. 
 
TEST PROCEDURE 
STEP 1: WHEN TO START TESTING: Determine the length of the menstrual cycle. The length of the menstrual cycle 
is the number of days from the first day of menstrual bleeding to the day before bleeding begins on the next period. 
Determine the usual length of the menstrual cycle over the last few months. Then, refer to the Ovulation Calendar 
Cycle Chart below to determine on which day of the menstrual cycle to begin testing. If your cycle is less than twenty-
one days or greater than forty days, consult a physician. 
Cycle Chart 
Your Cycle 
Length  
Day to Begin 
Testing 
21 days  Day 5  
22 days  Day 6  
23 days  Day 7 
24 days  Day 8 
25 days  Day 9 
E rror! Reference 
source not found. 
 Free Shipping! 
 Confidential Packaging 
Maximum Expiry Dates 
Accurate, Easy-to-Use 
Ovulation  Test  Strips 
  
Instructions for LH Ovulation Tests 
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26 days  Day 10 
27 days  Day 11  
28 days  Day 12 
29 days  Day 13 
30 days  Day 14 
31 days  Day 15 
32 days  Day 16  
33 days  Day 17 
34 days  Day 18 
35 days  Day 19 
36 days  Day 20 
37 days  Day 21  
38 days  Day 22 
39 days  Day 23 
 STEP 2: TESTING PROCEDURE 
 
1. To begin testing, open the sealed pouch by tearing along the notch. Remove the LH test from the pouch. Note: The 
ideal time to test is in the afternoon, not early morning, though testing may safely take please from 10am to early 
evening. 
E rror! Reference source not found.Dip end of strip into urine for 5 seconds. Do not exceed the max line. 
2. Carefully place the LH test vertically into the urine cup for 5 seconds and lay the strip flat on a clean, dry, non-
absorbent surface. IMPORTANT: Do not allow the urine level to exceed the line indicated by the arrows - MAX Line 
(Marker Line) - near the bottom of the test dipstick, otherwise the test will not perform correctly. 
3. Wait for colored bands to appear. Depending on the concentration of LH in the test specimen, positive results may 
be observed in as little as 40 seconds. However, to confirm negative results, the complete reaction time of 10 minutes 
is required.  
INTERPRETATION OF RESULTS 
Within three to five minutes, two color bands will appear. For best results, interpret the test at 5 minutes. Do not read 
the results after more than ten minutes. 
To determine your result, compare the color intensity, i.e. shade of color, lightness or darkness of color, of the test 
band to the control band. In determining a positive or negative result, it is important to compare the color intensity, for 
this will indicate whether or not the LH surge (indicating ovulation) is in progress. 
E rror! Reference source not found. 
 
1. Positive for the LH Surge 
If the test band is of equal or greater intensity (equal or darker) than the control band, this is a positive result and a 
good indication that the LH surge is occurring. 
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2. Negative for the LH Surge 
If the test band is of lesser intensity (lighter) than the control band or cannot be seen, this means the LH level of the 
sample is at or near its basal (normal) level and that the LH surge is not in progress. 
3. Invalid Result 
If no control band appears within five minutes, the test result is invalid and should be ignored. The control band will not 
appear if an insufficient volume of specimen is added into the test kit. Proper procedures may not have been followed 
in performing the test. Repeat with a new test kit.  
To Optimize the Use of Ovulation Predictor Kits, please visit our online Ovulation Test FAQ and our extensive articles 
library. 
 
HOW TO RECOGNIZE THE LH SURGE 
After each test, you must decide if you are having an LH surge. If your test result is positive, you are probably having 
an LH surge. An LH surge can last from one to three days. Ovulation is most likely to occur sometime in the day and a 
half following the first day of the LH surge. 
If your test result is negative, you are probably not having an LH surge. Remember that a pink-rose test band lighter 
than the control band shows that there is only a very low level of LH in your urine. Consult our online FAQ for more 
information about how to apply our test results. 
WHEN TO STOP TESTING 
Unless otherwise specified by a doctor, stop testing once the LH surge is detected. Six to ten days of testing may be 
needed to detect the LH surge, though additional testing may be required. Explanations for negative results include: 
1. Use of first morning urine. First morning urine should not be used for LH . 
2. The concentration of LH is too low to be accurately detect. 
3. Testing is performed too early or too late in the menstrual cycle (please re-read cycle chart).  
4. Testing is stopped before the surge occurs, and should have been continued for a few more days. 
THE LH SURGE, OVULATION & PREGNANCY 
A pregnancy begins with conception. A child is conceived when the male sperm successfully fertilizes the female egg. 
Successful fertilization is most likely during a 24 hour period one to three days following the LH surge. Since this 
ovulation "window" only opens once per month, and for only about 24 hours, being able to predict fertility it is very 
helpful when trying to become pregnant. Therefore, you should have intercourse during the one to three day period 
following the LH surge to increase chances of conception.  
 
LIMITATIONS OF THE TEST 
1) Directions must be followed carefully for accurate results. 
2) Do not open the foil pouch until ready to conduct the test. 
3) Do not use the results of this test as an aid for contraception. 
4) Consult a doctor if irregular or unusually long cycles are experienced. 
5) Do not use the test kit after the expiration date listed on the box. 
6) A test device can only be used once. Discard the test after use. 
QUESTIONS & ANSWERS 
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1) Should I restrict my diet before taking the test?  
No, diet will not affect the test results. 
2) Does alcohol, aspirin, or any other common drug affect the test? 
No, but some hormonal medications can interfere with test results. If such medications are being taken or are 
suspected, seek professional advice from a physician to confirm the test results. Clomid can cause false positives if 
you begin testing too early in your cycles. Please use the above ovulation calendar guide to determine when to begin 
testing.  
3) Should the test be used for contraception?  
No, the test is not designed to prevent or help prevent conception and should not be used to do so. 
4) Why is first morning urine not a good sample?  
If first morning urine is used with the test, the first day of the LH surge may not be detected. The best time to collect the 
urine is between 10:00 A.M. and 8:00 P.M.. Always try to collect it at about the same time each day. 
5) Today's control band is a different shade of red than yesterday's control band. Is this a concern? 
No. Variations in the color of the control band will not affect the test result. Always compare the color of the test band to 
that of the control band of the same device on the day the test is performed. Do not compare bands from different 
devices. 
6) Can test results be interpreted after five minutes?  
No. Test results must be read at 5 minutes. Though a positive result should not change for several days, a negative 
result may change to a false positive within minutes after the end of the testing period, which would not be an accurate 
reading. It is always best to read the results at the 5 minute testing period and then discard the test to avoid confusion. 
 
7) A pink background color and vertical streaking appeared in the result area during the testing period. Is this a 
concern?  
No. Each urine sample will vary in its chemical makeup, as will the humidity of the air in testing chamber (room). Such 
variations in physical conditions can cause the vertical streaking and/or the pink-rose background color but will not 
affect the test results. As long as the control band appears within five minutes, the test is working properly. 
STORAGE AND STABILITY 
Store the test kit below 28ºC; do not freeze. Refer to the expiration dates of the individual components for stability 
information. 
WARNINGS AND PRECAUTIONS 
1. The test kit is for in vitro (external) diagnostic use only. 
2. Do not use beyond the expiration date. 
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Appendix E 
 
Introductory Statement/ Cover Letter 
 
Dear Participant, 
 
Thank you for your interest in our research. We are currently conducting a study that is investigating visual 
functioning in women. Individuals who participate in this study will receive up to four points toward their 
credit in the introductory psychology course. 
 
In recent years, the discovery of effects exerted by hormones outside of simple reproductive function, has 
began to influence our conceptualization of such things as learning, memory, and perception. Research has 
demonstrated that hormonal receptors are located in diffuse regions throughout the mammalian brain, thereby 
implicating these regions in a variety of ,cognitive operations never before considered. Among these regions 
are the retina, and the hippocampus, a structure involved in learning and memory. This study aims to 
psychophysical measures designed to assess functionality in these  regions. 
 
Following completion of the screening questionnaire, some participants will be selected to participate in two 
approximately one-and-half-hour laboratory sessions. Each laboratory session will involve the collection of a 
salivary sample, a brief questionnaire, and 4 visual tests. These tests are based on standard psychophysical 
procedures. In all visual tasks, participants will be presented with various images and asked to make 
judgments based on the appearance of the image. A sub-sample of participants will be asked to collect 
salivary samples at home and return them to the lab the following morning. All participants will be asked to 
sign a consent form, which will be reviewed with the researcher upon entry into the lab. Following 
completion of the laboratory sessions, all participants will be fully debriefed, and provided with a list of 
project references and resources. 
 
All tasks involved in this study pose minimal risk to participants. If participants feel uncomfortable with any 
of the experimental tasks or procedures, or note any negative effects, they are free to withdraw their consent 
at any time. Participants will be supervised at all times. If at any time the researcher or participant feels that 
the experiments are causing any adverse effects, the session will be terminated. Early termination of the 
study will not have an impact on the offer of course credit. 
 
All information collected during the course this project will be held in strict confidence. At no time will any 
identifying information be divulged to individuals outside of the research team. All information will be 
stored in a secure location at Lakehead University for a period of five years. Findings from the projects will 
be made available to participants upon completion of the project. 
 
If you have any questions or concerns regarding the experiment, please do not hesitate to contact me directly. 
I can be reached by phone (807) 343-8418 or through e-mail (mrichar4@lakeheadu.ca). You may also 
contact Dr. Kirsten Oinonen (koinonen@lakeheadu.ca),  Dr. Michael Wesner (mwesner@lakeheadu.ca), or 
Lakehead University's Research Ethics Board at (807) 343-8283. 
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Thank you for your interest in the project. 
 
Sincerely, 
 
 
 
 
Meghan Richards, M.A. 
Doctoral Student, Clinical Psychology Program 
Lakehead University 
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Appendix F 
 
C O NSE N T F O R M A 
 
The purpose of the present study, conducted by Meghan Richards, Dr. Michael Wesner, and Dr. Kirsten 
Oinonen of the Department of Psychology at Lakehead University, is to examine visual functioning in 
women.  If you are currently enrolled in an Introductory Psychology section, one bonus mark will be 
awarded for the completion of this screening questionnaire. Information collected from the screening 
questionnaire will be used to select some participants for subsequent laboratory sessions.  Individuals who 
are selected for these sessions and who participate further in the study will receive an additional one to three 
bonus points (depending on the number of laboratory sessions attended) towards their final mark in 
Introductory Psychology. 
 
Your participation in the screening will involve the completion of a questionnaire that will take 
approximately 30-40 minutes. The questionnaire includes personal questions designed to collect information 
on: demographics, reproductive history, the menstrual cycle, emotion and personality, caffeine intake, and 
morningness-eveningness. 
 
Participation in this study is voluntary and you may withdraw at any time without explanation or penalty.  
Records of your participation will be kept in strict confidence. As well, the disclosure of any identifying 
information will be precluded in the dissemination of the results of this study.  As per university 
requirements, all data will be stored for five years in research laboratories at Lakehead University and remain 
anonymous and confidential. Individuals who meet specific criteria will be asked to participate in subsequent 
laboratory sessions. Therefore, we have asked for your name and telephone number on this form. Once we 
have determined who will be asked to participate in subsequent sessions, this information will be removed 
and information from your questionnaire will remain both anonymous and confidential. Throughout the 
study, participant information will be coded using a numbering system. There is no way that your name can 
be connected to your responses. There are no known physical or psychological risks associated with 
participating in this study.  If you have any questions or concerns regarding this study please contact the 
prinicipal investigator, Meghan Richards (343-8418), or Dr. Micheal Wesner (343-8457), or Dr. Kirsten 
Oinonen (343-8096) directly.  
 
I have read and understood the consent form, and I agree to participate in this study under these 
conditions. 
 
 
Name (Please Print): __________________________  Phone Number: _________________  
Email address_______________________________________________________________                              
Signature:  _____________________________________  Date: _______________________                                                                                      
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Appendix G  
D E BRI E F IN G F O R M A 
 Thank you for participating in the screening phase of our study.  The study is being conducted by Ms. 
M. Richards, Dr. M. Wesner and Dr. K. Oinonen. If you are selected to participate in the second part of the 
study, you will be contacted by one of the researchers in the next three weeks. Participants in the next phases 
of the study will receive between one and three additional points towards their final mark (if they are 
Psychology 1100 students).  If you are chosen to participate in subsequent laboratory sessions, you will be 
asked to complete several measures of visual functioning and provide two salivary samples. A portion of 
participants will be asked to collect additional salivary samples at home. These participants will be eligible 
for an additional bonus point. 
 Please be assured that once participants have been selected for the study, the consent forms will be 
dissociated from all identifying information. To conceal your identity, all of your responses will be coded 
using a numbering system, thus assuring that all data will remain anonymous.  If you have any questions, 
please feel free to contact any of the researchers using the contact information listed below. 
Meghan Richards, M.A.  Dr. M. Wesner      Dr. K. Oinonen 
Department of Psychology  Department of Psychology     Department of Psychology 
Lakehead University   Lakehead University      Lakehead University 
955 Oliver Road   955 Oliver Road      955 Oliver Road 
Thunder Bay, ON, P7B 5E1  Thunder Bay, ON, P7B 5E1     Thunder Bay, ON, P7B 5E1 
(807) 343-8418   (807) 343-8457      (807) 343-8096 
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Appendix H 
 
C O NSE N T F O R M B 
 
,DJUHHWRSDUWLFLSDWHLQWKHSUHVHQWVWXG\WKDWLVLQYHVWLJDWLQJYLVXDOIXQFWLRQLQJLQZRPHQ¶VKHDOWK,
understand that my participation is entirely voluntary: I may withdraw my consent from this experiment at 
any time, and this act will have no bearing on any remuneration I will receive, nor will it have any 
undesirable consequences. 
 
The following points have been explained to me:  
 
1. 7KHSXUSRVHRIWKLVUHVHDUFKLVWRILQGRXWZKDWIDFWRUVDUHUHODWHGWRZRPHQ¶VKHDOWK7KHEHQHILWVI 
may expect from the study are (a) an appreciation of research on health, (b) an opportunity to 
contribute to scientific research and (c) course credit (up to three additional bonus points). 
2. The procedure will be as follows: During a single session, researchers will obtain a salivary sample 
(via the technique of passive drool) and my body measurements (e.g. finger lengths). Following a 
brief visual screening test, I will then be required to complete a total of four tests of visual 
functioning. These tests of visual functioning will be repeated in a subsequent lab session scheduled 
following the completion of the first lab session. A subset of participants will also be given the 
necessary materials, and asked to collect salivary samples at home to be returned to the lab the 
following day. 
3. There are no known serious risks involved in participating in this study.   
4. All of the data collected as well as my salivary samples will remain strictly confidential. My 
responses will not be associated with my name. Instead, my data will be associated with a code 
number when the researchers store the data. 
5. The experimenter(s) will answer any other questions about the research either now or during the 
course of the experiment (other than specific questions about the hypotheses). If I have any other 
questions or concerns, I can address them to the principal experimenter, Meghan Richards 
(mrichar4@lakeheadu.ca) or Dr. M. Wesner 343-8457 (mwesner@lakeheadu.ca) or Dr. K. Oinonen 
343-8096, (koinonen@lakeheadu.ca). 
6. Upon completion of my participation, I will receive a more detailed written explanation about the 
rationale underlying this experiment. 
7. I am interested in receiving a summary of the results upon completion of the study:  
 yes  no      
If yes, please indicate your email address: ____________________________ 
 
 
 
________________________________  _____________________________ 
3DUWLFLSDQW¶V3ULQWHG1DPH   Signature 
 
 
 
_________________________________ ______________________________ 
Date      Experimenter Nam 
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Appendix I 
 
D E BRI E F IN G F O R M B 
We appreciate your participation in our study, and thank you for spending your time to help us with 
our research. When you arrived here you were told that the purpose of this study was to investigate visual 
functioning in women. One of the factors in which we are interested is how hormonal sensitivity may affect 
perception within the visual system.  In order to test this hypothesis, we have selected groups of women that 
the literature suggests are hormonally sensitive. These include women who experience Premenstrual 
Dysphoric Disorder (PMDD), severe symptoms of PMS, as well as women who are prone to experiencing 
oral contraceptive side effects. We did not include this information in the participant letter or screening 
questionnaires because we felt that this information may have influenced the responses of some women in 
the study, and consequently prevented a thorough, accurate investigation into the topic at hand.  We 
apologize, and hope you understand why it was necessary. In case you have any concerns regarding this 
procedure, we have attached the names of the principal investigators and provided you with a list of 
additional resources on the attached sheet. 
Given that this study involves some aspects of which you were not fully informed at the start, it is 
very important that you not discuss your experiences with other students until the end of the term.  If 
participants have prior knowledge of our specific predictions it may influence their results, and the data we 
collect would be not be reliable. Because you will be given a copy of this feedback to take home, please do 
not make it available to other students. If you do not keep this form, please dispose of it rather than leaving it 
somewhere that other students might read it. Please feel free to discuss with the experimenter any feelings 
you have about the study right away. Should you have further questions, do not hesitate to contact Meghan 
Richards, Dr. Michael Wesner, or Dr. Kirsten Oinonen, using the information listed below. 
In addition to examining visual functioning, we will also be using your salivary samples to obtain a 
measure of estradiol. Some participants may also be asked to collect measures of melatonin at home. These 
samples will assist us in examining additional parameters that could contribute to hormonal sensitivity, or 
have been previously found to differ in hormonally sensitive populations. We have included three references 
on the following page in case you are interested in doing further reading relating to the study topics. 
  We hope that you have enjoyed participating in our study, and thank you very much for your 
assistance. As noted on the consent form, you will receive a summary of the results of the study at its 
completion if you have indicated an interest. 
Principal Investigators:     
Meghan Richards, M.A.  Dr. M. Wesner   Dr. K. Oinonen 
Department of Psychology  Department of Psychology  Department of Psychology 
Lakehead University   Lakehead University   Lakehead University 
955 Oliver Road   955 Oliver Road   955 Oliver Road 
Thunder Bay, ON, P7B 5E1  Thunder Bay, ON, P7B 5E1  Thunder Bay, ON, P7B 5E1 
(807) 343-8418   (807) 343-8457   (807) 343-8096 
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Mental Health Resource Sheet 
 
Sometimes people can feel upset when thinking about their mood.  I f you feel as though you would like to 
talk to a mental health practitioner for any reason please consider the resources listed below: 
 
x Lakehead University Health and Counseling Centre: 343-8361 
 
x Family Services Thunder Bay: 626-1880 
 
x Catholic Family Development Centre: 345-7323 
 
x Emergency services are available at the Thunder Bay Health Sciences Centre 
 
x Thunder Bay Crisis Response (24 hours): 346-8282. 
 
 
If you are interested in doing further reading that is related to this study, here are three relevant journal 
articles that you might want to obtain. 
 
Lee, K. A., Shaver, J. F., Giblin, E. C., & Woods, N. F. (1990) Sleep patterns related to menstrual cycle 
 phase and premenstrual affective symptoms, 13 (5), 403-409. 
 
Oinonen, K., & Mazmanian, D. (2002).  To what extent do oral contraceptives influence 
mood and affect? Journal of Affective Disorders, 70, 229-240. 
 
Parry, B. L., Mendelson, W. B., Duncan, W. C., Sack, D. A., Wehr, T. A. (1989) Longitudinal  
 sleep EEG, temperature, and activity measurements across the menstrual cycle in patients with 
 premenstrual depression and in age matched controls. Psychiatry Research, 30, 285-303.   
  
 
 
 
